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EXECUTIVE SUMMARY 
 
The sequencing of the human genome has greatly facilitated the shift towards studying 
multi-factorial disorders rather than rare monogenic diseases and, as a result, has led to 
the development of more targeted therapeutic models (e.g. personalised drug therapies). 
These are highly dependent, however, on the ability to establish clear disease-genomic 
profile associations which requires the availability of large epidemiological studies and 
samples from well-characterised patient cohorts. For this reason, biobanks, i.e. the 
organised collections consisting of biological samples and associated data, have gained 
great significance for research and personalised medicine. 
 
While biobanks are increasingly recognised as a crucial infrastructure for research, at 
the same time the widely varied practices in biobanking regarding for example 
collection, storage and consent procedures may also pose a barrier to cross-border 
research and collaboration by limiting access to samples and data. In this context, a 
recent study indicates that the limited sharing and linkage of samples is a key barrier for 
research, such as pharmacogenetics. Wide variation is observed in the implementation 
of relevant existing regulation, which may add further burden to harnessing the public 
health benefit of these collections. Therefore, it has been suggested that there is a strong 
need for a harmonised approach on biobanking practices and improved networking of 
existing and new collections. Nevertheless, the extent of the actual activities and the 
impact of the level of networking and harmonisation have not been fully assessed.  
 
To address some of these uncertainties, the Institute for Prospective Technological 
Studies (IPTS) of the European Commission's Joint Research Centre, in collaboration 
with the European Science and Technology Observatory (ESTO), launched the present 
study. Its main objectives were: i) to obtain missing knowledge on the extent of 
biobanking in Europe and world-wide; ii)  to analyse the relevant options and 
challenges for networking and harmonisation.  
 
(i) To obtain missing knowledge on the extent of biobanking in Europe and world-
wide, the first stage of this study was a survey of existing European biobanks which are 
collecting samples for research and their practices regarding both technical aspects (e.g. 
storage conditions) and aspects of governance and ethics (e.g. sample and data sharing, 
consent procedures, collaborations etc.). Surveying biobanks is a daunting task given 
that there is seldom a requirement for declaration of research biobanks in a central 
registry. In total, 126 biobanks from 23 countries in Europe were surveyed. The vast 
majority of the biobanks investigated are found in Denmark (14), Sweden (12) and the 
UK (11). However, surprisingly, significant activity was also identified in Hungary and 
Romania. About 80% of the surveyed biobanks are public collections based either at 
universities or national/regional agencies and have been setup either for population-
based or disease-specific research purposes. Most of the collections are either small- or 
medium-sized and primarily consist of DNA, serum and whole blood, and/or cellular 
tissue samples stored at various conditions, and several types of associated data 
including medical, demographic, genetic and environmental.  
 
Interestingly, almost 70% of the surveyed biobanks were single collections (i.e. not 
forming part of a network or partnership) with database systems which, in most cases, 
were stand-alone. In addition to this limited networking, at least in terms of existing 
database infrastructures, only about half of the biobanks participating in the survey 
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indicated they have a policy for sharing samples across borders either within the EU or 
world-wide. Nevertheless, access to the biobank is, in most cases, either entirely free or 
restricted to a part of the repository. Fees for granting access to samples and/or data 
apply to about a third of the cases. Yet, scientific collaborations based on the use of 
each biobank are prominent. Eighty-five per cent (85%) of the survey respondents 
reported at least two collaborations with other researchers and 45% reported more than 
10. Moreover, 52% of the biobanks surveyed are involved in international 
collaborations.  
Significant variability emerged with regards to privacy and data protection requirements 
among biobanks in Europe. The present survey demonstrates that the majority of 
biobanks have at least one type of consent form that allows tissue (63.5%) and data 
(69%) sharing. Yet, a significant proportion of them utilise more than one type of 
consent depending on the sample. The use of samples defined in the consent form is 
also highly varied, ranging from research on specific diseases to blanket (as practiced 
for example in the case of the UK biobank). Importantly, 13 respondents indicated that 
they do not apply consent at all. Six of them belong to Eastern European Countries with 
the rest based in Western Europe. 
 
Such differences have been observed previously and may be partly attributed to the 
varied interpretation and implementation of EC directives covering aspects of 
biobanking by national authorities. One of the main complications being that, although 
the field of data protection is harmonised through the EC directive on data protection, 
the collection, storage and sharing of samples is not. Furthermore, in countries that have 
introduced special biobanks acts it is not always clear where the borderline lies between 
the scope of these acts and that of the Directive. There seems to be a trend to break 
down this sample/data dichotomy and to consider under "database" both the physical 
sample and the information derived from it, but a deeper international understanding 
and agreement still need to be reached.  
 
As discussed, the variability found with regards to privacy and data protection 
requirements might reflect diverse interpretations of the EC directives by national 
authorities. However, it should be noted that, according to the survey, biobanks within 
the same country reported different practices, suggesting that the problems of 
harmonization might be higher than expected and claimed. Not only are there different 
national laws, but apparently within EU member states biobanks do not implement 
homogenous practices on privacy and data protection issues.  
 
The role of research ethics committees is, in this context, gaining increasing importance, 
as shown by the large majority of the biobanks surveyed which are governed by an 
ethics board (86%). Properly addressing the ethical issues raised by vast biobanking 
projects can determine the successful clinical uptake of genomics. It is therefore 
important to understand how the different biobanks are actually dealing with these 
issues.  
 
ii) To analyse the relevant options and challenges for networking and 
harmonisation, desk research and expert interviews were done to complete the picture 
presented by the survey and the potential way forward. Experts widely recognised the 
need to improve collaboration and networking among the numerous existing biobanks, 
as well as new initiatives in Europe (and world-wide). Efficient organisation of these 
resources through the development, for example, of an infrastructure would potentially 
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facilitate financial sustainability and greatly contribute to the rapid progress of research 
and development of better diagnostic and therapeutic approaches. The model most 
favoured involved the development of a virtual biobank that would allow networking of 
biobanks across different countries and centralisation of data rather than samples. 
However, several organisational challenges (wide variation in biospecimen collection, 
processing, storage techniques, data comparability, definitions) may hamper such an 
effort. The lack of uniform regulatory and ethical requirements and/or practices may 
pose an additional barrier.  
 
The European Commission recognised the importance of international biobank projects 
and many of them have been funded and established in the context of the EU 
Framework Programmes (e.g. GenomEUtwin1, EuroBioBank2, NUGENOB3, PHOEBE4 
and BBMRI5, among others). The European Commission, DG Research in partnership 
with two EU-supported biobanking projects, PHOEBE and BBMRI, has recently 
organised a "Networking Meeting for EU-Funded Biobanking Projects", gathering the 
coordinators or senior investigators of 28 EU-funded projects with a significant 
biobanking component.The meeting identified challenges and critical issues to be 
addressed for the development, success and sustainability of biobanks. Among the 
recommendations formulated, the adoption of measures in favour of harmonisation was 
considered one of the most important. 
 
It has been widely recognised by all stakeholders that in order to accelerate scientific 
discovery it will be critical to improve biobank quality, interoperability and 
sustainability. The report from the aforementioned "Networking Meeting for EU-
Funded Biobanking Projects", also pinpoints this issue raised by the responsible 
investigators of these projects, and there is a general call for harmonisation of sample 
and data storage practices (standard operating procedures for both) but also clear 
procedures for ethical reviews and clarification of legal international requirements for 
data and sample sharing between different countries. Harmonization was also indicated 
as the critical process to stimulate and accelerate scientific discovery in a recent 
workshop jointly organized by P3G, PHOEBE, and BBMRI and sponsored by the 
European Science Foundation. 
 
To help promote networking of biobanks and thus maximise public health benefits, at 
least some degree of harmonisation must be achieved. Whether this should be achieved 
solely at the level of legal/regulatory requirements and practices and/or by technical 
standardisation requires further investigation. Experts suggested the establishment of an 
international (rathen than just a European) umbrella (or network) organization, 
which would establish common operating procedures in e.g. genotyping and 
phenotyping, quality assurance, information management and common approaches to 
                                                 
1 http://www.genomeutwin.org 
2 European Network of DNA, cells and tissue banks for Rare Diseases (http://www.eurobiobank.org) 
3 Nutrient-Gene Interactions in Human Obesity  (http://www.nugenob.com) 
4 Promoting Harmonisation of Epidemiological Biobanks in Europe (http://www.phoebe-eu.org/) 
5 Biobanking and Biomolecular Resources Research Infrastructure (http://www.bbmri.eu) 
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ethical and legal requirments such as consent, data protection and privacy, feedback of 
information to donors, etc. In this context, already existing initiatives with similar 
objectives should be taken into cons ideration and are discussed in this report. 
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1 INTRODUCTION 
 
The sequencing of the human genome as well as non-genomic analyses of various types 
of biological material has greatly facilitated a shift towards studying multi-factorial 
disorders rather than rare monogenic diseases and, as a result, has led to the 
development of more targeted therapeutic models. These are highly dependent, 
however, on the ability to establish clear disease-genomic profile associations which 
requires the availability of large epidemiological studies using samples from well-
characterised patient cohorts. For this reason, biobanks, i.e. the organised collections 
consisting of biological samples and associated data, have gained great significance as a 
resource for research. These collections range widely in scope, from small disease-
specific collections to large-scale population based repositories, and may be public or 
commercial [1]. 
 
Although biobanks do not represent a recent development, due to the growing interest in 
using them for large-scale epidemiological studies on genetic and environmental causes 
of common diseases, the number of such collections held in different settings (e.g 
universities, hospitals, pharmaceutical companies) and countries around the world, has 
rapidly proliferated. Consequently, there are also a growing number of population-based 
studies and other collaborative projects carried out, often supported by the EU (e.g. 
GenomEUtwin6, EuroBioBank7, NUGENOB8, BBMRI). Therefore, biobanks are 
increasingly recognised as a crucial component of research, in particular, for improving 
rational drug development and prevention strategies. However, it has also been 
suggested that they could pose a barrier to cross-border research and collaboration, one 
of the main reasons being the wide variety of existing practices with regards to e.g 
collection and storage of samples, and also to the implementation of relevant regulation. 
In this context, limited sharing and linkage of samples may pose an additional barrier 
for research [2]. 
 
Thus, it has been suggested that there is a strong need for a harmonised approach on 
biobanking practices and improved networking of existing and new collections globally 
[3]. Nevertheless, the extent of the actual activities and impact of the level of 
networking and harmonisation have not been fully assessed [4]. To address some of 
these uncertainties, the Institute for Prospective Technological Studies (IPTS) of the 
European Commission's Joint Research Centre9, in collaboration with the European 
Science and Technology Observatory (ESTO)10, launched a prospective study in 
January 2006.  
 
The ESTO group conducting this study consisted of the following experts: 
 
• Anette Braun and Sylvie Rijkers-Defrasne, VDI-FTD11; 
• Myléne Deschenes and Isabel Fortier, Public Population Project in Genomics 
(P3G)12 
                                                 
6  http://www.genomeutwin.org/ 
7  http://www.genomeutwin.org/ 
8  http://www.nugenob.com/ 
9  www.jrc.es 
10 http://esto.jrc.es/ 
11 http://www.vdi.de/vdi/english/organisation/schnellauswahl/fgkf/kfbt/organisation/11499/index.php 
12 http://www.p3gconsortium.org/ 
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• Jens Laage-Hellman, Vinnova (Swedish Governmental Agency for Innovation 
Systems)13; 
• Christian A. Scerri, Malta Council for Science & Technology (MCST, 
Eurobiobank)14.  
 
The study was conducted in collaboration with P3G (Public Population Project in 
Genomics) [5], benefiting from their previous knowledge and using their database for 
the survey. This initiative is pioneering in providing an international platform for 
sharing methods and information in the international genomics research arena.   
 
1.1 Objectives 
 
The main objectives of the study were: i) to obtain missing knowledge on the extent of 
biobanking in Europe and world-wide and ii) to analyse the relevant options and 
challenges for networking and harmonisation.  
 
A European survey was conducted and complemented by desk research to provide a 
comprehensive picture of human biobanks world-wide. The study compares the 
regulatory frameworks and visions world-wide, in order to emphasize similarities and 
differences and to identify possible strengths, weaknesses, opportunities and threats 
(SWOT) to improve biobank networking. It also explores the potential for a European 
harmonized approach to the networking of human biobanks.  
 
1.2 Definition and scope 
 
The study uses a wide definition of biobank, formulated by OECD15. For the purposes 
of these Guidelines, human biobanks and genetic research databases (HBGRDs) are 
structured resources that can be used for the purpose of genetic research, which include: 
a) human biological materials and/or information generated from the analysis of the 
same; and b) extensive associated information. 
 
Biobanks vary widely depending on the type of material they store (for example, they 
may collect DNA, tissue, living cells, associated data and any combination of these) and 
their purpose (e.g. therapeutic, research, clinical use etc.) (see Figure 0-1). This report 
has focused primarily on biobanks established for research purposes and, apart from a 
few exceptions, clinical biobanks created mainly for diagnostic purposes are not 
covered16.  
 
The report covers four geographical regions: 
 
                                                 
13 http://www.vinnova.se/misc/menyer-och-funktioner/Global-meny/In-English/ 
14 http://www.mcst.org.mt/ and European Eurobiobank Consortium (www.eurobiobank.org) 
15 OECD (2009): Guidelines for Human Biobanks and Genetic Research Databases. 
16 This report also does not include collections of forensic biobanks, therapeutic biobanks (like blood banks and 
tissue banks, including umbilical cord blood banks, for allogenic as well as for autologous grafts), and semen banks, 
as well as organ collections, assembled solely for clinical use. Such biobanks are mostly not designed for research 
purposes. 
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• Northern Europe in this context comprises the five Nordic countries (Sweden, 
Norway, Denmark, Finland and Iceland), the three Baltic countries (Estonia, 
Latvia, Lithuania), the UK and Ireland; 
• Central and Eastern Europe including Bulgaria, the Czech Republic, 
Hungary, Poland, Romania, the Slovak Republic, Belgium, the Netherlands, 
Luxembourg, Germany and Austria; 
• Southern Europe, which comprises in the context of this study, Cyprus, France, 
Greece, Italy, Malta, Portugal and Spain; 
• Non European countries, such as the USA, Canada and Asia. 
 
Representative examples of biobanks are given in section 2.2 for selected countries in 
each of the regions mentioned above. Annexes 2-4 list all the biobanks identified 
throughout the study. However, see the ESTO report available at www.jrc.es for the 
complete analysis 
 
Figure 0-1:  Biobanks classification 
 
 
 
Source: Fraunhofer-IBMT  
 
1.3 Identification of biobanks and survey 
 
The identification of biobanks was performed using different sources including the early 
involvement of network leaders of related EU-funded biobank projects (a list of EU-
funded projects provided by the EC is found in Annex 2), the P3G website and further 
available information17 via search engines like Pubmed and Google, reference websites 
or published reports, abstracts or proceedings of meetings and references provided by 
collaborators. A large effort was dedicated to identifying and mapping biobanking 
activities in Europe in a comprehensive way.  After identification of a first list of almost 
                                                 
17 P3G is not-for profit organization aimed at facilitating collaboration in the field of population genomics. P3G 
maintains a website with descriptive information about population based research, thanks to information provided 
directly by the research team (www.p3gobservatory.org). 
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250 potential biobank contacts, eligibility was validated and final selection performed, 
the main focus being large-scale biobanks established for research purposes. The survey 
questionnaire developed, aimed at obtaining information relating to the purpose, size, 
structure and relevant governance aspects of each biobank addressed (see Annex 1). It 
was sent by e-mail to each respective contact person, with a letter of invitation to 
participate in the survey from mid-March until mid-May 2006. Any additional and/or 
missing information was further collected through desk research. 
 
The survey addressed biobanks collecting samples only for research purposes. Complete 
mapping of all such biobanks existing world-wide was difficult due to the large number 
of biobanks existing in various settings and there is seldom a requirement for 
declaration of research biobanks in a registry. Thus, the principal focus was to identify 
at least the most important biobanks in each of the geographical areas researched. 
Furthermore, by reason of their potential interest for long-term collaboration, particular 
attention was allocated to longitudinal studies18 that included a biobanking component. 
Moreover, despite their strategic importance in the field of research, it was impossible 
to obtain information on biobanks collected by private pharmaceutical companies. 
Finally, the report only includes existing biobanks (i.e. some samples have at least been 
taken).  
 
The survey was sent by e-mail to 176 European organisations/biobanks: 31 of them no 
longer existed or had ended their biobank activities; among the remaining 145 active 
biobanks, 126 replies were received in total. Several factors may have influenced the 
response behaviour: 
 
 reluctance to divulge commercially-sensitive information; 
 sharing information and samples is considered a low priority for a number of the 
companies commercializing their biobanks; 
 sometimes (particularly in Eastern EU countries) general caution about revealing 
any information on biobank activities has been displayed; 
 a serious impediment to the mapping of biobanks is the lack of consistent 
concepts and terms referring to human biobanks: just as the legislation on 
biobanks differs in the various countries considered. Terminology is also 
different (biobanks, biorepositories, cell banks, tissue banks, blood banks, etc.); 
 availability of information in English was not always granted; 
 the survey depended on the willingness of private biobank investigators to 
provide information. The complete list of the 145 biobanks identified in Europe 
is presented in Annex 3.  
                                                 
18 Please note that the term ‘longitudinal studies’ in epidemiology or population based research means different 
things. The most common use of the term in epidemiology, which is the discipline using the large-scale population-
based biobanks, is a type of prospective study in which the cohort members are examined multiple times for the same 
characteristics in order to follow their development or changes over time, e.g. repeated blood 7sampling or 
measurement of height and weight, in contrast to the more simple cohort or follow-up studies in which there is only a 
baseline sampling or measurement. 
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The results of the survey, presented in section 2.1, were further complemented by a 
more in-depth analysis of the most important biobanks in the geographic regions 
mentioned earlier (the results of this analysis are set out in section 2.2).  
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2 BIOBANKING ACTIVITY IN EUROPE AND WORLWIDE  
 
As described, the first objective of this study, to obtain missing knowledge on the extent 
of biobanking in Europe and world-wide, was fisrt tackled through a survey of biobanks 
in Europe.   
 
This survey was complemented with desk research and data previously gathered by P3G 
providing an overview of existing research biobanks in four geographical regions of 
Europe: Northern, Southern Central and Eastern Europe, as well as major biobanks 
from non-European regions including the USA, Canada and Asia.  
 
The overview provided a selection of countries (where considerable activity was 
observed and/or had replied to the survey) within the above mentioned regions 
including a description of single biobank activities identified, national biobanking 
characteristics and regulative aspects observed. In addition – where appropriate based 
on the survey - a brief discussion on sample collections, access availability, sharing of 
samples, and consent requirements is included.  
 
The state-of-the-art regarding human biobanks for research purposes in Europe and 
world-wide, as described in this chapter is based on data collected by May 2006.  
 
2.1 Survey of European biobanks 
 
At the time of this survey no comprehensive list of of biobanks in Europe exists. A 
survey was sent to 176 European biobanks/organisations identified as described earlier, 
and a total of 126 completed questionnaires were received (a response rate of about 
72%). Table 2-1 lists the number of sent and returned questionnaires per country.  
 
 
Table 2-1: Number of respondents per country 
Country Biobanks Surveyed Country Biobanks Surveyed 
 Sent Response  Sent 
Respons
e 
Austria 6 1 Latvia 1 1 
Belgium 5 2 Malta 1 1 
Bulgaria 2 1 Netherlands 11 8 
Denmark 15 14 Norway 9 9 
Estonia 1 1 Poland 3 3 
Finland 5 5 Romania 12 12 
France 2 2 Slovakia 1 1 
Germany 10 9 Slovenia 1 1 
Greece 1 1 Spain 2 2 
Hungary 17 17 Sweden 14 12 
Iceland 5 4 UK 12 11 
Italy 9 8 Total 145 126 
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Since a number of the biobanks addressed were found to have ended their activity, the 
response rate of active biobanks is nearly 87 %. The vast majority of the biobanks 
surveyed are found in Denmark (14), Sweden (12) and the UK (11). However, 
surprisingly, significant activity was also identified in Hungary and Romania.  
 
The response rate was homogeneously high for almost all countries (between 90 and 
100%), with the exception of Austria (16%), Belgium (40%), Bulgaria (50%), and The 
Netherlands (73%). 
  
The variability in the number of biobanks per country could be at least partially 
explained by the existence in some countries of network infrastructures or consortia that 
provide visibility to individual biobanks. For example, the "Genomic Research for 
Human Health Consortium" supported by the EU 6th Framework Programme and the 
foundation of the Hungarian National Biobank Network19 were the reasons behind the 
inclusion of an unexpectedly high number of Hungarian biobanks in the sample.   
 
 
2.1.1 Biobanks composition and purpose 
 
The majority of the surveyed biobanks (68%) are single (stand-alone) banks20, whereas 
thirty-two percent (32%) have instead formed a partnership with other biobanks located 
either in the same (20%) or in a different (12%) country, for sharing samples and/or for 
carrying out research (see Figure 2-1). Within the last cathegory 62,5% (20% of the 
whole sample) is involved in a partnership with biobanks in the same geographical 
location, and 37,5% (12% of the whole sample) form a partnership with banks in 
different locations.  The data available indicate that the formation of trans-national 
biobanks partnerships or networks is rather limited, even if we cannot specify the type 
of collaboration. 
 
 
Figure 2-1:  Biobank partnerships (left panel) and geographical location (right panel)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
19 www.biobank.hu 
20  As stand-alone biobank we mean a biobank that does not consist of a partnership of banks (See Annex 1 – 
Question 5) 
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92% of the responding biobanks (116) sampled have a clear ownership (see Figure 2-2). 
The majority of these are owned by universities (39%), national/regional agencies 
(39%) or non-profit organisations (19%) and only few (3%) are private. Moreover, 
when asked the principal reason for the creation of the biobank, the majority of the 
respondents replied that it was created for public research only (36%) or for both public 
and clinical research (mainly aiming at diagnosis, 24%) (see Figure 2-3).  
 
 
Figure 2-2:  Ownership 
 
Figure 2-3:  Research models 
 
 
To gain further insight regarding the purpose of the sampled biobanks, a question in the 
survey considered participant selection. Table 2-2 lists the anwers received per category 
(including combinations). The majority of the collections are either disease specific 
(27%) or from a random population (21%) but a considerable number of them are 
collecting both types of samples (16%). About a fourth of the responding biobanks 
stated they additionally collect samples of specific demographic characteristics (e.g. 
isolates or healthy elderly). 17 respondents further specified the other types of sample 
collection. Table 2-3 summarises these answers.  
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Table 2-2: Sample/Participant selection 
Objective Number 
Random Population 26 
Disease Specific 31 
Random Population & Disease Specific 20 
Demographic 4 
Random Population & Demographic 13 
Disease & Demographic 4 
Random Population, Disease Specific & Demographic 8 
Other objectives 7 
Disease specific and Other reasons 6 
Other combinations of objectives 4 
No answer 3 
Total 126 
 
Table 2-3: "Other" activities 
Type of activity Number 
Blood donors 2 
Controls/Healthy volunteers 3 
Pregnant women 1 
Research projects 2 
Stem cells 1 
Tissue specific 2 
Twins 2 
Birth Cohort 1 
Embryos 1 
No description Given 2 
Total 17 
 
Our data suggest an acceleration in biobanking activities in recent years. While a few of 
the biobanks identified started collection in the 70's, they have been built up relatively 
recently (during the 90s) with 37% of the surveyed biobanks starting their activity after 
2000 (see Figure 2-4), obviously reflecting the burst of genome-wide association studies 
and the search for disease susceptibility genes and diagnostic biomarkers.after the 
completion of the human genome sequencing project.. The majority of the biobanks 
(>74%) of the biobanks do not foresee an end to their sampling activities and indicate a 
high potential for growth, showing the dynamic nature of biobanking and an increasing 
role in research 
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Figure 2-4:  Year biobank started 
 
 
 
 
2.1.2 Sample and data collection 
 
Regarding the targeted size of the biobanks that participated in the survey, the majority 
of the respondents seem to be small (less than 1000 samples) or medium sized 
repositories (up to 10000 samples) (see Figure 2-5). This might reflect the fact that most 
of the biobanks surveyed are disease specific and that population based biobanks have 
been instituted rather more recently. Nevertheless, about a third of the respondents 
indicated they collect up to 50000 samples or more. 57% of the repositories also 
reported that they do not have any specific sample target number for the future.  
 
 
Figure 2-5:  Number of samples 
 
 
 
Participants to the survey were also asked to specify the type of material stored in the 
respective biobanks. Types included DNA, serum, whole blood, tissues or other, and 
respondents could select any answer that applied. The survey shows that most biobanks 
store DNA combined with serum, whole blood and/or different types of tissue (see 
Figure 2-6), whereas only 12% store DNA alone. Other tissues stored (as specified by 
the respondents) include, for example, stem cells and RNA, urine, dried blood and red 
blood cells.  
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Figure 2-6:  Type of material stored 
 
 
 
Finally, the survey investigated who carries out the collection of samples (e.g. hospital 
staff, patient interest groups, staff specifically employed for the respective 
project/biobank). Interestingly, in the majority of the cases, sample collection was 
carried out either by associated hospital staff, primary care workers or a combination of 
both (see  
 
Figure 2-7). Approximately half of the respondents (60) stated that sample collection is 
carried out by staff specifically employed for the project, either alone or with other staff 
(e.g. primary care workers, hospital staff etc.) (see  
 
Figure 2-7, bottom panel). This is perhaps not surprising as the biobanks surveyed are 
largely public (either owned by national agencies/hospitals or universities) (see Figure 
2-2). Interestingly, some respondents indicated that data collection may also be carried 
out by patient interest groups.  
 
 
 
Figure 2-7:  Staff involved in the collection of samples 
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The survey also addressed the types of data that are stored and associated with the 
collected samples (see Figure 2-8). By far, the most commonly stored data are medical 
(113 replies), genetic (79 replies) and demographic (83 replies), potentially reflecting 
the type of research activities undertaken by the respective biobanks. About half of the 
surveyed biobanks stated they also collect environmental data (60 replies). Respondents 
were asked to include all types that applied. The bottom panel of Figure 2-8 breaks 
down the shares of the replies by all the combinations provided.  
 
 
 
Figure 2-8:  Type of data collected and stored 
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Regarding data connectivity, a stand-alone database system is the type mostly utilised 
by the biobanks that responded to the survey (46%) although, at times, they may be 
networked through a restricted intranet and/or an internet system as well (see Figure 
2-9). This may not be too surprising though as most of the responding biobanks are not 
part of a network (see Figure 2-1).  
 
 
Figure 2-9:  Types of data storage systems 
 
 
 
2.1.3 Access 
 
The majority of biobanks sampled have a policy that allows sharing samples across 
country borders either within the EU (17%) or world-wide (33%) (see Figure 2-10). 
However, a considerable share of the respondents indicate that biobanks may only be 
accessed by the researchers who collected the samples (20%) or all researchers that 
belong to the same institute (10%). The lack of proper networking (see Figure 2-9) may 
provide an explanation for the limited access to certain biobanks beyond other legal 
restrictions.  
 
Figure 2-10:  Biobank use by location 
 
 
As most biobanks sampled are publicly funded and owned either by public agencies or 
universities, it is not too surprising that, by far, the largest majority (see Figure 2-2), 
(84%) offer their samples either totally free or offer a part of their repositories free (see 
Figure 2-11). Though free, most institutions have some restrictions mostly in terms of 
the mode and extent of use of the biobank, as well as specific ethical requirements. 
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Decision on the granting of access for the utilisation of samples, is split between the 
governing body (39%) and the curator of the biobank (27%) (see Figure 2-12). 
 
Figure 2-11:  Type of access 
 
 
 
Figure 2-12:  Decision on access 
 
 
 
2.1.4 Consent and privacy 
 
Significant variability emerged with regards to privacy and data protection requirements 
among biobanks in Europe. Although informed consent for approval of biobank-based 
research is almost ubiquitously required, the actual consent requirements and related 
procedures vary widely among biobanks, depending on the national laws and guidelines 
applied. The present survey demonstrates that the majority of biobanks have at least one 
type of consent form that allows tissue (63.5%) and data (69%) sharing. Yet, a 
significant proportion of them utilise more than one type of consent depending on the 
sample. The use of samples defined in the consent form is also highly varied, ranging 
from research on specific diseases to blanket (as practiced for example in the case of the 
UK biobank). Importantly, 13 respondents indicated that they do not apply consent at 
all. Six of them belong to Eastern European Countries with the rest based in Western 
Europe. 
 
As would be expected (in view of the various legislative directives) almost all biobanks 
sampled are regulated by an Ethics board approval. A large majority of the biobanks 
have a legal consent structure allowing tissue (63.5%) and data (69.0%) sharing. Most 
of the banks have at least one type of consent form, though many (40%) utilise more the 
one type, depending on the sample.   
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Figure 2-13:  Ethics board 
 
 
Figure 2-14:  Type of consent 
 
 
 
The consent forming 72.2% of banks allows the donor to withdraw his/her consent for 
the storage of the donated sample, whilst 15.1% withdrawal of consent is not allowed 
(12.7 % of the sampled biobanks chose not to answer this question). 
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Figure 2-15:  Does consent form allow sharing with researchers from other countries? 
 
 
 
Information gathered from any tests carried out on samples is referred back to the 
donor. This is the case for 37% of the banks if consented to and 6% in all cases. 57% of 
the biobanks would never refer back any data to the donor. Most of the biobanks (76%) 
protect the privacy of their donors by coding the samples. Most probably this reflects 
the fact that, in most of the banks samples are disease related or are specific population 
where, either feedback or data retrieval are considered necessary and, as such, the 
possibility of identifying the donor is a prerequisite. 
 
 
Figure 2-16:  Is information referred back to the donor? 
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Figure 2-17:  Coding 
 
 
 
2.1.5 Scientific Output 
 
The majority of biobanks (78.2%) require researchers utilising samples of the bank to 
feedback on the outcome of tests and results. Similarly, the largest majority of biobanks 
(84.9%) follow the publications emerging from the tests and research carried out on their 
samples.  
 
Figure 2-18:  Scientific output 
 
 
Biobanks also have good records of collaboration with outside researchers: 85% reporting 
at least two collaborations and 45% more than 10. This is also reflected by the number of 
papers published with 84% showing at least one, 38% more than 10 and 10% more than 
100 publications. 52% of the biobanks report having been involved in international 
collaboration and only 26% report having had some problems in sharing samples.  
 
Most of these problems relate to the storing of samples, dry ice shipments and legislative 
barriers especially in countries (e.g. Hungary) where the transfer of samples to foreign 
countries is not permitted. Most of the biobanks sampled (75%) allow both sending and 
receiving samples from other countries, with 16.4% from the EU and 83.6% from the rest 
of the world. 
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Figure 2-19:  Number of scientific collaborations (left) and publications (right) 
 
 
The fact that only 16% of biobanks have not produced any scientific publication is a 
positive sign of the contribution of biobanks to medical research, though ideally, the 
efficiency of this type of investment (in terms of money and sample donation) should be 
evaluated taking into account the impact of the research published, investigating 
bibliometric indexes of biobank publications.  
 
2.2 Biobanks world-wide 
 
2.2.1 Biobanks in Northern Europe 
 
Northern Europe, in the context of this report, comprises the following countries: the 
five Nordic countries (Sweden, Norway, Denmark, Finland and Iceland), the three 
Baltic countries (Estonia, Latvia, Lithuania), the UK and Ireland.  
 
Regarding the Nordic countries, the identification of biobanks was mainly done by 
using previous knowledge and existing contacts. Sweden has been used as a particular 
case to illustrate the phenomena also present in other Nordic countries, based on their 
existing similarities. It was easy to identify two important biobanks in the Baltic 
countries, since these are associated with well-known genome projects in Estonia and 
Latvia. Our contacts have confirmed that there are no other biobanking activities in 
these countries worthwhile covering in this study. Several research biobanks exist in the 
UK at universities and university hospitals, the main of which have been identified. 
However, given the short time-frame during which this study was carried out, the 
mapping is not exhaustive. No major biobanks dedicated specifically to research were 
identified in Ireland at the time of the survey. However, there was a proposal to 
establish a network of clinical biobanks involving several hospitals: Biobank Ireland21. 
They have started their networking activity in February, with the Department of 
Pathology in the Galway University Hospital as a first step forward for the 
establishment of the network. 
 
Information on relevant laws and regulations in different countries has been gathered in 
a compilation carried out in 2005 by the Department of Health and Human Services in 
the UK: International Compilation of Human Subject Research Protections (Second 
Edition, October 1, 2005). Additional information on specific laws has been obtained 
from various websites and other publications. 
                                                 
21 http://biobankireland.com/ 
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The mapping of biobanks in Northern Europe has focused primarily on research 
biobanks, and apart from a few exceptions, clinical biobanks created mainly for 
diagnostic purposes are not covered. There are very large numbers of samples stored in 
clinical biobanks, not least in the Nordic countries since there has been a long-standing 
tradition to save tissues and other samples taken during routine medical care. In 
Sweden, for example, it is estimated that there are 50-100 million human samples stored 
in biobanks of the healthcare system, increasing by 3-4 million samples every year.22 
The majority of these samples are stored in departments of clinical pathology, cytology 
and microbiology. Similarly in the UK, it is estimated that 150 million tissue samples 
are taken every year during medical operations and procedures.23 
 
The situation found in the different countries is described in the following sections, 
starting with Sweden, which is given some more space than the others due to the 
reasons mentioned above. 
 
 
2.2.1.1 Biobanks in Sweden 
 
Biobanks identified 
The following 13 biobanks, in Sweden, are covered in this study: 
 
⇒ Medical Biobank 
⇒ Northern Sweden Maternity Cohort 
⇒ Malmö Preventive Medicine 
⇒ Malmö Diet & Cancer 
⇒ Malmö Microbiology Biobank 
⇒ Botnia Study 
⇒ ”Biobank SC153” 
⇒ Karolinska Instiutet Biobank 
⇒ Swedish Institute for Infectious Disease Control Biobank 
⇒ PKU Biobank 
⇒ ULSAM 
⇒ ABIS (All babies in Southeast Sweden) 
⇒ Epidemiology Group, Sahlgrenska University Hospital 
 
The list comprises all large research biobanks in Sweden, although a few clinical 
biobanks are also included.  
 
In accordance with the Swedish Biobanks in the Medical Care Act, in force since 
January 2003, all biobanks originating in the healthcare system are to be registered 
regionally, and under supervision by the National Board for Health and Welfare. This 
ongoing registration work shows that there is an incredibly large number of biosamples 
stored at the large hospitals. The main purpose of 25 of these biobanks/collections is 
diagnostics and treatment. However, according to this national register, many of them 
are also used for research. The majority of the biobanks have been created specifically 
for the purpose of research or clinical trials (often a combination of these). However, 
                                                 
22  www.biobank.se 
23  BBC News, 23 June 2004 (http://news.bbc.co.uk/2/hi/health/3832333.stm) 
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the clinical biobanks dominate completely in terms of number of samples, accounting 
for 95% of all samples. Nonetheless, there are in total more than 500 000 samples stored 
in various research biobanks at the region’s hospitals. The situation in Stockholm is 
similar. That is, besides the large clinical collections, there are also many research 
collections. 
 
Malmö Microbiology Biobank exemplifies a large clinical biobank located at Malmö 
University Hospital which, to a large extent, is also used for research. It contains, in 
total, 1.2 million samples from 454 000 individuals. Most of the samples stored are 
serum samples submitted since 1969 for diagnosis of blood-borne viral infections. Of 
particular importance, from an epidemiological research point of view, is a sub-
collection of 120 000 samples resulting from a population-based screening for virus 
infections and rubella immunity during pregnancy24. The PKU Biobank consists of 
blood samples from newborns originating from a national screening of certain metabolic 
diseases. Such blood samples, now amounting to more than 2.7 million, have been 
stored in a specific biobank at the Karolinska Hospital since 1974. It has been used for 
research only to a very limited extent. This is probably due to the organization and the 
fact that the biobank has not been positioned as a resource for research. 
 
The three largest research biobanks in Sweden are located in Umeå and Malmö. The 
Medical Biobank at Umeå University, which started collecting samples in 1985, 
consists of three cohorts and contains samples from 90 000 unique individuals.. Besides 
its large size and long follow-up, the high value of this biobank comes from the attached 
database which contains rich information on environmental and life-style factors as well 
as results from previous analyses. Like other Swedish biobanks, its usefulness in 
scientific studies is further enhanced by the possibilities to link the biobank with 
reliable disease registries. This is also why the biobank has been used in a large number 
of epidemiological national and international studies. It has been used, for example, in 
international pooling projects such as MORGAM25 and EPIC (the European Prospective 
Investigation into Cancer and Nutrition26). As a result, it was concluded in an 
international evaluation of Swedish biobanks that “this is one of the best Swedish 
biobanks and can be utilized in various genetic and epidemiological studies in the 
future”.27 
 
Additionally, there is another population-based biobank in Umeå, namely the Northern 
Sweden Maternity Cohort, which contains serum and DNA samples from cervical 
screening. Samples have been taken from 85 000 unique individuals on 115 000 
sampling occasions. The oldest samples date back to 1975.  
 
Malmö Preventive Medicine (1974-2006) and Malmö Diet and Cancer (1991-96) are 
two other prospective observational population-based biobanks belonging to the 
Department of Medicince at Lund University but located at Malmö University Hospital. 
They comprise 33 000 and 30 000 individuals respectively. Like the Medical Biobank 
                                                 
24 Another large mainly serum-based biobank exists at the Swedish Institute for Infectious Disease Control. Despite 
having a large number of samples from a 50-year period, which through the patient’s personal registration number 
can be linked to other databases, this biobank has not been extensively used for scientific purposes.  
25 See www.ktl.fi/morgam/ 
26 See www.iarc.fr/epic/ 
27 International Evaluation of Swedish Biobanks, 18 March, 2005 (available on www.biobanks.se) 
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in Umeå, the Malmö Diet and Cancer biobank is an associated member of EPIC.28 Both 
of the Malmö biobanks contain a comprehensive collection of phenotypic and 
environmental data. They have been used in several research projects leading to 
numerous publications (more than a hundred each). However, the need for continuing 
external collaboration was recognised as an important factor for harnessing the full 
benefit of the Malmö Diet and Cancer biobank for research29. 
 
Besides these relatively large population-based research biobanks there are, as already 
mentioned, many smaller biobanks, many of which are disease-specific. We can take 
the Southern Healthcare Region as an example to illustrate how these biobanks are 
organised. This is one of Sweden’s six healthcare regions with some 1.6 million 
inhabitants. The ongoing work on a regional biobank register, imposed by the Biobanks 
Act, shows that there are in total 13 million samples, most of which have been taken for 
diagnostic purposes. But there are also many research biobanks. Besides the two large 
ones mentioned above, there are about 40 university departments at the region’s two 
university hospitals, with at least one research collection each, often more. The samples 
are typically stored locally in the departments’ own freezers. The number of samples or 
individuals typically ranges from 100 to 1 000, but some collections may be 
significantly larger. One example is the biobank related to the so-called Botnia Study, 
the aim of which is to elucidate the genetics of Type 2 diabetes. This study is carried out 
in the very north of Sweden and Finland (the Botnia area with some 120 000 
inhabitants) by a research group at Lund University’s Wallenberg Laboratory in Malmö. 
An original set of samples has been collected since 1990 from approximately 10 000 
individuals and 1 400 families in both Sweden and Finland. Besides the biological 
material, researchers have also collected a comprehensive amount of environmental and 
clinical information. The Botnia study has resulted in a large number of scientific 
publications. Two years ago, a new population-based study called PPP (Prevention, 
prediction and prevention of diabetes) was started in Botnia. The aim was to collect 
samples and data from 5 000 individuals (reaching more than 10 percent of the 
population). At present, 3 000 individuals have been covered. That is why “the Botnia 
biobank” today contains samples and data from 13 000 individuals in total. Within a 
near future, a genome scan of these 3 000 individuals will be completed. 
 
This research group also has a regional diabetes registry comprising samples from 8 000 
individuals. This will now be transformed into a registry for all newly diagnosed 
diabetes cases in the Skåne Region. Besides these large biobanks, the group also has 
more than 10 smaller collections comprising 50 to 400 individuals. They have been 
established in connection to different research projects on obesity and other diabetes 
complications. One example is “Biobank SC153” consisting of DNA and serum 
samples collected in 2000 from 375 patients. The samples have been used by several 
research groups at the university, some of which are involved in international 
collaboration (i.e. samples have been sent for analysis to Norway and the USA30). 
 
It can be assumed that the situation is similar in other healthcare regions in Sweden. The 
above list includes a few research biobanks from other parts of the country: ULSAM 
                                                 
28 While the samples collected through EPIC are normally stored in a centralized biobank at IARC in Lyon, the 
participating centres from Sweden, Denmark and Norway have chosen to store the samples in their own local 
biobanks. 
29 International Evaluation of Swedish Biobanks, 18 March, 2005 (available on www.biobanks.se) 
30 Remaining material is going to be returned to Sweden, as required by the Swedish Biobanks Act 
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(Uppsala), ABIS (Linköping) and the Epidemiology Group, Sahlgrenska University 
Hospital (Gothenburg). These are relatively well-known in the scientific community, 
but should be regarded mainly as examples. The last-mentioned biobank is established 
within the INTERGENE project, in which the genetic influence on the absolute risk for 
coronary disease is investigated.31 The study is a combined control and cohort study of 
2 000 consecutive patients, with coronary artery disease from hospitals situated in 
western Sweden. The control group is selected from patients' relatives and 
approximately 10 000 healthy individuals randomly selected from the population. The 
study design provides possibilities for further analyses where the odds ratio, for a 
number of risk factors, can be estimated in relation to the genetic disposition. 
 
One of the professors interviewed, with long experience in biobanking as well as in 
international research collaboration states that the picture in southern Sweden is 
probably quite typical for the whole Nordic region. He indicates that a policy to save 
original biological material was already established in these countries many decades 
ago, in some cases even a century ago. He also mentions that during the last decade or 
so, the previous policy to discard the oldest samples to make room for new ones has 
been abandoned and the sample collections are, therefore, nowadays growing 
continuously. However he is uncertain as to what extent the same patterns have 
developed in other parts of Europe. 
 
The Karolinska Institutet (KI), in Stockholm, is Sweden’s largest medical school and an 
internationally leading medical research institution. Many sample collections of varying 
size have been created over the years linked to various research projects. However, 
there are no large population-based biobanks similar to those in Umeå and Malmö. But 
since 2004, KI is heavily investing in building up a modern infrastructure for 
biobanking. A core facility called KI Biobank has been established with financial 
support from the Wallenberg Foundation. The aim is to build up a non-commercial 
resource for collection, handling and storage of human biosamples to be used in 
molecular and genetic research in Sweden. The biobank is, thus, positioned as a national 
resource. Another ambition is to increasingly use the biobank in international 
collaboration, for example, in the field of genetic epidemiology. Such collaborations 
have already started in some projects (e.g. GenomEUtwin and several studies funded by 
the National Institutes of Health in the USA). 
 
The availability of donor information has been found to be a crucial precondition at KI 
for the effective use of collected biosamples in research. Therefore, in order to enhance 
the biobank’s scientific usefulness, large resources are invested in building an advanced 
informatics structure. A central part of the biobank is, thus, the Biobank Information 
Management System (BIMS), which will facilitate linking samples and large databases 
containing phenotypic and genotypic information on the sample providers. This system, 
now under construction in cooperation with IBM, is argued to be unique in the world 
and is expected to significantly enhance the importance of the biobank. Other features 
of the KI Biobank are a strict quality control system, strong emphasis on ethical issues 
(e.g. existence of informed consent), and large-scale DNA extraction facilities. 
 
The KI Biobank functions as host for several sample collections at the KI., There are 
today, in total, samples from around 15 000 individuals stored in this biobank. The 
                                                 
31 www2.sahlgrenska.gu.se/intergene/eng 
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Swedish Twin Registry (with phenotypic data from 140 000 twins) accounts for 
approximately half of these samples, including 5-6 000 samples collected in the late 
1990s. The Twin Gene Project is an important ongoing biobanking activity aiming to 
transform the registry from a primarily epidemiology research into a strategic resource 
for functional genomics studies and gene-environmental interactions in complex genetic 
diseases. The goal is to create a collection of samples from 20 000 individuals. At 
present, samples are collected at a rate of approximately 250 twins per week, which 
means that the goal will be reached within less than two years. The updated twin 
registry, with its biological samples collection, will be used as an open-accessed 
resource for national and international scientists. Within the frame of the GenomEUtwin 
project, KI is already collaborating with twin registries in Finland, Denmark, Norway, 
the Netherlands and Italy. 
 
The other half of the KI Biobank consists of smaller collections from approximately 10 
different studies. All of these projects are new and begun after 2004 when this core 
facility was established. Outside the KI Biobank there are nearly 200 other collections 
stored at different departments around KI. Some of them may be integrated in the KI 
Biobank in the future. For example, there is an ongoing large study on prostate cancer 
with 6 000 samples that will be taken in [based on interview], but most of the existing 
collections will not be integrated, since they do not meet the quality standards applied 
by the KI Biobank. For example, samples may not have been stored at the right 
temperature, informed consent may be too narrow or missing, or the available data on 
the donors may be inadequate. As pointed out by the executive director, the role of the 
KI Biobank is to take care of those collections particularly valuable for future research. 
LifeGene32 is a new large-scale biobanking project at the KI, which is still in an up-start 
phase.  It is a population-based prospective cohort study on lifestyle, health, and 
genomics. The goal is to collect samples and information from at least 500 000 Swedes, 
thereby, creating a large, open resource for research on disease aetiology and daily 
health problems, such as obesity, diabetes, allergies, psychiatric disorders, and 
infections. The project is still in a preparation phase, which means that collection of 
samples and data has not yet begun. In an initial phase, LifeGene intends to utilize 
existing resources such as the Twin Registry and start with all first-degree relatives of 
the twins in this registry. 
 
An important feature of LifeGene, fully in line with the strategy of the KI Biobank, is to 
make maximum use of modern information and communications technologies. This 
means, for example, that following the initial use of existing databases, enrolment will 
be made through contact via mass e-mails and advertisements. Assessment of in-depth 
exposure information on research subjects will also be made by using electronic means, 
such as Internet, cell phones, digital papers and TV. The use of electronic 
questionnaires will enable frequent data collection and the building of a rich database. It 
is expected that the availability of this database will enhance the value of the biobank 
itself (in the past, the value of existing biobanks has often been limited by the lack of 
donor information). 
 
 
National Biobank project 
                                                 
32 http://lifegene.ki.se/ 
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The National Biobank Project (NBP) is a joint national program supported by the 
Wallenberg Foundation from 2002 to 2005 with a budget of approximately 5 million 
euros.33 The background of this initiative was that Sweden, for a number of reasons 
(such as the existence of several large biobanks, the extensive use of unique personal 
identification number and high-quality health data registries), offers excellent 
conditions for carrying out population-based genetic studies of complex diseases. It was 
concluded that the bottlenecks preventing efficient use of biobanks were not due to the 
lack of samples or information, but rather to the downstream level. The aims of NBP, 
therefore, were to: 
 
• enhance the overview and knowledge on the Swedish biobanking system; 
• characterize and improve the quality of biobanks; 
• increase the usefulness and accessibility of biobanks; 
• raise the protection of integrity of individual donors, by using improved, formal 
quality standards for biobank-based studies and upgrade ethical awareness. 
 
Among the various activities carried out within the NBP, are the funds used to support 
additional collections of samples (e.g. fresh-frozen tissue), delivery of samples and data 
for research, creation of new facilities for sample handling and analysis, training in 
ethics and law, and building of a pilot Regional Biobank Registry. One of the more 
important results is the creation of a common Quality Assurance manual for biobanking, 
called “Good Biobanking Practice” (GBP). This system has been recommended by the 
Swedish County Council Association and its implementation around the country is 
under way. Another result is the development of common standards for the protection of 
the donors’ integrity. 
 
Biobanks in industry 
There are many pharmaceutical and biotechnology firms carrying out R&D in Sweden. 
The multinational AstraZeneca has three of its largest R&D centres in Sweden. The 
biotechnology sector is the fourth largest in Europe34. During the last ten years, well-
characterized human biobanks have become an increasingly important resource for 
development of new drugs and diagnostics. First, biobanks were used in the companies’ 
early-phase of drug discovery activities to identify drug targets (which could then be 
taken, in the next step, as a starting point for product development). Second, 
pharmaceutical firms also collected and stored biosamples in connection to clinical 
trials, for example, for the purpose of pharmacogenomic studies. A study carried out a 
few years ago showed that pharmaceutical and biotechnology firms in Sweden had, with 
a few exceptions, chosen not to build up their own biobanks [7]. Instead, they 
established collaboration with academic researchers with access to biosamples and data 
(either collected by themselves or available in other public biobanks). Usually, the 
research was carried out by academic researchers, but in close cooperation with 
scientists from the sponsoring company. Sometimes, the biosamples were analysed by 
the industrial partner, but as a rule there was no transfer of biobank materials to the 
company. The latter was primarily interested in the research results and not the material 
per se.  
 
                                                 
33 An evaluation report on Swedish biobanks written by an international evaluation committee is available on the 
NBP’s homepage (www.biobanks.se). The NBP is described in one of the appendices. 
34  Ernst and Young Refocus: The European Perspective 2004 
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From the industry’s point of view, this mode of cooperation offered many advantages 
compared to in-house biobank research. Not least, researchers, in universities and 
hospitals, had contacts with patients who could be recruited as research subjects and 
donors, and also access to valuable information through various registers. Companies 
like AstraZeneca and Pharmacia & Uphohn (today Pfizer) had such projects of 
collaboration with many research groups both in Sweden and abroad. They also had 
research contracts with biotech companies, mainly foreign ones, that had access to 
samples and data either from proprietary or external biobanks. 
 
It is worth mentioning that in the late 1990s, an attempt was made to commercialize the 
Medical Biobank in Umeå and, as inspired by deCode genetics in Iceland, 
UmanGenomics was established. The business idea was similar to deCode’s, i.e. to 
carry out human genetic studies on behalf of the pharmaceutical industry. But the 
organizational set up was different (e.g. with regard to ownership, funding, and 
relationships with hospitals and universities). Unlike deCode, UmanGenomics would 
not have its own biobank. Instead, it was given exclusive rights to use the public 
Medical Biobank for commercial research. However, for several reasons this venture 
failed. Triggered by the establishment of UmanGenomics, a severe conflict regarding 
the disposal rights arose between researchers associated with the biobank on one side, 
and the university and the county council on the other. This made it impossible for the 
company to effectively use the biosamples to develop its business.  
 
Sample collections 
For the three large population-based biobanks the selection of participants is by 
definition random – in the case of the Medical Biobank also demographic-specific. The 
collection of samples has been carried out by specifically employed staff and, in the 
case of the Medical Biobank, also by primary care workers. For the other research 
biobanks, participant collection is disease-specific and/or random (often both). The 
sample collection is often made by using a combination of different channels: 
associated hospital staff, staff specifically employed for the project and primary care 
centres. For the Malmö Microbiology Cohort, participant selection is random and 
disease-specific. The sample collection is carried out by primary care workers. The 
Swedish Institute for Infectious Disease Control selects participants both, on the basis 
of diseases and other project-specific criteria. It has its own staff dealing with the 
sample collections. For all biobanks, public research is the principle reason for creating 
the biobank. In several cases, including clinical biobanks, clinical research diagnostics 
is another reason. 
 
Access to and sharing of samples 
Access to samples from the three population-based biobanks is free, in the sense that 
there is no fee to be paid, but access is restricted by scientific priority (e.g. in relation to 
main research questions in grant applications). For the Medical Biobank, decision on 
access is made by expert groups and a steering board. For the two Malmö biobanks, the 
decision is made by a scientific priority committee. Other research biobanks, in general, 
do not demand any payment for using samples.  
 
An exception is the KI Biobank, which is using the self cost principle (this biobank has 
been created specifically as an infrastructure resource for biobanking at the Karolinska 
Institute). Even if there are no fees involved, access to samples and data from the 
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research biobanks is usually restricted in other ways. One factor is availability of DNA. 
Furthermore, research collaboration with the responsible organization is often required. 
 
For all biobanks, cross-border sharing of samples and data is allowed, as long as 
samples are sent abroad only for analysis (according to the Swedish Biobanks Act). 
However, sharing of samples in international projects is associated with certain 
problems due to legal differences between countries. This is discussed in more detail in 
another section of this report [see section 3.1.2]. 
 
Consent 
All three large population-based biobanks that replied to the survey use a broad consent 
to biomedical research. The other research biobanks usually use a more narrow consent, 
for a specific study or for research in a certain research area. The KI Biobank, which is 
hosting a number of individual collections, uses a set of different consent forms (these 
range from those used for a specific study, to those used for biomedical research on a 
broader scale). The Malmö Microbiology Cohort did not use any explicit consent before 
2004 (when there was no specific law on biobanking). Since 2004, it uses a broad 
consent form to biomedical research. 
 
As a rule, Swedish biobanks covered in this study do not refer back personal results to 
the donors. One exception is ABIS, which does if requested. Also, the KI Biobank 
reports that, in a few studies, clinical chemistry data is reported back to the study 
subjects. 
 
In all biobanks, donors can withdraw their consent to the storing of samples. 
 
Regulatory aspects 
The Medical Care Act applying to Swedish biobanks entered into force on 1 January 
2003, and will be revised in the near future. The present act only covers biobanks under 
the healthcare system. However, in reality many research biobanks are also concerned 
since sampling is often carried out by staff employed at hospitals and medical care 
centres. If sampling is made without involving healthcare providers the Medical Care 
Act will not apply. However, according to a proposal by the National Board for Health 
and Welfare, the revised Act will also cover all research biobanks. 
 
The Swedish Biobanks Act, and its application has been heavily criticized by the 
research community, which complains about the increasing bureaucracy that it entails 
(also see section 3.1.2). Among other effects, some law elements make it more difficult 
to participate in international research cooperations – at least according to some leading 
biobank researchers. The current proposal to let the law cover all research biobanks, 
irrespective of who carries out the sampling, is not appreciated. 
 
There seems to be a wide-spread opinion among leading Swedish biobank researchers 
that recent legislative changes, such as the new Biobanks Act and a new act on the 
ethical review of research involving humans (in force since 2004), have resulted in a 
transfer of powers from scientists to authorities (both at national and local level). For 
example, it used to be the individual scientist who applied for and received the ethical 
approval. Now, it is the employer (e.g. the university or the county council) who is the 
applicant and the possessor of the approval. In reality, in most cases, there have not yet 
been significant changes in the practical handling – since, in general, the authorities are 
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not interested in controlling research in detail. But there are exceptions. The Medical 
Biobank in Umeå is one case where the authorities have taken advantage of their power, 
and this has created severe conflict between the university and the county council on the 
one hand and the researchers who operate the biobank on the other. Even if this is an 
exceptional case, there is increasingly wide-spread concern among researchers 
regarding the harm this development will cause them. There are those who believe that 
“free research” is threatened and that Sweden’s leading position in biobanking and 
biobank-based research will be at risk. It remains to be seen whether this concern is 
justified. 
 
Privacy/data protection 
Like other Member States, Sweden has implemented the Directive 95/46/EC on the 
protection of individuals with regard to the processing of personal data and to the free 
movement of such data. The Personal Data Act from 1998, has been complemented by 
the Personal Data Ordinance (1998). There are a number of other Swedish laws which 
have relevance to the protection of personal data in relation to biomedical research: the 
Medical Care Registers Act, the Health Data Registers Act, and the Act on Research 
Registers for Forensic Psychiatry, the Security Act, and the Archives Act [8]. 
 
In a public law study relevant to the use of biobank samples, it was concluded that it is 
not entirely clear how biobank materials are looked upon in the legislation on data 
protection.35 In the traveaux préparatoires of the Swedish Personal Data Act, the 
processing of biosamples is not even mentioned. However, the government has declared 
that DNA samples and other parts of the human body should, in principle, be considered 
as living persons. At the same time, the borderline between a biological sample and a 
document is not that sharp in legislation – “at a time where DNA can be digitalised and 
many other characteristics of human tissue and cells can be registered in enlarged 
photographs etc.” The study also concluded that the borderline between the scope of the 
Swedish Biobanks Act and that of the Personal Data Act is rather vague. For example, it 
is not clear which of the laws gives precedence in case of conflict.  
 
Ethics discussion 
A public debate on biobanks suddenly arose in Sweden in the late 1990s. The 
background was the increasing interest in biobanks and genomics research shown by the 
biotech and pharmaceutical industry. In the spring of 1999, one of the major tabloids, 
Aftonbladet, run a series of articles on biobanks. Headlines such as “Your life is for 
sale”, “They make money on your cells” and “Swedish physician helped company to 
enter the biobanks” reveal a critical attitude towards the use of biobanks for research in 
general and industrial involvement in particular. It was, in fact, these articles that 
triggered the Swedish government to start an investigation into biobanks with a view to 
preparing new legislation. As a result, a Swedish Biobanks Act came into force in 
January 2003. Another reaction to this debate, was that academic research on ethical, 
legal and social aspects on biobanks was initiated. Since then, several research projects 
have been carried out by scientists from different disciplines (one example is the 
National Biobank Project mentioned above). Today, biobanks are one of the important 
research themes of the Centre of Bioethics at the Karolinska Institutet and Uppsala 
University. There is, thus, ongoing research and debate in the scientific community, 
                                                 
35 Ibid. 
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among experts and professionals, but one cannot say that there are any public debates 
on biobanks ongoing today.36 
 
2.2.1.2 Biobanks in Norway 
 
The following nine biobanks, in Norway, are covered in this study:  
 
⇒ JANUS Serumbank (Cancer Registry of Norway) 
⇒ HUBRO (Health Study of Oslo) 
⇒ OPPHED (Health Study of Oppland and Hedmark) 
⇒ HUNT Biobank (Health Study of Nord-Trøndelag) 
⇒ Tromsø Health Survey 
⇒ HUSK (Health Study of Hordaland) 
⇒ MoBa (The Norwegian Mother and Child Cohort Study) 
⇒ Sami Health Survey 
⇒ Women and Cancer 
 
There are many research biobanks in Norway at universities and research institutes. One 
of the oldest and best known is the so-called Janus Serumbank, which is owned and 
financed by the Norwegian Cancer Society. This biobank contains some 700 000 serum 
samples, collected from 1972 to 2005 from 330 000 donors. The purpose of the project 
is to search the material for changes that can help to discover the development of cancer 
at an early stage or indicate increasing risks for certain types of cancer. To date, the 
material has been used in more than 10 different studies, including in both national and 
international studies. For example, the Janus Biobank has been used in several EU-
funded projects (such as ERICBSB, VIRASKIN and CCPRP).  
 
Since the beginning of the 1970s, regional health surveys have periodically been carried 
out in different parts of Norway. For example, in Nord-Trøndelag surveys were 
conducted in 1984/86 and 1996/97, and a new one is planned for 2006/08. In more 
recent years, blood samples and data have, in some cases, been stored for research 
purposes. Today, biobanks built up linked to the following health studies constitute 
important resources for research: HUNT (Nord-Trøndelag), HUSK (Hordaland), 
HUBRO (Oslo), OPPHED (Oppland and Hedmark), and Tromsø Health Survey. 
Some of these biobanks (e.g. HUNT, owned by the Norwegian University for Science 
and Technology in Trondheim and comprising samples from 65 000 people) have 
already been used in a number of research projects. Other biobanks that started 
sampling later, have not yet come that far. Generally, these Norwegian biobanks have 
been positioned as resources for domestic researchers, but they are also available for use 
in international projects. 
 
A few years ago, CONOR (Cohort of Norway) was established by the Norwegian 
Institute of Public Health (FHI) as a network/umbrella organization for these five 
regional health surveys.37 The purpose is to achieve a national (population-based) high-
quality collection of biological material, as well as responses to standardized 
                                                 
36 A couple of years ago, a local debate took place in the County of Västerbotten regarding UmanGenomics and its 
right to commercialize the Medical Biobank in Umeå. The conflict, among the different parties involved, was 
covered by the local press and also, to some extent, by the national press. 
37 For more information on CONOR and the Norwegian health surveys, see www.fhi.no. 
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questionnaires. At present, CONOR has samples and data from approximately 185 000 
adults. 
 
CONOR is open to researchers, who can apply for data and samples from a central 
steering group. The data supplied to researchers, always collected with consent from the 
donors, are anonymized (although a key code is maintained by the FHI). If such data are 
to be combined with data from other registers or if analysis is to be carried out on the 
samples, permission from the Data Protection Agency is required. 
 
MoBa (Mother and child study) is another large-scale project of interest from the 
biobank-based research point of view. In this ongoing study, carried out by FHI and 
includes collection of blood samples, the goal is to follow 100 000 mothers and 
children. The purpose is to enable research on factors causing diseases in mothers and 
children. 
 
"The Sami Health Survey" and "Women and Cancer" are two relatively large research 
biobanks at the University of Tromsø. The former has so far been used only in domestic 
research projects, but the latter is part of EPIC38. 
 
With financial support from the Norwegian Functional Genomics Program, 
BIOBANKS FOR HEALTH (also called “Biohealth Norway”) has been formed as a 
network, or technology platform, for genetic epidemiological research. The platform, 
hosted by FHI, is built upon the biobanks in CONOR and MoBa and also involves the 
universities in Oslo, Bergen, Trondheim and Tromsø. The aim is to create a biobank 
with samples and data from 450 000 Norwegians from different ages, that is, 
approximately 10% of the population. Biohealth Norway is one party in a new 
collaboration between Norway and Great Britain. In October 2005 a Memorandum of 
Understanding was signed between FHI, the University of Bristol (responsible for the 
so-called ALSPAC study) and UK Biobank. The basic idea is to pool samples and data 
from the different biobanks and thereby improving the efficiency of research. 
 
Sample collections 
The collection of samples for the regional health studies is made at random and 
demographic specific. The actual work for the collection of samples and data is carried 
out by specifically employed staff and, in some cases, also by associated hospital staff. 
In addition the MoBa biobank, currently with samples from 166 000 mothers and 
children, is also random. For "Women and Cancer" and the "Sami Health Survey", 
which are two studies carried out at Tromsø University, the participant selection is a 
combination of random, disease-specific and demographic. The large Janus Serumbank 
has recruited participants among blood donors and people undergoing public health 
surveys. For these biobanks, the collection has been carried out by associated hospital 
staff and/or specifically employed personnel. 
 
Access availability and sharing of samples 
The health survey biobanks are used by researchers at the collecting institutions as well 
as from other institutions in Norway. Several of them are also used in international 
collaborative projects. As a rule, access to biobank material is associated with payment 
and in all cases, the decision to grant access is made by a governing board. Some of 
                                                 
38 http://www.iarc.fr/epic/  
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these biobanks allow cross-border sharing of both data and tissue but two of them 
(Tromsø Health Survey and HUSK) report that they only allow sharing of data. 
 
Both the Janus Serumbank and MoBa allow both tissue and data sharing with foreign 
researchers. 
 
Consent 
The regional health surveys use a variety of consent types, ranging from specific studies 
to biomedical research. One study (Tromsø) provides donors, in all cases, feedback of 
their personal results, while two others (HUSK and HUNT) do not. In these two other 
cases, this remains to be decided. With one exception (HUBRO), donors can withdraw 
their consent. 
 
The Janus Serumbank and MoBa use consent to research in certain areas and to 
biomedical research respectively. None of them give any feedback of personal results. 
Both the Sami Health Survey and Women and Cancer use different types of consent, 
again ranging from specific study to biomedical research. The former gives donors 
feedback of their personal results (in all cases), while the latter does not.  
 
All these four biobanks allow donors to withdraw their consent. 
 
Regulatory aspects 
Like in Sweden, a new Biobanks Act entered in force Norway in July 2003 and a 
national biobanks register will also be established. This work is now under way and 
according to current plans, the register will be completed by mid-2006. In this context, 
new research biobanks will require evaluation of a regional committee for medical 
research ethics and the Social and Health Directorate. The Medical Use of 
Biotechnology Act (1994) is another law of relevance. 
 
Privacy/Data protection 
The Norwegian Personal Data Act is in effect from 2000. 
 
2.2.1.3 Biobanks in Denmark 
 
The following fifteen biobanks, in Denmark, are covered in this study:  
 
⇒ The National Danish Birth Cohort 
⇒ The National PKU Biobank 
⇒ The Diet, Cancer and Health Biobank 
⇒ The Copenhagen City Heart Study 
⇒ The Copenhagen General Population Study 
⇒ The Copenhagen Ischemic Heart Disease Study 
⇒ The Copenhagen Carotid Stenosis Stroke Study 
⇒ The Copenhagen Breast Cancer Study 
⇒ The Danish Twin Registry 
⇒ NUGENOB 
⇒ ORG/ADIGEN 
⇒ Pelvic Mass 
⇒ HPV 
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⇒ The Danish Psychiatric Biobank 
⇒ Research Centre for Prevention and Health (Copenhagen County) 
 
It seems that the biobanking situation in Denmark is relatively similar to the one in 
Sweden. At large hospitals and universities there are many small research biobanks. The 
list above is not exhaustive but contains some of the more important biobanks, some of 
which are relatively large. One of them is the Diet, Cancer and Health Biobank (with 
samples from 57 000 individuals). This biobank constitutes the Danish part of the 
European Prospective Investigation into Cancer and Nutrition (EPIC). This biobank is 
owned by the Danish Cancer Society and used for epidemiological research, both in 
connection to EPIC and other national or international projects (e.g. the EU-funded 
DIOGenes). 
 
NUGENOB is an example of a more recently created research biobank. It was 
established through the 3-year long project financed by FP5 and coordinated by a 
Danish institution (NUGENOB = Nutrient-gene interactions in human obesity: 
implications for dietary guidelines). There were 12 partners in 7 European countries. 
Samples and data have been collected from 890 individuals. Material is stored in three 
places: Copenhagen (buffy coat and extracted DNA), Maastricht (serum and plasma) 
and Toulouse (mRNA). Information is stored in an intranet database. Today, the three 
NUGENOB biobanks are used by members of the NUGENOB consortium in multiple 
ongoing projects addressing related research questions. In the future, the biobanks may 
be used in other collaborative projects, as therehas been a considerable interest in 
collaboration with external users, both academics outside the NUGENOB grou and the 
industry. There are for example ongoing negotiations on access with the FP6 Network 
of Excellence NUGO. An important issue for the consortium that owns the biobanks is 
to obtain financial resources to support their maintenance and exploitation. 
 
The Danish Psychiatric Biobank is among several other valuable research biobanks.. 
This biobank, founded in 2001 and currently containing some 1200 samples, is located 
at St. Hans Hospital in Roskilde, where there is a research institute for biological 
psychiatry. However, recruitment of donors and sampling are carried out by several 
psychiatric departments and laboratories in greater Copenhagen. Thanks to this 
collaboration, individual studies can be based on larger sample sizes. Foreign 
researchers have shown a keen interest in this biobank. They can gain access to material 
by establishing collaboration with the Danish researchers. There are, today, 
collaborative projects with Brazil, Iceland, Canada, Norway and Sweden. Moreover, in 
collaboration with the Blood Bank at the hospital, the Psychiatric Biobank has 
established a collection of samples from 15 000 blood donors. These can be used as 
controls in the research. The use of anonymized DNA samples from these donors has 
been approved by the ethics committee. Access to this material can also be granted to 
researchers working outside the psychiatry. 
 
Like in Sweden, Denmark has a national PKU Biobank, which is hosted by Statens 
Serum Institut. Neonatal screening for several diseases has been carried out in Denmark 
in the last twenty years. After analysis, blood samples are stored in a biobank mainly for 
medical care reasons. These screening samples can also be used for research. However, 
we have no information as to what extent this potential has been exploited. 
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In the medical research community in Denmark, biobanks are generally considered to 
be a key facility, both for current and future researchers.39 One important reason is that 
Denmark, like for instance the other Nordic countries, has many high-quality registers 
covering the population (such as the national patient register, the cancer register, and the 
death cause register). This is believed to create excellent conditions for conducting 
biobank-based research – since it is possible to efficiently link the biological material to 
detailed and reliable information on the patient’s disease and treatment. In this kind of 
environment the individual can be followed `from womb to tomb´. It is also argued that 
the Danish population is interested in research and therefore it is possible for people to 
accept that biological material is stored and used for scientific purposes. 
 
At the Copenhagen University Hospital (“Rigshospitalet”), Denmark’s largest hospital, 
there are several existing clinical biobanks. Given the development of new molecular 
biological methods for diagnostics in recent years, there are now createing a central 
biobank function, called Rigshospitalet’s Biobank. The primary purpose is to collect 
DNA, plasma and fresh-frozen tissue for diagnostics and optimisation of treatment 
(such as personalized medication). A secondary purpose is to use the biobank for 
research, in accordance with informed consent from donors and after approval of a 
special steering group. It is expected that DNA and plasma samples will be collected 
annually from 45 000 patients. Tissue samples will be taken from 5 000 patients per 
year. In 2008 the finishing touches were made and the biobank is now in operation40.  
 
Sample collections 
Eight of the biobanks that replied to the survey make a random selection of participants. 
The other six are disease-specific biobanks. The former group of biobanks generally use 
several channels for sample collection, including associated hospital staff, specifically 
employed personnel and primary care workers. In addition, the Twin Registry uses self 
collection. The disease-specific biobanks use associated hospital staff with one 
exception – NUGENOB, which has specifically employed staff.  
 
Access availability and sharing of samples 
In the first group mentioned above, all but one biobank are open to researchers from 
Denmark as well as from other countries. The exception is the Danish HPV cohort 
which at least, so far, has been used only by the researchers who collected the samples. 
Four biobanks report that payment is a condition for access, at least in some cases. 
Access to the others is free. In most cases, access is restricted in some way, for 
example, to scientific relevance. One of the respondents writes: “anybody can submit 
proposals to the steering committee. If judged good science and we perceive no conflict 
of interest, usually even external researchers are given a go-ahead.” 
 
If we look at the disease-specific biobanks group, all of them are used both nationally 
and internationally (in some cases only in Europe). None of them require any payment, 
but like the former group, access is usually restricted, that is, requiring approval by a 
steering committee or similar body. For all the Danish biobanks in our study, decisions 
on access are usually made by either a governing board or a steering committee. In one 
case (The Danish HPV cohort) decisions are made by the principal investigator. Sharing 
of tissue as well as data is allowed in all cases. 
                                                 
39  Biobanker – fremtiden är begyndt (Biobanks – the future has begun), special issue on research, Hovedstadens 
Sygeghusfællesskab, November 2005. 
40 http://www.rigshospitalet.dk/RHenglish/Menu/Diseases+and+Conditions/New+biobank/ 
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Consent 
With a few exceptions, the type of consent used by the Danish biobanks is for research 
in a certain area and/or for biomedical research. One exception is NUGENOB, which 
asks the donors only to consent to the study. Some biobanks use blanket consent in 
combination with other broad types of consent (the Copenhagen General Population 
Study, the Copenhagen City Heart Study and the Danish Twin Registry). Moreover, 
half of the biobanks report that they send personal results back to the donors and the 
other half do not. All but one biobank (NUGENOB) allow donors to withdraw their 
consent. 
 
Regulatory aspects 
Denmark does not have a separate “biobanks act” in the same way as, for example, 
Sweden and Norway. Instead, biobanks are primarily regulated by the Processing of 
Personal Data Act. The Danish Data Inspection Agency has decided that biobanks are to 
be seen as manual registries (i.e. biobanks must be registered with the Authority). 
 
However, new rules for biobanks became in force in Denmark in May 2004 through 
Law No. 312 adding certain provisions to the existing Danish Legal Status of Patients 
Act (No. 482 from 1998). In 2005, new provisions were added once more. The new 
rules affect the use of biobanks in several ways. For example, patients can now decide 
whether or not they wish stored samples to be used for research. This decision is then 
entered into the so-called Tissue Use Registry (Vævsanvendelseregisteret). 
 
Also certain recent provisions to the Act on Research Ethics Committee System from 
2003 are of importance for the use of biobanks. The Act allows, for example, the use of 
broad consent when establishing new research biobanks. That is, samples cannot only 
be used in specific projects but also for other studies on the same type of disease.41 
 
To judge from comments made by interviewees, Denmark has the most “liberal” 
biobanks legislation in the Nordic countries, causing the least problems and bureaucracy 
from the researchers’ point of view. 
 
Privacy/Data protection 
In 2000, the EU Directive 95/46/EC on the protection of individuals with regard to the 
processing of personal data and on the free movement of such data, was implemented to 
national law through the Act on Processing of Personal Data. As already mentioned, in 
Denmark this Act plays a particularly important role for the use of biobanks. In fact, 
Denmark is unique- in having clearly and officially declared that biobanks are subject to 
personal data legislation. This seems to be the main reason why Denmark has not 
introduced general biobank legislation [8]. 
 
2.2.1.4 Biobanks in Finland 
 
The following five biobanks, in Finland, are covered in this study:  
 
⇒ KTL Biobank 
⇒ The Finnish Twin Cohort 
                                                 
41  For a short discussion on biobank legislation in Denmark, see ibid. 
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⇒ Helsinki Sudden Death Study (Tampere University) 
⇒ Tampere Coronary Study (TCT) 
⇒ Tampere Acute Coronary Syndrome (TACOS) Study 
 
In Finland, like in the other Nordic countries, there are many small research biobanks 
established by various researchers and research groups at the universities. Especially 
interesting about Finland is the role played by the National Public Health Institute 
(“KTL”) in the field of biobanking.42 KTL is a state-owned institute and expert body 
under the Ministry of Social Affairs and Health. It was established in its present form in 
1982, but has its roots in the Serum Laboratory founded in 1911. The aim of KTL is to 
promote the population’s possibilities to live a healthy life, and it provides professionals 
and citizens with information needed to make choices. In the end of 2004, KTL had a 
staff of about 900, of which more than one third (approximately 350 employees) 
worked as researchers. The budget for 2004 amounted to 62 million euros, 63%of which 
was covered by the state. External co-financing of research projects amounted to 15% 
of the budget. 4% of the funding came from the EU. 
 
Performing high-level research with broad international collaboration is one of the most 
important functions of KTL. Research is carried out at a number of various departments, 
such as Molecular Medicine and Epidemiology and Health Promotion. 
Collection of biosamples has been carried in connection to several studies carried out by 
KTL, often in collaboration with other research centres in Finland or abroad. The largest 
cohorts with biological material have their origin in the following studies: ATBC Study, 
FINNRISK, Helsinki Heart Study, Health 2000, Finnish Mobile Clinic Health, NPHI 
psychiatric cohorts and Finnish Maternity Cohort. 
 
To take one example, the ATBC study was a randomised, double-blind, placebo-
controlled study on lung and other cancers. From 1985 to 1988, 29 000 smokers were 
recruited. All of them gave written informed consent, and the study was approved by 
the institutional review boards of KTL and the National Cancer Institute in the US, 
which was a co-funder. Today, DNA has been extracted from more than 2 000 
participants, and blood for DNA extraction is collected from 22 000 participants 
altogether. Serum is available for analysis for all participants. The material has been 
used in several international collaborations such as the Harvard Cancer Pooling Project, 
the MORGAM project, which examines the gene-environment interactions for 
cardiovascular diseases, and the Nordic Biological Specimen Banks on Cancer Causes 
and Control. 
 
All samples collected in KTL projects are stored in a centralized biobank, which today 
contains DNA and serum/plasma samples from 200 000 Finns (approximately 5% of the 
population). This biobank constitutes an important national resource, increasingly used 
in international research projects in which Finnish researchers from KTL and other 
institutions are involved in. 
 
The list above includes some other large biobanks in Finland. The Finnish Twin 
Cohort was first established in 1974, to investigate genetic and environmental risk 
factors for chronic disorders. Several sub-studies concentrating on different phenotypes 
have been carried out at different universities. DNA collection and storage has been a 
                                                 
42 www.ktl.fi 
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routine feature since the mid-1990s. Currently, the biobank contains samples from 55 
000 twins recruited from 1974 to 1996. For the moment, there are no plans to expand 
the cohort. 
 
The twin biobank has been used in many international projects several of which have 
been funded from the EU through FP5 or FP6. Other studies have been funded by the 
National Institutes of Health in the US. Normally, samples are not sent abroad, but there 
are some exceptional subprojects where the genotyping has been done by foreign 
partners. Both DNA and phenotype data were shared with a US partner in a project, but 
this was then specifically covered in the consent form. 
 
Helsinki Sudden Death Study, Tampere Coronary Study and Tampere Acute Coronary 
Syndrome Study exemplify three smaller biobanks. The first one mentioned is a 
prospective consecutive autopsy study on acquired and genetic risk factors for sudden 
cardiac death and genetic factors for alcohol induced diseases. 
 
Sample collections 
The large KTL biobank contains samples which have been collected through both 
population-based and disease-based sampling. The institute has used its own personnel, 
specifically employed for different projects, as well as primary care workers. The 
individuals included in the twin cohort by definition are twins. Sampling is carried out 
by specifically employed staff. In the case of the Tampere biobanks, samples have been 
collected by the researchers themselves or other members of the study group.  
 
Access availability and sharing of samples 
The KTL biobank is used primarily by the researchers who have collected the samples 
stored in this biobank. These researchers may, however, be involved in collaboration 
with external research partners in Finland or abroad. The decision on access is made by 
a governing board at KTL. A research contract with KTL is required for external 
researchers to gain access to the material. International sharing of samples, as well as 
data, is currently difficult. There are problems with the interpretation of consents which 
are now being discussed in legal and advisory bodies. Until these uncertainties have 
been sorted out, no sharing of data or samples can take place. 
 
The Finnish Twin Cohort is used extensively for research including collaboration with 
foreign researchers. Access to samples, on which decisions are made by an official 
manager, is restricted based on the need and availability of data. Sharing of data, but not 
tissue, is allowed if made anonymously.  
 
The three disease-specific biobanks in Tampere are used not only by the researchers 
who collected the samples but, also by other Finnish and foreign researchers. Decisions 
on access are made by the researchers collecting samples. For two of these biobanks 
(TACOS and TCT), sharing of both tissue and data is allowed. For the third biobank 
(Helsinki Sudden Death Study) only data can be shared. 
 
Consent 
The samples in the KTL Biobank have been collected in connection to various studies 
for which study-specific consents have been obtained. No information on personal 
results is fed back to individuals. For the Twin Cohort, the type of consent varies from 
specific studies to biomedical research depending on the sub-study. Information is 
Biobanking activity                    
   45
reported back to donors, if consented to. The TACOS study uses the process of consent 
to research in a certain area or biomedical research. No personal information is fed 
back. For the other two biobanks in Tampere there is no need for consent procedures at 
all as the samples have been taken from dead persons. In all cases, except the two latter, 
donors can withdraw their consent.  
 
Regulatory aspects 
An Act on the Medical Use of Human Organs and Tissues (No 101/2001) came into 
force in Finland in  2001. However, this act is primarily concerned with the use of 
organs and tissue for transplant purposes. Importantly, in the same year another act (No 
32/201) regulating the activities of the National Public Health Institute (KTL) came into 
effect in Finland. This law is of great relevance to biobanking, given the key role played 
by KTL in this kind of activity. For example, it gives KTL the possibility, under certain 
circumstances, to build and use biobanks without individual informed consent (e.g. 
archived samples from maternity screening). In Finland, KTL is in charge of many 
activities which in other countries are carried out by other actors (e g. healthcare 
providers and universities). Therefore, other countries, in general, do not have the 
prerequisite for making the same type of legislation [9]. 
 
Privacy/Data protection 
The EU Directive 95/46/EC on the protection of individuals with regard to the 
processing of personal data and on the free movement of such data was implemented to 
national law through the Personal Data Act (1999). In 2000 the Act on the Amendment 
of the Personal Data Act came into effect. 
 
2.2.1.5 Biobanks in Iceland 
 
The following five biobanks, in Iceland, are covered in this study:  
 
⇒ Icelandic Biobank (deCode) 
⇒ UVS Biobank (decode) 
⇒ The Icelandic Cancer Society Biological Specimen Collection 
⇒ Reykjavik Heart Study 
⇒ Tissue Archives, University Hospital 
Iceland is an interesting country from a biobanking perspective. Its plan to create a 
national Health Sector Database (HSD) has attracted a great deal of attention far outside 
the country. One reason is that the right to build and run this database was licensed out 
to a private Icelandic company, deCode genetics43. This is a biotech company founded 
in 1996. Based on certain unique characteristics of the Icelandic population and using a 
human genetics approach, deCode conducts research into the inherited causes of 
common diseases. At the beginning, deCode could be characterized as a “clinical 
genomics company” with the business idea to sell results from its genomics research 
(e.g. identified disease genes) to other companies, mainly in the pharmaceutical and 
diagnostics industry. Over the years, the business strategy has drifted, which means that 
deCode has now integrated forward to become a developer of new drugs and DNA-
                                                 
43 The parent company has its legal site in Delaware, USA, but most of the operations are carried out in Iceland by 
Icelandic employees. The company is also carrying out research in the US in acquired companies. 
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based diagnostic products. It also offers a range of related services to the 
pharmaceutical industry and the healthcare sector.44 
 
DeCode was founded on the assumption that Iceland offered unique opportunities to 
carry out clinical genomics research, thanks to the following four national 
characteristics: 
 
• availability of genealogical records dating back, in some cases, to the settlement 
of the country in the ninth century. 
• relative genetic homogeneity of the population, that is, clear “founder effects” 
facilitating the identification of disease genes. 
• a centralized healthcare system since 1915. 
• a well-educated population that tends to be cooperative when approached by 
physicians and medical researchers. 
 
Dr Kari Stefansson, who founded deCode together with Jeffrey Gulcher, had two 
objectives. One was to establish a commercial company to carry out research where 
genetic information, obtained by analysing human biosamples, would be linked with 
clinical information and genealogies. The second objective was to construct a large, 
computerized database containing genetic, genealogical and phenotype information on 
the Icelandic population. 
 
In the context of its gene and drug target discovery programs on some fifty diseases, 
deCode has collected a large number of biosamples and related donor information, 
through collaboration with hundreds of Icelandic general and specialist physicians. 
These collections together make up deCode’s biobank, named “Icelandic Biobank”. In 
total, this biobank today contains samples from more than 100 000 persons (i.e. over 
half of the adult population; the response rate has been high, meaning that over 90% of 
individuals contacted have agreed to participate).  
 
All stored samples and data have been obtained after receiving explicit consent from the 
donors (these can choose whether they wish their samples to be destroyed after the 
study’s completion or allow to store them for future use; a large majority of the 
participants choose the latter alternative). Collected samples and data, in combination 
with information from the genealogy database, are used by the company in its own 
research projects for which it has obtained approval from the National Bioethics 
Committee and the Data Protection Authority (DPA). To protect the integrity of the 
donors, deCode uses, in accordance with the regulation, an advanced third-party identity 
encryption system. It ensures that all information on individuals (genetic, medical and 
genealogical) employed in the research is “anonymized”, that is, only identified by an 
encrypted ID code generated and kept by the DPA. 
 
The research projects carried out by deCode, either in-house or in collaboration with 
external scientific partners, have resulted in the identification of a large number of drug 
targets in many of the most common diseases, such as heart attacks, strokes, 
                                                 
44 The text on deCode in this section partly builds on an unpublished research report written by Jens Laage-Hellman, 
Chalmers University of Technology (“Commercialization of biobanks: a study on biotech companies dedicated to 
human genetics”, 2003). Information on the company can be obtained from its website, www.decode.com. 
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hypertension, asthma, schizofrenia, type 2 diabetes and prostate cancer. Many of these 
targets now serve as the basis for deCode’s drug discovery and development programs. 
 
As to the second business objective mentioned above, deCode was awarded, in 2000, a 
12-year exclusive licence by the Icelandic government to build, operate and 
commercialize a Health Sector Database (HSD). The basic idea of this database is to 
assemble encrypted data from medical records of the National Health Service and store 
it in high-security computer systems. Participation is based on the principle of presumed 
consent, but there is a possibility to opt-out for citizens who do not wish to participate. 
The intention is that the database should enable users, including deCode (the licensee) 
and others (e.g. Icelandic physicians), to conduct population-based analysis of 
longitudinal healthcare data and trends. In particular, it is thought that combining 
information from this database with genealogical data and genetic data, available in two 
other databases, would give valuable opportunities to study the impact of environmental 
and genetic factors in common diseases. 
 
This project and the related legislation have triggered an intensive debate in the country 
and has attracted attention by the mass media, both in Iceland and abroad. There has 
been criticism regarding issues such as consent procedures, confidentiality and scientific 
openness. Partly resulting from the debate, the HSD Act underlying the licence requires 
a very high level of security, both with regard to the database itself and the combination 
of its content with other data. deCode, various government authorities (especially DPA) 
and the healthcare providers have been involved in long-lasting and complex 
discussions and negotiations regarding security and other issues related to the 
excecution of the project. Still, many problems remain to be solved. This is why the 
actual work on the transfer of data to the HSD has not yet begun. It seems that the 
extremely strict security targets will make the database very expensive to operate and 
will also reduce its scientific usefulness. The question is to what extent deCode and 
others will be able to use it as an efficient research tool. Therefore, there seems to be an 
increasingly widespread belief that the project will never be undertaken, at least not in 
the intended form. deCode, though, still holds the licence. However, the company does 
not dependent on the HSD for its development and growth. As described, it is already 
carrying out population-based genetic studies using data it has collected by its own 
means. 
 
Outside Iceland, there is a common misunderstanding that there exists a national 
biobanking project in Iceland. However, as we have seen, the planned HSD is another 
type of database, although it is intended to be linked with genetic data originating from 
the analysis of biosamples. The biobank has been built separately by deCode through a 
number of disease-specific studies. Over the years, deCode has in this way collected 
such large number of samples that the biobank can now be described as being 
population-based. 
 
Urdur Verdandi Skuld (UVS) is another, smaller clinical genomics company in 
Iceland founded in 1998. UVS is using a similar population-based research approach as 
deCode, but is entirely focused on cancer. UVS is carrying out the Icelandic Cancer 
Project together with some 50 clinicians, the two largest hospitals in the country and the 
Icelandic Cancer Society. With help from its clinical collaborators, UVS has collected 
blood samples and tissue. At present, the biobank contains material from 22 000 
individuals, including 6 000 cancer patients. It has been used in several collaborative 
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projects both with pharmaceutical companies and academic institutions. UVS has, for 
example, received a grant from the EU (3 million euros) to study the genetics of breast 
and prostate cancer. In January 2006, deCode acquired UVS in order to enhance its own 
cancer program. This means that deCode, today, has two different biobanks for which 
they have separate licences from the Icelandic government. 
 
There are, as indicated in the list above, a few other important biobanks in Iceland. 
Reykjavik Heart Study is a prospective health study of heart diseases carried out, 
since 1967, by the private Icelandic Heart Association (IHA), which has its own 
research institute. The study comprises 31 000 men and women, many of whom have 
supplied serum and DNA samples now stored in IHA’s biobank. The biobank and the 
rich amount of clinical and lifestyle data collected are used in different studies, some of 
which are carried out together with foreign partners, such as the US National Institute 
on Aging. IHA is also one of deCode’s domestic research partners. 
 
Another large biobank, comprising 12 000 individuals, is owned by the Icelandic 
Cancer Society. This organization is one of UVS’ partners, and it is also involved in 
several international projects some of which are funded by the EU (e.g. Breast Cancer 
Linkage Consortium and International BRCA1/2 Carrier Cohort Study). 
 
The largest biobank in Iceland is the Tissue Archives at the Pathology Department of 
the University Hospital in Reykjavik. Since 1935 tissue specimens from approximately 
200 000 individuals have been collected. This is a clinical biobank, but it is also used 
for research purposes (after approval by the National Bioethics Committee and DPA, 
and usually on the condition that informed consent is obtained from the patient). The 
biobank has been used in numerous academic studies, some of which have been carried 
out together with partners in Europe and the USA. deCode has also used tissue samples 
from this biobank in some projects. 
 
Sample collections 
The selection of donors for deCode’s two biobanks as well as for the Icelandic Cancer 
Society’s biobank is both random and disease-specific. The Tissue Archives consist of 
all histopathological specimens accessioned. 
 
The Icelandic Cancer Society (like the Icelandic Heart Association) has its own staff 
that carrying out the sampling. Interestingly, deCode and UVS have created special 
centres which play an important role in the collection of samples and data. In 
accordance with requirements from the DPA, both of them have created service units to 
which the donors are invited. These service units are non-profit organizations, financed 
by the companies but physically and organizationally separated from the rest of the 
companies. The personnel of these units encode samples and information using methods 
approved by the DPA. The key code is kept by the DPA. 
 
Access availability and sharing of samples 
While the Icelandic biobank is used in deCode’s own projects (sometimes undertaken 
together with others), the UVS biobank is used in several collaborative project, both in 
Iceland and with foreign partners. Both the Tissue Archive and the collection of the 
Icelandic Cancer Society are seen as national resources. The latter is also available to 
foreign researchers with active collaboration in the Society. 
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In all cases, access to samples is restricted. Approval is required by the DPA and the 
National Bioethics Committee. Sharing of samples takes place only within the context 
of collaboration, on a person-unidentifiable format and after approval of the authorities. 
According to deCode and UVS, samples are normally not shared with collaboration 
partners – it is more common that only results are shared. In the former case, informed 
consent is always required from donors. 
 
Consent 
Icelandic law requires people to give informed consent if samples are to be stored in a 
biobank. But if the biosample has been obtained for clinical reasons, tests or treatment, 
then presumed consent will be sufficient. In line with existing regulation, deCode asks 
donors to give consent to a specific study while UVS, as well as the Icelandic Cancer 
Society, use a broader consent procedure covering a whole research area (cancer). The 
Tissue Archive does not need explicit consent. Commenting on the different rules 
applying to research and clinical biobanks, an Icelandic ethics scholar states that this 
difference has been criticized and also affected people’s willingness to give their 
consent. Except for the Tissue Archives, which is a clinical biobank used primarily for 
medical care purposes, personal information is not referred back to the donors. In all 
cases, it is possible for donors to withdraw their consent. 
 
Regulatory aspects 
In May 2000, the Icelandic parliament passed an Act on Biobanks whereby Iceland 
became the first country in the world to construct legal guidelines for scientific and 
clinical biobanks. In the following year, this law was complemented by Regulations on 
the Keeping and Utilization of Biological Samples in Biobanks. The Act on the 
Icelandic Health Sector Database (HSD) was passed in 1998. In 2000, the same year in 
which the licence was granted to deCode, the Government Regulation on a Health 
Sector Database came into effect. 
 
Privacy/Data protection 
In 2000, an Act on the protection of Privacy as Regards the Processing of Personal Data 
came into force in Iceland. This Act gives the Data Protection Authority an important 
role with regard to biobanks. 
 
Ethics discussion 
An ethics debate related to biobanks has primarily taken place in connection to the HSD 
project. The passing of the bill in 1998, which gave the government the possibility of 
granting an exclusive licence to a private company, was preceded by a 9-month 
intensive debate, both within the parliament and outside. Criticism put forward by the 
Icelandic Medical Association, among others, led to several changes in the bill 
compared to the original proposal. For example, an opt-out clause was included. 
However, despite these changes the whole HSD project, and related legislation, became 
subject to continued criticism and discussion, both domestically and internationally. 
Among other issues, concern has been raised regarding consent procedures, privacy and 
confidentiality, scientific openness and the appropriateness of monopolizing the 
database. A result of the debate is that the HSD Act demands very high level of 
security. There is no doubt that the delay in executing the project is related, inter alia, to 
the tough, cost-driving security targets and complex monitoring system to be put in 
place. 
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It is interesting to note that while the HSD project has caused such an intensive debate, 
there has not been much public discussion on the Icelandic Biobanks Act. It can be 
argued that biosamples contain more sensitive information on the individuals (e.g. 
genetic data) than the proposed database.  
 
2.2.1.6 Biobanks in the Baltic countries 
 
There are two particularly interesting biobanks in the Baltic countries created in 
connection to genome research initiatives:  
 
⇒ Estonian Biobank 
⇒ Latvian Genome Database 
 
The best known of these initiatives is the Estonian Genome Project (EGP), which has 
been mentioned or described in several news and journal articles during the last years. 
This population-based research project was started in 2001, very much inspired by 
developments in Iceland. The goal is to create a database of health, genealogy and 
genetic data that would comprise a large part of the Estonian population. The database 
will be used for carrying out research on linkages between genes, environmental factors 
and common diseases – thereby making new discoveries in genomics and genetic 
epidemiology and contributing to improved healthcare. The project is run by the 
Estonian Genome Project Foundation, which is a non-profit government organization. 
The databank is available for research both in Estonia and outside. 
 
A pilot study including collection of blood samples started in 2002. To date, samples 
and associated data of the donors from approximately 10 300 individuals have been 
collected. The target number is 100 000 individuals, to be achieved in 2010 at the latest. 
This means that the database will comprise nearly 10 % of the Estonian population. 
 
DNA samples and data have been used for research since 2004. Up to now EGP has 
been involved in approximately ten studies, some of which are international. 
 
A somewhat similar initiative to create a national genome database has been taken in 
Estonia’s neighbour country Latvia. Sampling started in the same year (2002). 
However, the target number of participants seems to be more modest than in Estonia. 
The current size of the biobank and databank is 2 500 individuals. There is no specified 
limit on the size. Another difference is that the Latvian biobank is, primarily, intended 
for research carried out in Latvia. This means that, so far, none of the more than ten 
studies carried out have been carried out at international level. 
 
Sample collections 
While the Estonian Biobank collects samples randomly, the Latvian Biobank selects 
participants based on specific diseases or conditions. In both cases, the collection is 
carried out by primary care workers. 
 
Access availability and sharing of samples 
As already mentioned, the Latvian Genome Database is seen as a resource for domestic 
research while the Estonian Biobank is also open for international collaboration. Access 
to the latter is free for academic researchers. However, commercial companies have to 
pay a fee. The use of biosamples from the Latvian biobank is always free but every 
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project has to be approved by the Central Committee of Ethics and the Genetics 
Research Board., There is no legal barrier to cross-border sharing of samples or data in 
these countries. 
 
Consent 
The Estonian Biobank asks its donors to give broad consent to biomedical research. In 
Latvia, donors consent to a specific study or research in a certain area. Information of 
personal results is sent back to donors if consented to. Donors have the right to 
withdraw their consent if they wish. 
 
Regulatory aspects 
Estonia has not adopted a specific law governing all kinds of human research, as the 
ratification of the Biomedicine Convention 1997 is considered sufficient [10]. But 
Estonia, like Iceland, has enacted a special act to cover its genome project: Human 
Genes Research Act (2000). There is no special law regulating the use of human 
biological material in Latvia or in Lithuania. However, there is a Human Genome 
Research Act (2003) in Latvia 
 
Privacy/Data protection 
There is a Personal Data Protection Act (1996) and a Databases Act (1997) in Estonia. 
Similarly, Latvia has a Personal Protection Law (2000) and Lithuania has an Act on 
Legal Protection of Personal Data (2003). 
 
Ethics discussion 
As already mentioned, the Estonian Genome Project (EGP) started with inspiration 
from developments in Iceland – with deCode and plans for a national Health Sector 
Database. But in designing the project, people and organizations behind EGP have tried 
to learn from the Icelandic case to avoid creating the same type of controversy. 
Developing a good relationship with the public and others concerned has, therefore, 
been given high priority. The aim is to be an active party and give as much information 
as possible to all target groups. EGP also includes a strong educational component, i.e. 
informing the public on genetics and developments in the field of gene technology and 
biotechnology in general. 
 
Ever since 1999, Estonian as well as the foreign media has expressed considerable 
interest in EGP. This has resulted in hundreds of articles both in newspapers and science 
magazines.45 In general, it seems that the attitude of both Estonian and the foreign 
media towards the project has been positive. But there have also been some critical 
analyses. It has, for example, been questioned why millions of Estonian crowns are 
poured into EGP at the expense of the overall health care. Independence of the ethical 
committee has also been called into question. 
 
Several investigations have been carried out in order to establish awareness levels and 
opinions of the Estonian population regarding EGP. According to information available 
on EGP’s homepage, a study carried out in March 2003 showed that 65% of the 
population was well-informed. Only 2% of the inhabitants in the counties where the 
pilot study took place said they were against the project. 
 
                                                 
45  Many articles can be accessed through EGP’s own website, www.geenivaramu.ee.  
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2.2.1.7 Biobanks in the UK 
 
The following twelve biobanks, in the UK, are covered in this study:  
 
⇒ Generation Scotland: Genetic Health in the 21st Century  
⇒ Generation Scotland: Scottish Family Health Study 
⇒ EPIC Oxford 
⇒ UK Women’s Heart Study 
⇒ Twin Research Unit Laboratory 
⇒ National study of colorectal cancer 
⇒ International familial CLL consortium 
⇒ Liverpool Lung Project 
⇒ EUELC (Early lung cancer) 
⇒ UK DNA Banking Network 
⇒ UK Cord Blood Bank Ltd 
⇒ Oxagen Ltd46 
 
The UK has an advanced publicly funded healthcare system and many prominent 
universities. Large public and private resources are invested in medical and 
biotechnology research, and it can, therefore, be assumed that there are many 
collections of human biosamples built by various academic research groups. Like in 
other countries, most of these biobanks are relatively small, but there are also some 
large ones. The most important research biobanks are presented in this report (although 
the list is non-exhaustive).  
 
Undoubtedly, there is a large and increasing interest in biobanking in the British 
research community. Such activities have, for many years now, been actively supported 
in different ways by e.g. the Medical Research Council (MRC), the largest public 
financier of medical research in the UK. For example, following the mapping of the 
human genome in 2000, the MRC identified genetic epidemiology as a strategically 
important research area. Among other initiatives, the MRC made awards to enable 
collection of large numbers of samples in 13 common diseases. As will be described 
below, these samples are now stored and managed centrally as national resources. 
 
Other relatively large population-based biobanking projects under way is Generation 
Scotland. Sampling for the main study (Scottish Family Health Study) has recently 
begun (the current size of the repository is 24 individuals!). The aim is to have achieved 
by 2011 a family-based cohort comprising 50 000 individuals and approximately 10 000 
families. The biobank will be used for studying the genetics of health areas of current 
and projected public health importance, such as heart and mental diseases. Samples and 
data will be made available anonymously to Scottish researchers. It is envisaged that 
these will use the resource in collaborative projects with colleagues from other countries 
around the world. In a separate study Generation Scotland will build a “random 
population biobank” with samples from 2 500 individuals. The objective is to establish 
the genetic profile of a control population of people living in Scotland. It is a family-
                                                 
46  We have not received a questionnaire from this company but, have useful information on the company’s biobank 
activities thanks to previous research. 
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based study, those registering interest are then asked to determine the interest of other 
adult family members.47 
 
Two English universities, Cambridge and Oxford, are participating in the international 
EPIC project on cancer and nutrition. The two UK cohorts, recruited from the 
general population, consist of 30 000 and 57 000 participants respectively (recruited 
from 1993 to 1999). The Oxford centre has collected blood samples from 20 000 
individuals. These are stored in several locations in the country.48 
 
The UK Women’s Heart Study and the Twin Research Unit Laboratory at St 
Thomas Hospital are two other relatively large research biobanks in the UK. The 
former, located at the University of Manchester’s Cardiovascular Research Group 
Division, comprises samples from 20 000+ individuals. The participants are female 
employees of Marks’ and Spencer’s shops throughout the country. The sampling took 
place from 1988/1991. The database, which is of the stand-alone type, contains a broad 
set of data (medical, demographic, environmental, and socio-economic and ethnicity). 
So far, the biobank has only been used by the researchers who collected the samples, 
which has produced around ten publications. The research group is now seeking funding 
for DNA extraction, the creation of a permanent biobank and for the collection of 
follow-up data (lifestyle and health questionnaires; checking death certificates etc.) and 
data entry to convert this into a prospective study. 
 
The list above includes some independent disease-specific biobanks. These should be 
seen mainly as examples, since there are many others not covered by our mapping. 
 
The UK DNA Banking Network (UDBN)49 is an interesting biobanking venture. This 
is not a research project in itself but, a biobanking infrastructure set up in collaboration 
between scientists and funded by the Medical Research Council (MRC). The basic idea 
is to offer scientists, carrying out case-control or family studies on particular diseases, a 
modern and efficient infrastructure for management of samples and data. The studies 
are carried out by 13 independent groups of clinical scientists who collect blood 
samples and data from their research subjects (in a given disease area). The UDBN has 
been given the task to manage samples, as well as data, so as to ensure that these are 
kept uniformly and safely and used in an efficient way. DNA samples are managed at 
UDBN’s archive in the University of Manchester’s Centre for Integrated Genomic 
Medical Research (CIGMR). Cell samples are managed at the Health Protection 
Agency’s European Cell and Culture Collection in Salisbury (ECACC). The 
responsibility for data management means creating links between databases holding 
clinical, sample and experimental data. The custodianship (ownership) of both samples 
and data remains with the collectors (clinicians). 
 
UDBN’s archive was set up in 2003. The DNA extraction is carried out either by the 
sample collector or by the archive. At present, the archive stores samples from 25 000 
individuals. The target size is 40 000 individuals, but the total capacity of existing 
facilities is over 100 000 samples. The samples and data stored by UDBN can be 
accessed by other researchers in the UK or abroad who want to establish collaboration 
                                                 
47 www.generationscotland.org 
48 We have not managed to get the corresponding information regarding the Cambridge cohort. 
49 www.dna-network.ac.uk 
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with collectors. Access requires registration as a network user, technical, scientific and 
ethical approval and the payment of a fee for labour and consumables.50 
 
The UK Biobank project51, a national prospective study of genes, environment and 
health proposed in the late 1990s, has received much publicity during the last 5-6 years. 
It is probably the world’s largest project of this kind and aims to create a unique and 
powerful resource for genetic epidemiological research. Following two years of 
planning, the original three partners – the Wellcome Trust, the MRC and the 
Department of Health – agreed in April 2002, to establish the biobank at an estimated 
cost of £63 million52. Using information from DNA samples and medical records of 500 
000 volunteers, aged 45-69, the study would capitalize on the sequencing of the human 
genome accomplished by the Human Genome Project. 
 
The aim of this long-term project is, thus, to build a comprehensive resource for 
medical research on susceptibility genes, gene-environment interaction, disease 
pathways and genetic markers. It is expected that the biobank project will provide 
healthcare providers and government with information, helping them to improve the 
health service for future generations. 
 
Having completed a pilot study comprising 318 individuals, the recruitment of 
volunteers through general practitioners throughout the country began in 2006. It is 
expected that the full recruitment of the 500 000 participants will be completed by 2011. 
In addition to physical examination and blood samples, taken after having obtained a 
written consent, information on the donors’ lifestyle will be collected through 
questionnaires and interviews. Medical information will be obtained by links to medical 
records and other databases in the public sector. The recruitment of volunteers and 
collection of samples and data are managed by 6 regional collaborating centres, each 
consisting of a network of academic and research institutions. In total, 22 universities 
will be involved in these centres. It is envisaged that the biobank, during the coming 
decade, will be used in many different research projects dealing with various diseases. 
However, only studies that are scientifically and ethically fully approved, will be 
allowed to use the biobank. 
 
With regards to the organization and governance of the project, the UK Biobank is 
hosted by the University of Manchester but it is centrally managed by a charitable 
company, UK Biobank Ltd, which coordinates the activities of the 6 collaborating 
centres. The headquarters, based in Cheadle, is responsible for delivering the project, 
including data management and quality assurance, computing, financial management 
and formal custodianship of samples and data. Overall responsibility for the direction, 
management and control of the project lies with a board of directors accountable to the 
MRC and The Wellcome Trust. The board also receives advice from a science 
committee and the Ethics and Governance Council (EGC). The creation of such an 
oversight body, entirely separated from the management structure of the biobank, is a 
unique feature of this project. The role of EGC is to act as an independent guardian of 
the UK Biobank, to safeguard the interests of the participants and the wider public and, 
to ensure good ethical practice. The funders are well aware of the fact that this type of 
                                                 
50 http://www.dna-network.ac.uk/From+registration+to+access/. 
51 www.ukbiobank.ac.uk 
52 Besides the three founding organizations, the UK Biobank is currently also funded by Scottish Executive and the 
Northwest Regional Development Agency.  
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study, to be carried out over a long period of time, raises many ethical concerns. 
Therefore, to set a high ethical standard they have committed to developing a public 
Ethics and Government Framework (EGF). A description of the EGF can be found on 
UK Biobank’s homepage.53 
 
Biobanks in the pharmaceutical and biotech industry 
There are several large pharmaceutical companies with major R&D units in the UK. As 
already mentioned, due to “the genetic revolution”, human biobanks have become 
important resources for drug discovery and pharmacogenomic studies. It is well-known 
that large pharmaceutical firms collect samples and data in connection to clinical trials 
and other projects. Since these collections are regarded as proprietary assets, it is in 
general difficult to get information about them. Therefore, we have not even tried to 
include such biobanks in our mapping. As described in the above section on Swedish 
biobanks, it is common that pharmaceutical firms collaborate with academic researchers 
having access to publicly owned biobanks at universities and hospitals. It can be 
assumed that this mode of industrial biobank use is frequently used also in the UK. 
 
Oxagen Ltd54 is a genomics and drug discovery company using an interesting approach 
to biobanks [11].55 This company, originally a spin off from Oxford University and the 
Wellcome Trust Centre for Human Genetics, has established collaboration with some 
30 academic groups in the UK and other European countries. The clinical partners 
collect samples and data locally and carry out research in collaboration with Oxagen 
and, sometimes, with other industrial partners. Although the researchers retain the 
custodianship of the samples, these are physically stored in Oxagen’s biobank. Oxagen 
has invested in state-of-the-art facilities for biobanking and carry out high-throughput 
genotyping on the material. All together, the collections managed by Oxagen in 2003 
comprised samples taken from some 34 000 individuals in different countries. 
 
PROCARDIS can be mentioned as an example of a project where Oxagen has worked 
with multiple centres, namely from the UK, Germany, Italy and Sweden. The 
international project group, also supported by AstraZeneca, has collected and genotyped 
samples from 4 000 families (15 000 individuals) with the purpose of studying the 
genetic factors behind coronary artery disease. In accordance with the company’s 
policy, the samples were collected with appropriate informed consent from the donors. 
The samples were coded by the collecting institutions before being sent to Oxagen for 
storage and analysis. 
 
Cord blood banking 
The list of biobanks includes one cord blood bank: UK Cord Blood Bank Ltd 
(UKCBB).56 It is part of the New England Cryogenic Center founded in Boston, USA in 
1982. This company expanded its cryogenic storage services to include cord blood stem 
cells in 1995 by establishing the New England Cord Blood Bank, Inc. UKCBB was the 
first private cord blood bank in the UK and has provided cord blood processing and 
storage services to clients throughout Europe since 2000. 
 
                                                 
53 www.ukbiobank.ac.uk/ethics/efg.php 
54 www.oxagen.com. 
55 Laage-Hellman, J., “Commercialization of biobanks: a study on biotech companies dedicated to human genetics”, 
Chalmers University of Technology, 2003 (unpublished research report). 
56 www.cordbloodbank.co.uk. 
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UKCBB currently utilises the 45 000 square foot laboratory and cryogenic facility in Boston. 
This facility is accredited by the American Association of Blood Banks (AABB), registered 
with the US Food and Drug Administration (FDA) and licensed by the states of Massachusetts 
and New York, signifying adherence to the highest international standards of quality and 
excellence. 
 
UKCBB is in the process of setting up a dedicated processing and storage laboratory 
which is part of The University of Manchester’s Core Technology Facility. While the 
company does not currently undertake any research (the cord blood stem cells are stored 
on behalf of parents who retain full ownership of them), it intends to participate in 
research, once its facility is fully established. The company collects blood from clients 
in different European countries. It does not experience any problems per se in this 
regard. However, it is mindful of the regulations in place in various EU countries (e.g. 
Italy) governing the transport of cord blood samples. 
 
Sample collections 
We can identify two main groups of biobanks. The following biobanks select 
participants randomly: Generation Scotland (both biobanks), EPIC Oxford, Liverpool 
Lung Project (LLP) and the UK Cord Blood Bank. The following ones are disease-
specific: UDBN, EUELC, International familial CLL consortium, National study of 
colorectal cancer and Oxagen. The Twin Research Unit and UK Women’s Heart Study 
use other criteria, as explained above. 
 
Most biobanks use a combination of several channels to collect samples, typically 
including hospital staff, primary care workers and staff specifically employed for the 
project. 
 
Access availability and sharing of samples 
There are five biobanks presently only used by the researchers who collected the 
samples: EPIC Oxford, UK Women’s Heart Study, EUELC, CLL consortium and 
National study of colorectal cancer. The others are used also in domestic or 
international collaborative projects (except for the UK Cord Blood Bank currently not 
used for research). 
 
Besides the UK Cord Blood Bank, which is a commercial biobank, only Generation 
Scotland reports that access to samples may be associated with payment. However, for 
most biobanks there are other restrictions for access, such as collaboration with the 
responsible organization. Decision on access is usually made by a governing board or 
an official manager but, in some cases, it is the principal investigator who is in charge. 
In the case of UK Cord Blood Bank, the Chief Scientific Officer is the decision maker. 
It should be noted, though, that stem cell samples are wholly owned by the parents, who 
are able to arrange access to their samples at any time. 
 
Most biobanks report that they are allowed to share samples, as well as data, with other 
researchers outside the country. An exception is Generation Scotland that only allows 
sharing of data. 
 
Consent 
About half of the UK biobanks ask for consent to a specific study or a certain research 
area (e.g. lung cancer). Both EPIC Oxford and the Twin Research Unit, apply a broader 
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type of consent procedure. Interestingly, three biobanks use blanket consent. With the 
exception of Generation Scotland, which gives feedback of personal results in all cases, 
other biobanks do not. With the exception of the Twin Research Unit, in all other 
biobanks surveyed donors can withdraw their consent to store samples in the biobanks. 
 
Regulatory aspects 
On 15 November 2004, the Human Tissue Act obtained Royal Assent. The background 
was that the previous law on removal, retention, and use of human tissue contained 
many uncertainties (e.g. proved in connection to several organ retention scandals in the 
country, such as the one at the Alder Hey Hospital). The government’s response was to 
draft an entirely new bill. In the subsequent debate, this bill was criticized by the 
research community fearing that the proposed bill would compromise medical research. 
For example, scientists were concerned that it would outlaw the use of any human tissue 
for research without the patient’s explicit consent. Modifications to the bill meant that 
patients could be presumed to have given consent unless explicitly having stated the 
opposite. But such tissue samples would only be possible to use on the condition that 
the patient’s identity is protected and that the study has been officially approved.  
 
The new Act deals broadly with the removal, storage and use of human organs and 
tissue, which means that it also has important implications for the use of biobanks in 
research. An important result of the Act is the establishment of the Human Tissue 
Authority (HTA).57 This is a new public body the role of which is to regulate the 
removal, storage, use and disposal of human bodies, organs and tissue for a number of 
“scheduled purposes” set out in the Human Tissue Act and in regulations. As part of 
this, the HTA issues Codes of Practice to ensure that best practice is adhered to. 
Moreover, the HTA is responsible for licensing a number of activities (including all 
forms of transplants from living donors) and carrying out inspections, to ensure licence 
conditions are met. These licensable activities are: 
 
• the storage of human bodies for anatomical examination and related research. 
• the carrying out of post mortem examinations, including removal and storage of 
human tissue.  
• the removal of tissue from the body of a deceased person for scheduled purposes 
except transplants.  
• the storage and use of human bodies or parts for public display.  
• the storage of human tissue for other scheduled purposes, for example, for 
research.  
 
From 7 April 2006, anyone storing human tissue or cells for human application must be 
in possession of a licence from the HTA. Other activities under the HTA's remit, will 
become licensable in September 2006. 
 
Also of great importance to biobank-based research in the UK is the MRC guidelines on 
human tissue and biological samples for use in research issued in 2001 [12]. In 2005, 
following the passage of the Human Tissue Act, the MRC issued a clarification. These 
guidelines, recognizing the crucial importance of human tissue for medical research, 
emphasize the need for patient confidentiality, consent and information. It states that the 
public and research participants must be confident that such material has been obtained 
                                                 
57 www.hta.gov.uk 
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lawfully and with appropriate consent, and will be handled and used sensitively and 
responsibly by scientists. 
 
Privacy/Data protection 
The EU Directive 95/46/EC on the protection of individuals, with regard to the 
processing of personal data and on the free movement of such data, was implemented to 
national law through the Data Protection Act (1998). A number of Statuary Instruments 
have been developed to implement this Act. In 2003, the MRC issued specific 
guidelines on Personal Information in Medical Research. 
 
Ethics discussion 
The ethics debate on biobanks has primarily taken place in relation to the UK Biobank 
project in the UK. The two initiators, the Wellcome Trust and the MRC, early realized 
that such a project would raise a number of important social and ethical issues, such as 
“ownership” and accessibility of data. The project has been not unexpectedly criticized 
by various individuals and groups since its inception. Public concern has been caused, 
for example, by questions related to data storage and use and the role of commercial 
interests (e.g. the pharmaceutical industry).58 Much of the criticism has been channelled 
through GeneWatch UK, an independent stakeholder group monitoring the use of 
genetic technology. In 2002, GeneWatch called for the project to be frozen until the law 
was changed to guarantee that individuals’ genetic information remained private and 
protected from commercial control.59 GeneWatch has identified 5 questions that 
potential volunteers should ask before agreeing to take part:60 
 
• What type of research is going to be carried out on my sample? 
• What are the benefits and dangers of this research? 
• Will my sample ever be used for research I do not agree with? 
• Will any of my genes be patented and if so, when will I be informed about this? 
• Can I change my mind? 
 
The funders of UK Biobank have responded to the criticism and debate by initiating 
research on ethical issues and engaging the public and professionals in consultations. 
Over the years, a number of consultations and workshops have been carried out both 
with the general public and with special groups in society (such as scientists, primary 
health care workers and industry representatives). This consultation process, undertaken 
to ensure that all interested stakeholders have been given the opportunity to comment, 
has affected the design of the project in different ways, including the development of 
the Ethics and Governance Framework (EGF). The intention is that the EGF will 
continue to evolve, adapting to scientific, ethical, legal and other developments, with 
advice from the previously mentioned Ethics and Governance Council, the Science 
Committee and other parties concerned. 
 
Despite this extensive consultation process, the UK Biobank project is still subject to 
public criticism. Many scientists have accused the project of being badly designed and 
likely to give misleading results.61 The question has been raised as to whether the 
                                                 
58 See e.g. Guardian, “Fury at plan to sell off DNA”, 23 September 2001. 
59 Guardian, “Safeguards fail at gene bank says watchdog”, 14 January 2002. 
60 “BioBank UK: A Question fo Trust: A consultation exploring and addressing questions of public trust”, Report 
prepared for The Medical Research Council & The Wellcome Trust, People Science & Policy Ltd, March 2002. 
61 Guardian, “Critics’ U-turn as the world’s biggest medical project begins”, 15 March 2006. 
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project should be straight epidemiological or focus on genetics. According to a recent 
statement from GeneWatch: “UK Biobank is based on false assumptions about the role 
of genes in the major killer diseases today”. GeneWatch is also concerned about the 
lack of legal safeguards to protect participants and others from future misuse of their 
genetic information. For example, there are no laws to prevent discrimination by 
insurers or employers and inadequate controls on access by the police or by commercial 
companies.62  
 
2.2.2 Biobanks in Eastern Europe 
 
In the context of this study, Eastern Europe comprises the countries: Bulgaria, the 
Czech Republic, Slovak Republic, Poland, Hungary and Romania. No large-scale 
biobank for research purposes was identified in Bulgaria. Although it can be assumed 
that some small-scale biobanks for research exist in many hospitals but it was only 
possible to retrieve one of them: the Laboratory of Molecular Pathology63 which houses 
the National DNA Bank of the Republic of Bulgaria, founded in 1990 and storing DNA, 
serum and tissues (7000 samples) paired with demographic, ethnic, medical and genetic 
information on the donors for public research and clinical research diagnostics. This 
biobank is not connected to other biobanks and is used for research only by those 
scientists who collected the samples. Furthermore, the access availability to the samples 
is restricted through a Material Transfer Agreement. However, this biobank was already 
involved in international projects, like BIOMED-2, Concerted Actions for CF Research 
and Therapy, MDA-USA. The shipment of the DNA samples stored is deemed to be an 
impediment for international collaboration.64 Similarly, relevant biobank activities were 
difficult to identify in Poland, Slovakia and the Czech Republic (for more details on 
these countries see ESTO report).  
 
2.2.2.1 Biobanks in Hungary 
 
14 public biobanks devoted to public research and/or clinical research diagnostics were 
explored in Hungary: 
 
• the NEPSYBANK collecting DNA, tissues, fibroblast stored in a -80°C freezer;  
• the biobank at the Uzsoki Teaching Hospital, collecting DNA, serum, whole blood 
and tissues stored in liquid nitrogen;  
• the Preterm infants and full-term neonates, collecting whole blood, dried on filter 
paper and stored at room temperature;  
• and 11 Biobanks all at the same institution, the Department of Medical Genetics 
and Child Development, each storing DNA in -20°C freezer and devoted to a 
specific disease or a specific population.65 
 
Beyond this, the survey identified 1 commercial biobank (KRIO Institut66); 1 private 
biobank for public research and clinical research diagnostics (the “Prof. Korányi 
András” Dunántúli Génbank67) 68, and the Danubian Biobank Consortium. 
                                                 
62 www.genewatch.org/Press/Releases/pr86.htm 
63 http://ivo.medfac.acad.bg/ 
64 Cf. returned questionnaire.  
65 Mitochondrial disease, roma, shizofrenia, stroke, metabolic syndrome, huntington, heart attack, familiar deaf, 
crohn, asthma, adult coeliacia. 
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The identification of public Hungarian biobanks for research was mostly based on the 
analysis of, a database listing all biobanks in Hungary (and also the research methods 
employed and the facilities of the laboratories) which was set up by a group of scientists 
and is accessible through the website www.biobank.hu.69  
 
The Department of Genetics, Cell- and Immunobiology of the Semmelweis University 
in Budapest, is the coordinator of this project and has the following aims: 
 
• to establish a register of biologic specimen collections in Hungary;  
• to provide a possibility to search for opportunities for collaboration for 
registered users, such as sharing of specimen collections and methodology;  
• to establish a forum for research groups using molecular biological techniques;  
• to provide information on genomic research.  
 
Most biobanks cited above - except the KRIO Institute - are public biobanks set up for 
the purpose of public research or clinical research diagnostics. They are affiliated to 
hospitals or clinics and store DNA, tissues, umbilical cord blood, etc., together with 
demographic, ethnic, medical and lifestyle data on the donors depending on the diseases 
targeted. These biobanks are small (less than 5000 samples) and are either stand-alone 
or networked. Most of these biobanks seem to be only accessible to Hungarian 
researchers and have not been involved in international studies yet. Furthermore, the 
consent conditions are very heterogenous: either the donors have to give their consent to 
a specific study or to biomedical research in general, either they even have (can?) to 
give any consent.70 
 
Sample collections 
The selection of donors for the public biobanks and also for “Prof. Korányi András” 
Dunántúli Génbank is made on the basis on whether they have a specific disease or 
whether they belong to a specific demographic group or random selection. There is no 
selection of participants at the KRIO-Institute. Apart from the “Prof. Korányi András” 
Dunántúli Génbank, where also Centres/Staff specifically employed for the project are 
involved, the samples have been collected by the associated hospital staff and/or 
primary care workers.  
 
The size of the biobanks which perform public research, varies considerably: some have 
less than 50 samples, although they have been collecting some for several years, and 
some have ca. 3000 samples. Apart from the Preterm infants and full-term neonates, 
which collects demographic information and environmental/lifestyle information and 
genetic data about the data, all the research biobanks collect medical/phenotype 
information on the donors, sometimes also demographic, ethnicity and 
environmental/lifestyle information and genetic data. The KRIO Institute is the only 
biobank which collects samples not only in Hungary but also from other countries.  
                                                                                                                                               
66 The KRIO Institute stores, against payment, sperm, egg and umbilical cord blood bank in liquid nitrogen. 
However, the KRIO Institute also carries out commercial research. 
67 Collecting DNA, serum, mononulear cells and storing them in a -80°C freezer and in liquid nitrogen 
68 In contrast to other private/commercial institutions the KRIO Institute, as well as the “Prof. Korányi András” 
Dunántúli Génbank, answered the questionnaire openly and completely.  
69  lso the “Genomic investigation for Human Health” Consortium (GKEE), founded in 2001, registers all Hungarian 
human biobanks. However, no more information in English language about this project was available.  
70 Cf. returned questionnaires.  
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Access availability and sharing of samples 
Most of the biobanks for research stand-alone. Only the NEPSYBANK is networked 
and on the internet, but with restricted access, and the KRIO Institute and the biobank at 
the Uzsoki Teaching Hospital both have an intranet system.  
 
The “Prof. Korányi András” Dunántúli Génbank, the NEPSYBANK and the biobank at 
the Uzsoki Teaching Hospital are used by researchers in the same country or, even in 
other countries. The other biobanks are only used by researchers at the same institution. 
The access to samples and data is free for all biobanks dedicated only to Public 
research. However, access to the samples of the biobank at the Uzsoki Teaching 
Hospital is restricted depending on specific, individual agreement. For the rest, access is 
only possible against payment.  
 
The current consent form and legal framework allow sharing tissues and samples data 
with researchers outside country. Only the KRIO Institute cannot share tissues with 
researchers outside country, but only data. This is not very surprising, since the samples 
collected from this biobank are partly devoted to subsequent, autologous uses. Though 
sharing of samples and data is possible for almost all biobanks (apart from the KRIO 
Institute), none of them has already been involved in international projects. For all 
biobanks, researchers using the samples are always required to feed back results to the 
biobank.  
 
Consent 
The handling of consent is not homogenous. Almost all biobanks devoted to public 
research require consent to biomedical research in general, or to a specific study. 
However, the Preterm infants and full-term neonates biobank, as well as the “Prof. 
Korányi András” Dunántúli Génbank, both working on research do not require any 
specific consent. Moreover, in these two cases, information arising from biobank 
studies cannot be sent back to individuals (personal results). Yet, in all other cases, it 
can indeed if donors have consented to it. The KRIO Institute handles consent issues in 
a completely different manner but did not specify how.  
 
The Preterm infants and full-term neonates biobank and the biobank at the Uzsoki 
Teaching Hospital are the only biobanks for which it is not possible for donors to 
withdraw their consent to store samples in the biobank. For the “Prof. Korányi András” 
Dunántúli Génbank, the privacy of donors is protected through anonymization but 
without any key code, whereas for all other biobanks a key code is used to anonymize 
the samples.   
 
Privacy/data protection 
Data Protection found itself on the Hungarian agenda, following the political and 
economic changes of 1989. Data Protection, and the ability of citizens to be able to 
monitor information collected, was seen as an important element of the rule of law and 
human rights. Act LXIII of 1992 on the Protection of Personal Data quickly followed 
(“Act LXIII of 1992 
on theProtection of Personal Data and Public Access to Data of Public Interest”). On 
26 July 2000, the European Commission decided that Hungarian law ensured an 
adequate level of protection of personal data within the meaning of Article 25(6) of 
Directive 95/46/EC. Act LXIII of 1992 was later amended by Act No XLVIII of 2003. 
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71 The EU Directive 2002/58/EC concerning the processing of personal data and the 
protection of privacy in the electronic communications sector was translated to national 
law in the Act of 2003 on Electronic Communications adopted by Parliament at its 
session of 24 November 200372.  
 
2.2.2.2 Biobanks in Romania 
 
Given most of the Romanian internet sites are only in Romanian language, it was very 
difficult to retrieve information regarding the biobanking situation in Romania by desk 
research. Requests for information sent to scientists and to the Romanian Ministry of 
Health or to the Romanian Academy remained unanswered. However, 12 questionnaires 
were received from the Agentia de Transplant Romania73, corresponding to 12 
biobanks, all of them apparently public ones, inasmuch as the answers to the 
questionnaires allow this conclusion74.  
 
There are 10 medical centres allowed to carry out organ and tissue transplants (3 for 
kidney transplants, 3 for liver transplants, 4 for heart transplants, 1 for spinal cord 
transplants and 1 for skin transplants).75 Furthermore, it might be assumed that some 
small (tissue, blood, etc.) biobanks are established in hospitals, designed for diagnostic 
or therapy purposes. Also, a first commercial umbilical cord blood bank has been 
founded in Romania.   
 
Four biobanks are devoted to research purposes and/or clinical research diagnostics:  
 
• The Skin Bank of the Center of Excellence for Scientific and Technological 
Research in the Domain of Tissue Transplant and Skin Grafts, collecting skin 
tissues stored in liquid nitrogen. 
• The Human Skin Liquid Nitrogen Storage Service, also collecting tissues stored 
in liquid nitrogen. 
• The Biobank at the M. G. - International Center RUA, collecting human tissues 
stored at room temperature.  
• The Biobank at the IVF Center “Victor Babes” of the University of Medicine 
and Farmacy in Timisoara, also collecting human tissues stored at room 
temperature.  
 
Six biobanks are devoted to Public Research and/or Clinical Research Diagnostics as 
well as for transplant purposes or, in the case of the biobank at the University Hospital 
“Panait Sarbu” in Bucharest for IVF purposes:  
 
                                                 
71 http://www.privireal.org/content/dp/hungary.php  
72 http://en.ihm.gov.hu/data/25087/eht_eng.pdf  
73 The National Transplant Agency, subordinated to the Ministry of Health, was created in 2004 with the aim a. o. to 
coordinate and control transplant activities (organs and tissues) in Romania, in accordance with the European 
Directive., The National Transplant Agency was specially mandated to set up a “National Transplantation Register” 
including available human organs and tissues for transplants to facilitate their allocation. The questionnaires received 
may correspond to biobanks monitored in this scope. http://www.cdep.ro/proiecte/2004/600/70/3/leg_pl673_04.pdf.  
74 It has been realized after having set up and sent the questionnaire that therein only the reason for the creation of the 
Biobank has been asked for but not whether the biobank is a public or a private one. As some biobanks investigators, 
in other countrie,s indeed ticked both of the responses on “Public research” and on “Private Commercial Research”, it 
seems important to make a distinction between the stated purpose of creation of one biobank and its 
funding/administrative status.  
75  http://assembly.coe.int/Mainf.asp?link=/Documents/WorkingDocs/Doc04/FDOC10260.htm 
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• the Colentina Biobank, collecting tissues stored in liquid nitrogen. The stored 
bones and ligaments are also used for allograft transplants in orthopaedic surgery.  
• the Marburg Bone Bank Lobator SD-2, collecting tissues and bones, stored in a -
80°C freezer. This Biobank is also a Bone Bank for Transplant purposes.  
• the Heart Valve Bank in Timisoara, collecting tissues stored in a 4°C refrigerator 
or in liquid nitrogen. This biobank also provides allografts for heart valve 
replacements.  
• the Biobank at the University Hospital “Panait Sarbu” in Bucharest is settled in 
the Department for Assisted Reproduction Department. The sperm samples and 
embryos collected are stored in liquid nitrogen and used for research as well as for 
treatment of infertility.  
• the Biobank at the Medsana Bucharest Medical Center and the Med New Life 
Biobank are biobanks storing embryos and sperm for IVF purposes.  
• the Bone Bank stores bones and the “Corneas Bank” stores corneas, both for 
transplantation purposes.  
 
Sample collections 
Among the 10 biobanks for research purposes, the selection of donors is not 
homogenous, even among those which are devoted only to research and not to 
transplant. 3 biobanks select the donors on basis of whether they have a specific disease: 
the Human Skin Liquid Nitrogen Storage Service, the Colentina Biobank and the 
Marburg Bone Bank Lobator SD-2. In addition to this condition, the Skin Bank of the 
Center of Excellence for Scientific and Technological Research also collects samples 
from random population and the biobank at the University Hospital “Panait Sarbu” from 
specific demographic groups. The Biobank at the MG - International Center RUA and 
the Biobank at the IVF Center “Victor Babes” select donors from demographic specific 
groups. The Heart Valve Bank in Timisoara selects donors from random population 
without further restriction. For all biobanks, the samples have been collected either by 
the associated Hospital Staff, Primary Care Workers (including Hospital Staff) or by 
Centres/Staff specifically employed for the Project. The Marburg Bone Bank Lobator 
SD-2 additionally collects samples left over after surgery.  
 
The Colentina Biobank is the biggest of the 8 biobanks with samples from 248 
individuals. The Marburg Bone Bank Lobator SD-2, the Heart Valve Bank and the 
Biobank at the University Hospital “Panait Sarbu” have between 20 and 87 samples. 
Concerning the size of their sample collection, the Skin Bank of the Center of 
Excellence for Scientific and Technological Research, the Biobank at the M. G. - 
International Center RUA and the Biobank at the IVF Center  
 
The type of data stored, in combination with the samples, also varies. The Marburg 
Bone Bank Lobator SD-2 only collects demographic data. The Biobank at the M. G. - 
International Center RUA and the Biobank at the IVF Center “Victor Babes” only 
collect “IVF data”. The other 5 Biobanks all collect demographic data, in addition to 
medical/phenotype data and/or genetic data and/or environmental/lifestyle data and/or 
ethnicity. The biobank at the University Hospital “Panait Sarbu” also keeps track of the 
quality of the samples and embryos collected. It might be supposed that this 
corresponds to the “IVF data” stored by the 2 other biobanks active in the IVF field.  
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Access availability and sharing of samples 
Except for the Skin Bank of the Center of Excellence for Scientific and Technological 
Research, all biobanks are stand-alone. However, the Heart Valve Bank in Timisoara 
states it is stand-alone, and provides restricted access to its collection through the 
internet.  
 
Samples and data from the Heart Valve Bank in Timisoara, the IVF Center “Victor 
Babes”, the biobank at the M. G. - International Center and the Skin Bank of the Center 
of Excellence for Scientific and Technological Research are used by the researchers 
who have collected the samples, and by other researchers at the same institution or 
elsewhere in the country. For the other biobanks, samples and data are only used at the 
institution where they have been collected. No biobank samples and data are used by 
researchers from other countries and no biobank has already been involved in 
international research projects.  
 
Only one biobank provides access to samples and data against payment: the biobank at 
the University Hospital “Panait Sarbu”. In the other cases, access is free although 
sometimes restricted (IVF for the Biobank at the M. G. - International Center RUA and 
the Biobank at the IVF Center “Victor Babes” and limited number of samples for the 
Marburg Bone Bank Lobator SD-2). It is interesting to notice that all the biobanks 
considered are regulated by a Research Ethics Board approval. According to the 
answers to the questionnaire, the current consent form and legal framework seems to 
allow biobanks to share tissue and sample with researchers outside the country.  
 
Consent 
The Biobank at the University Hospital “Panait Sarbu” is the only one which requires 
informed consent from the donors. Apart from the 2 other IVF Biobanks, which require 
specific IVF consent, the other 5 biobanks do not require any consent or require only a 
blanket consent. In almost all biobanks considered, information arising from biobank 
studies cannot be sent back to individuals (personal results Personal communication?). 
Only at the Colentina Biobank and at the Heart Valve Bank in Timisoara, this 
information can be sent back to donors if they have consented to it. In the case of the 
Biobank at the University Hospital “Panait Sarbu”, information is reported back to 
patients even without consent it is even so in all cases. For half of the biobanks, donors 
can withdraw their consent to store samples in the biobank.  
 
Finally, For the Human Skin Liquid Nitrogen Storage Service, the Biobank at the M. G. 
- International Center RUA and the Biobank at the IVF Center “Victor Babes”, privacy 
of donors is protected through an anonymous procedure but without any key code. All 
the other biobanks use coding with a coding key.  
 
Regulatory aspects 
The procedures related to organ transplants in Romania, are regulated through the 
following laws: 
- Law n° 2/1998 related to the utilisation of human organs and tissues;  
- Law n° 104/2003 related to dealing with dead bodies and organ removal from dead 
bodies for transplant purposes. 
 
Privacy/Data Protection  
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Data Privacy is regulated through law No. 677/2001 for the Protection of Persons 
Concerning the Processing of Personal Data and Free Circulation of Such Data (2001), 
enacted in November 2001 by the Romanian Parliament76. The law closely follows 
Directive 95/46/EC.  
 
2.2.3 Biobanks in Central Europe 
 
2.2.3.1 Biobanks in Austria 
 
Biobanking in Austria is very much linked to universities and public hospitals. Here, the 
comparison with Germany is important, as the Austrian system of pathology and also 
the applicable legal regulations allow the collection of tissue from diseased persons and 
human corpses, in the course of the diagnostic procedure. This favours, to a certain 
extent, the emergence of biobanks. In general, biobanks are not deliberately established. 
In most cases, pathological archives were the basis and starting point for the biobanks. 
Most of the collections in Austria are tissue biobanks.  
Two public biobanks were found affiliated to hospitals or non-profit making firms, 
devoted to diagnostic, therapeutic and research purposes, and three private and profit-
making cord blood banks.  
 
The Austrian Tissue Bank is a non-profit making organization, specialized in the 
nationwide supply of tissue grafts, especially of allogenic bone grafts.77 
 
BioResource-Med is a biobank specifically designed to support the needs of systems 
biology approaches to human diseases, drug discovery, and public health. BioResource-
Med is an interdisciplinary research platform of the Medical University Graz, which 
mainly builds on one of the world’s largest collection of diseased human tissues of the 
Institute of Pathology at the Medical University Graz (approx. 2.9 mio samples from 
888000 patients). In the context of the Austrian Genome Program GEN-AU I,78 tissue 
collection has been developed into a biobank, by establishing the logistics and 
technologies for coordinated and standardized collection of various human biological 
samples, medical and experimental data as well as human disease-associated animal 
models. Furthermore, high-throughput genomics (cDNA-arrays) and proteomics (tissue 
microarrays) analysis platforms, and an IT-infrastructure, which enables proper access 
and usage of biological samples, as well as associated data, have been established. The 
further development of BioResource-Med focuses, on the one hand, on extensive 
annotation of already existing archival tissues with medical data and, on the other hand, 
on the prospective collection of human tissues, blood samples and patient-related data in 
an internationally standardized manner. 79 
 
Regulatory aspects 
                                                 
76 http://www.avp.ro/leg677en.html 
77 Bärwald, H., ”Biologische Selbstorganisation und Möglichkeiten ihrer technischen Nutzung”, Kurzstudie im 
Auftrag des isw - Institut für Strukturpolitik und Wirtschaftsförderung, Gemeinnützige Gesellschaft mbH, Halle, 
2005. 
78 The Austrian Genome Program GEN-AU, financed and organised by the Federal Ministry for Education, Science 
and Culture, covers a widespread variety of research activities. GEN-AU’s focus is medical biotechnology, but there 
are also projects in agricultural and animal genomics. The GEN-AU program, strongly supports biobanking, as an 
instrument for GEnome Research in Austria, as well as in cooperation with foreign Genome Projects. The anticipated 
benefit of biobanking is to understand disease processes and the development of more efficient diagnostics and 
therapies. www.gen-au.at  
79 www.bioresource-med.com  
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For human biobanks, general regulations concerning medical purposes are valid. The 
processing of medicines is regulated in the Austrian Pharmaceuticals Act (AMG) and 
the regulations on blood safety. If human biologic material is used for genetic testing, 
the regulations of the Austrian Gene Technology Act provides special conditions to be 
considered: purpose of testing, handling of samples, institution, equipment, 
qualification of staff, protection of data and genetic counselling are regulated.80 By 
Austrian legislation, existing human tissue collections, containing tissues from patients 
that have died, can be used for scientific investigation without specific informed consent 
as long as patient confidentiality is maintained and approved by the local ethical 
committee. This is in accordance with the emerging opinion in most European 
countries81. For newly collected samples, specific informed consent is obtained. 
Informed consent is also in line with the recommendations of the German Ethics 
Council and other international guidelines.  
 
Privacy/Data Protection 
The EU Directive 95/46/EC on the protection of individuals, with regard to the 
processing of personal data and on the free movement of such data, has been translated 
to national law in the “Data Protection Act” 2000 (“Bundesgesetz über den Schutz 
personenbezogener Daten, Datenschutzgesetz 2000 - DSG 2000”).82 The EU Directive 
2002/58/EC, concerning the processing of personal data and the protection of privacy in 
the electronic communications sector was translated to national law through the 
Telecommunications Law of 20 August 2003 (“Telekommunikationsgesetz”, 
Stammfassung: BGBl. I Nr. 70/2003).83 
 
Ethics Discussion 
Until 2004, no public debate on human biobanks took place in Austria.84 In 2005, the 
(Austrian) Bioethics Commission85 cooperated with experts from the German National 
Ethics council86 regarding an opinion on biobanks for research purposes.87 Yet, 
biobanking has not caused any broad public discussion in the media.  
 
2.2.3.2 Biobanks in Belgium 
 
According to the results of our survey, there are several biobanks in Belgium affiliated 
to hospitals, designed for local research or therapeutic purposes and devoted to the 
treatment of specific diseases but, no large-scale biobank for research purposes. Among 
                                                 
80 European Commission Research Directorate-General, Directorate E Biotechnology, Agriculture and Food, “Survey 
on opinions from National Ethics Committees or similar bodies, public debate and national legislation in relation to 
human biobanks”, edited by Line Matthiessen and Kimmo Pitkänen, Update October 2004. 
81 For review, see the Opinion of the German Ethics Council and the Report from the EU Working Group on 
Biobanks for Health: ”Optimising the Use of European Biobanks and Health Registries for Research Relevant to 
Public Health and Combating Disease”, workshop, Oslo, 21-23 Jan 2003.  
82 http://www.dsk.gv.at/dsg2000d.htm  
83 http://www.rtr.at/web.nsf/deutsch/Telekommunikation_Telekommunikationsrecht_TKG+2003#p1 
84 “Survey on opinions from National Ethics Committees or similar bodies, public debate and national legislation in 
relation to human biobanks”, European Commission Research Directorate-General, Directorate E Biotechnology, 
Agriculture and Food, Edited by Line Matthiessen and Kimmo Pitkänen, Update October 2004 
85Established at the Federal Chancellery in 2001: 
http://www.bundeskanzleramt.at/DesktopDefault.aspx?TabID=3455&Alias=BKA  
86 www.ethikrat.org 
87 http://www.ethikrat.org/_english/publications/Opinion_Biobanks-for-research.pdf  
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the tissue banks, cord blood banking is well-established in Belgium, with the banks at 
Leuven and Liege as members of NetCord88.  
 
The Biobank of the University Hospital of Liege contains Hematopoietic Stem Cells, 
Umbilical Blood and also plans to store tissues like cornea, bones, arteries, etc. in the 
future.89 No English information could be retrieved regarding the DNA Bank, at the 
Renal unit of the Faculté de médecine/Département de médecine interne of the 
Université catholique de Louvain, the DNA Bank, Service de Chirurgie digestive, 
Cliniques Universitaires de Bruxelles, Hôpital Erasme, the PSY-GEN Biobank or the 
De Leuvens Navelstrengbloedbank.  
 
The DNA Bank of the Renal Unit of the Catholic University of Louvain is a member 
of the European Renal Genome Project, an interdisciplinary research program, 
integrates European excellence in research on renal development and pathogenesis. 
Their goal is to discover genes responsible for renal development and disease, their 
proteins and their actions.90 
 
The University of Liege is a parent member of the Belgian Cord Blood Bank, which 
also includes the Free University of Brussels (ULB) and the Catholic University of 
Louvain (UCL). This bank was established in 1993, with funds obtained through the 
fund raising operation TELEVIE. More recently, an additional storage facility has been 
added at the Institut Bordet, a cancer institute situated in Brussels with funds from la 
Fédération Belge contre le Cancer, Fonds Ariane and les Amis de l’Institut Bordet. In 
April 2003 Netcord and BMDW recorded 7484 and 7581 Belgian Cord Blood Units 
respectively.  
 
The Tissue Bank of the University Hospital Saint-Luc in Brussels was founded in 
1983 and is specialized in tissue supply for allogenic grafts. Additionally, scientists at 
the Tissue Bank have developed therapies for autologous grafts since 2001.91 
 
The Global Allergy & Asthma European Network (GA²LEN) is a network of centres 
with high clinical and experimental research competence across Europe, conducting and 
providing platforms for clinical, translational, intradisciplinary and multidisciplinary 
research. The overall objective of GA²LEN is to establish an internationally competitive 
network, to enhance the quality and relevance of research, address all aspects of the 
disease and eventually decrease the burden of allergy and asthma throughout Europe. 
The network brings together epidemiological, basic and clinical researchers carefully 
considering ethical and gender issues. It investigates allergy and asthma across the life 
course, including intra-uterine life and foeto-maternal interface, interaction between 
genetic and environmental factors in early life, translation of allergic sensitisation into 
disease and persistence of the disease.  
 
Cryo-Save is a private firm specialized in the isolation and storage of (adult) stem cells. 
Stem cells can be harvested from umbilical cord blood and also from mature bone 
                                                 
88 The "NetCord Virtual Office" is an online search system for unrelated cord blood of the 14 leading cord blood 
banks world-wide (www.netcord.org).  
89 http://www.chuliege.be/sm/78.html#activities  
90 ”Stem Cells - European Research Projects Involving Stem Cells in the 6th Framework Programme”, ed. by Joliff-
Botrel, G. and Perrin, P., EC, Dec. 2005.  
91  http://www.saintluc.be/hospitalisation/dpts-serv/banque-tissus/   
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marrow. In contrast to embryonic stem cells, ethically disputed, these cells are an 
excellent alternative for transplants. Cryo-Save is a member of the Life-Sciences Group 
N.V., a Dutch holding with affiliates and partnerships in 20 countries and a nominal 
capital of more than 5 million Euros. Cryo-Save has a central laboratory in Brussels and 
a cooperation partner in Germany, and is one of the largest service providers in the 
world in the field of stem cell storage with more than 30000 stem cells samples.92 Cryo-
Save is currently the only private cord blood bank in Belgium. 
 
Regulatory aspects 
The legislation on human tissue use and human tissue banks in Belgium is currently 
based on two principal texts: the Crown Order of 13 June 1986 and the Crown Order in 
Council of 15 April 1988.  
 
• the Crown Order of 13 June 1986 regulates the retrieval and grafting of organs and 
tissues, with a limited scope to therapeutic uses.  
• the Crown Order in Council of 15 April 1988 regarding human tissue banking, 
addresses the care and storage of human tissue from the time of donation until 
transplant in the recipient. Its goal is to promote tissue quality and safety in non-
profit human tissue banks through tissue bank accreditation and activity 
supervision. Under the Royal Order, a Human Tissue Bank (HTB) is defined as “a 
technical unit in a hospital, with the assignment guaranteing quality of the tissues 
from the moment they are retrieved, to the moment they are used as an allograft, 
more particularly during the preparation, storage, distribution, transportation, and 
delivery.” Establishment of an HTB requires prior approval by the Minister of 
Health (in conjunction with certain other specified criteria), authorization for the 
HTB granted for a limited duration and HTB activities are subject to strict 
monitoring. Accordingly, the Royal Order requires clinical, biological, 
microbiological, and immunological donor and donor tissue testing. The Royal 
Order also mandates the keeping of detailed records, tracking the origin, 
processing, and handling of human tissue, thereby ensuring traceability of the 
tissue implant [13].  
 
The Crown Order in Council of 15 April 1988, was actually revised in 2002 and 
replaced by the Crown Order in Council of 23 December 2002. According to this 
Crown Order and an opinion given by the Belgian Health Council on 7 December 2001 
on tissue banks’ legislation93, the therapeutic autologous uses of human tissues for 
deferred preventive intentions is prohibited, as well as advertising and profit-making of 
commercial blood banks.94 However, this Crown Order was suspended by the Council 
                                                 
92  http://www.cryo-save.com/   
93 The Belgian Health Council on 7 December 2001 gave an opinion on the revision of tissue banks’ legislation In 
particular it recommends for the cord, cord blood and derived cells that: 
• “The cord and cord blood cells are part of the legislation regulating tissues and cells;  
• Quality standards for cord blood banks have to be worked out; 
• The therapeutic autologous uses for deferred preventive intentions have to be prohibited.” 
The Health Council, in its Annex II, lists the conditions of approval and authorisation of the activities relating to cell 
and tissue banks. It stipulates, in particular, that “each cell or tissue bank has to be approved by the Minister after a 
report of the relevant service and after the opinion of the Health Council and that this approval can only be granted 
for (…) non-profit-making organisms”. Cf. Opinion n° 19 : "Ethical aspects of umbilical cord blood banking" , The 
European Group on Ethics in Science and New Technologies to the European Commission, 2004. 
94 Demande d'explications de Mme Clotilde Nyssens au ministre des Affaires sociales et de la Santé publique sur «les 
banques de sang de cordon ombilical» (nº 3-1384), Annales, Sénat de Belgique, 16 Feb 2006. 
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on 24 February 2005 after the legal proceedings, initiated by the private cord blood 
bank Cryo-Cell Europe95, established in Malines.  
 
A Royal Decree is under preparation by the Ministry of Public Health in order to have a 
clearer legislation regarding human tissues and particularly, umbilical cord blood banks. 
The draft Decree provides that all tissue banks will have to be accredited by the 
Ministry of Health. The Royal Decree proposes that the accreditation will be granted to 
non-profit organizations only. The draft Decree also clearly forbids the use of umbilical 
cord blood cells for deferred preventive intentions, as well as all discrimination aiming 
at favouring a person’s access to therapeutic possibilities linked to tissues of human 
origin, any form of publicity and the research of profit. This preliminary draft was 
planned to be submitted to the Council of Ministers in March 200694. 
 
Privacy/Data Protection 
The EU Directive 95/46/EC on the protection of individuals, with regard to the 
processing of personal data and on the free movement of such data, was implemented to 
national law on 11 December 1998, and came into force on 1 September 2001.  
 
2.2.3.3 Biobanks in Germany 
 
In Germany there are many public, more or less small-scale biobanks affiliated to 
hospitals and designed for research. These biobanks are mostly devoted to the research 
of treatment of specific diseases. They are stand-alone or networked and accessible to 
researchers on site or available for international research groups.  
 
Five public biobanks are devoted to research and/or clinical research diagnostics: 
- the Jose Carreras Cord Blood Bank Düsseldorf, collects neonates cord blood DNA, 
serum of the mother, whole blood (cord blood) and plasma of cord blood units. 
Serum and plasma are stored in a -80°C freezer, cord blood units in liquid nitrogen.  
- the European Searchable Tumour Line Database (ESTDAB) collects cancer cell 
lines stored in liquid nitrogen. 
- the KORA-gen biobank collects DNA, Serum, Whole Blood, urine and EBV 
immortalized cell lines stored in a -80°C freezer and in liquid nitrogen.  
- the Kryoforschungs- & Demonstrationsbank der Fraunhofer Gesellschaft 
“Eurocroyo SAAR” collects serum and tissues stored in liquid nitrogen. This 
biobank is also devoted to technology development, automation and demonstration. 
- the Patient DNA collection at Institute of Human Genetics Heidelberg, collects 
DNA stored in a -20°C freezer. 
• One public biobank devoted to allogenous grafts for transplants: the Tissue Bank at 
the Charité – Universitätsmedizin Berlin, collects tissues stored at room 
temperature or in a -80°C freezer.  
                                                 
95 Cryo-Cell Europe is an affiliate of the American company Cryo-Cell International. It is represented, so far, in 
Austria, Belgium, Germany, Luxemburg, the Netherlands, Switzerland and the UK but aims to collect and store 
blood from 18 European countries. Cryo-Cell has recently acquired the German biotechnology company MainGen in 
Frankfurt, with interests in cell expansion and cell therapy. Cryo-Cell Europe currently holds over 5,000 CBU stored 
for autologous and family use. Cf. Opinion n° 19 : "Ethical aspects of umbilical cord blood banking" , The European 
Group on Ethics in Science and New Technologies to the European Commission, 2004. 
 http://www.europa.eu.int/comm/european_group_ethics/publications_en.htm  
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• Two biobanks devoted to public research and clinical research diagnostics, as well 
as to private commercial research: 
o the ITI DNA-Bank, collects DNA and whole blood stored in a -80°C 
freezer; 
o the Human Melanoma Biobank, collects DNA, serum, whole blood and 
tissues in -20°C freezer, -80°C freezer and in liquid nitrogen.  
 
The breast and colorectal biobank of Germany, the European Searchable Tumour Line 
Database (ESTDAB), the International German Melanoma Tissue bank, the 
AUTOROME biobank, the Tissue Bank of the university hospital in Heidelberg 
(devoted to the study of cancer diseases) and KORA-gen cited above, are representative 
of biobanks affiliated to hospitals and designed for research purposes. They are 
designed only for public research and clinical diagnostics research but, sometimes also 
for commercial research (e.g. the Human Melanoma Biobank). These biobanks store 
DNA, serum, whole blood, and tissues, mostly combined with demographic, genetic, 
ethnicity or lifestyle data. They can be networked or stand-alone but, mostly allow 
international researchers to use their samples and data in their studies. Furthermore, 
some of these biobanks have already been involved in some international research 
studies.96  
 
The Bayerische Stammzellbank GmbH and the José Carreras Stammzellbank 
Düsseldorf are representative of public tissues and blood banks.  There are five non-
profit cord blood banks in Germany. These are situated in Düsseldorf, Dresden, 
Mannheim, Dresden, Düsseldorf, Freiburg, Mannheim und München97. The José 
Carreras Cord Blood Bank in Düsseldorf, is the longest established blood bank, having 
been opened for family donation in 1992 and then for unrelated donors in 1993. The 
Düsseldorf bank is a founder member of NetCord98, an online search system for 
unrelated cord blood of the 14 leading cord blood banks world-wide, and is also a 
partner in the EUROCORD III project. The bank aims to preserve a broad ethnic mix of 
CBU. It also stores DNA and cord blood plasma. The Düsseldorf bank is devoted to 
public research, clinical research diagnostics.  
 
Besides these five public cord blood banks, the following private cord blood banks have 
been identified: Basic Cell GmbH, Cryo-Care GmbH, Cryostore Deutschland GmbH, 
Lifecord.de GmbH, Vita 34 AG Deutschland, eticur) GmbH. VITA 34, established in 
1997, was the first private cord bank to be set up in Europe. On 1 January 2003, VITA 
34 held 12,000 CBU of which >99% were stored for autologous/family use and <1% 
were donated for research. Patients are recruited through the VITA 34 web site and 
through advertising in the press. In its publicity material, VITA 34 recommends that 
prospective parents, who do not wish to bank cord blood privately, should consider 
donating their baby’s cord blood to a public bank for unrelated use. The bank ran at a 
loss between 1997 and 2001 when it reached break even point. In 2003, the bank moved 
to new laboratories at Leipzig Bio City, a biotechnology and biomedical centre being 
established by the State of Saxony in association with the University of Leipzig. VITA 
                                                 
96 For instance: the Human Melanoma Biobank in the EU OISTER project (5th framework program) and ENACT 
(6th framework program) or KORA-gen in P3G - Public Population Project in Genomics, International meta 
analyses, International replication studies, e.g. with US Framingham Heart Study. 
97 http://9monate.qualimedic.de/Nabelschnurblut_einlagerung.html  
98 www.netcord.org  
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34, has also established a research base and collaborates with: the Institut für 
Immunologie und Transfusionsmedizin at the University of Leipzig on cell expansion 
and stem cell differentiation into neural tissue; the University of Rostock, on the 
development of cell therapy for the treatment of cardiac infarct using cord blood stem 
cells and with the Ruhr University Bochum, on the development of cell therapy for 
Alzheimer’s disease using cord blood stem cells. 
 
The Cytonet Group is active in the field of medicine and biotechnology and develops new 
pharmaceuticals for cell therapy until they are marketable. Cytonet GmbH & Co. KG partners 
are internationally leading university clinics. Cytonet is currently developing an entirely new 
liver cell product to be used in the treatment of severe liver diseases and metabolic liver defects 
in newborns and small children. EU marketing authorization by the European Medicines 
Agency (EMEA) is expected in approximately the next two years. Today, Cytonet is Germany's 
largest company involved with cell therapy. The city of Weinheim is home to the management, 
administration and marketing organization of the Cytonet Group, established in April 2000 by 
spinning off the Cell Therapy division of Roche Diagnostics GmbH. The operative production 
and development activities take place at Cytonet's locations in Hannover, Heidelberg and Sofia. 
The Hannover location was established as the first site, for collaboration between Cytonet and a 
university clinic. The Center for Cell Therapy was opened jointly with the Hannover Medical 
School (Medizinische Hochschule Hannover – MHH) in 1997, by the company formerly known 
as Boehringer Mannheim GmbH, now Roche Diagnostics GmbH. The establishment of the 
Hannover subsidiary was additionally supported by the Investment Promotion Agency of the 
state of Lower Saxony. As a result, the Cytonet Group has been operating the most modern 
German center for cell therapy in Hannover since January 2002. Since May 2000, Cytonet has 
been collaborating with the University of Heidelberg in the form of a joint company, Cytonet 
Heidelberg GmbH. Like the Hannover subsidiary, this branch also manufactures blood stem cell 
and bone marrow transplants for oncology and hematology departments. Pursuant to Section 13 
of the German Medicines Act, the company was granted a manufacturing permit for the new 
premises for blood stem cell products, T-cell preparations and bone marrow transplants in July 
2003. This manufacturing permit was extended to the production of stem cell products from 
bone marrow, for the treatment of acute cardiac infarction in the spring of 2004. The 
corresponding clinical validation studies with the departments of Professor Katus, Heidelberg 
University Clinic, and Professor Drexler, Hannover Medical School, have already begun. Apart 
from the Heidelberg University Clinic, Cytonet collaborates with the German Cancer Research 
Center (DKFZ) and supports the implementation of research projects in clinical applications, in 
compliance with all applicable guidelines of the state and federal authorities for cell therapy 
products.  
 
Sample collections 
Even among the biobanks devoted to research, the selection of donors is not 
homogenous: for the European Searchable Tumour Line Database (ESTDAB), the 
Patient DNA collection at Institute of Human Genetics Heidelberg, and the ITI DNA-
Bank, the selection of donors is made on the basis of whether they have a specific 
disease. In contrast to this, the selection at José Carreras Cord Blood Bank Düsseldorf 
and at the KORA-gen biobank is random. The participant selection for the Tissue Bank 
Charité is also random: this is not very surprising insofar as this biobank was founded to 
provide musculoskeletal transplants (allografts). For the Kryoforschungs- & 
Demonstrationsbank der Fraunhofer Gesellschaft “Eurocroyo SAAR”, the selection is 
random as well as based on a specific disease or based on stem cells. For all biobanks, 
the samples have been collected either by the associated hospital staff, primary care 
workers (including Hospital Staff) or by centres/staff specifically employed for the 
Project.  
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Apart from the European Searchable Tumour Line Database (ESTDAB biobank) which 
has only samples from 200 individuals, the biobanks devoted to research are quite large 
and have at least 5000 samples. However, we have no information on the size of the 
Tissue Bank, Charité – Universitätsmedizin Berlin and of the Kryoforschungs- & 
Demonstrationsbank der Fraunhofer Gesellschaft “Eurocroyo SAAR”.  
 
The only information the Tissue Bank, Charité–Universitätsmedizin Berlin collects 
from the donors, is the tissue bank-ID. This is not surprising, as this biobank is a 
provider of muskuloskeletal transplants (allografts). All the other biobanks are devoted 
to research and collect at least medical/phenotype information from the donors and 
often also demographic, ethnicity, genetic information and information on the 
environment/lifestyle of the donors. The KORA-gen biobank also collects medication, 
physical investigations and Laboratory parameters. The European Searchable Tumour 
Line Database (ESTDAB) collects medical/phenotype information and genetic data 
indeed and additionally immunological parameters.  
 
The Patient DNA collection at Institute of Human Genetics Heidelberg, the European 
Searchable Tumour Line Database (ESTDAB), the Kryoforschungs- & 
Demonstrationsbank der Fraunhofer Gesellschaft “Eurocroyo SAAR” and the Human 
Melonoma Biobank all collect samples from different countries. No problems have been 
reported thereby.  
 
Access availability and sharing of samples 
Most of the surveyed biobanks are stand-alone or provide only a restricted access 
through intranet or internet to their data and samples. However, some of the biobanks 
mention they were stand-alone as well as providing a restricted access through internet: 
for instance, the Kryoforschungs- & Demonstrationsbank der Fraunhofer Gesellschaft 
“Eurocroyo SAAR”, the José Carreras Cord Blood Bank Düsseldorf and the Human 
Melanoma Biobank.  
 
Many of the biobanks considered are used from researchers from European countries or 
even from the rest of the world: the José Carreras Cord Blood Bank Düsseldorf, the 
KORA-gen biobank, the ESTDAB Biobank, the Kryoforschungs- & 
Demonstrationsbank der Fraunhofer Gesellschaft “Eurocroyo SAAR” and the Human 
Melanoma Biobank. All these biobanks have been already involved in international 
projects. Only the José Carreras Cord Blood Bank Düsseldorf mentioned the sampling 
size as a problem when sharing samples/data with international partners. The other 
biobanks are used by either only researchers in Germany (the ITI DNA-Bank) or by 
researchers on site (the Tissue Bank Charité and the Patient DNA collection at Institute 
of Human Genetics Heidelberg) and have, therefore, no experience of sharing samples 
in the scope of an international research project.  
 
The Kryoforschungs- & Demonstrationsbank der Fraunhofer Gesellschaft “Eurocroyo 
SAAR”, the Human Melanoma Biobank are the only biobanks which provide partly free 
access to their samples and data: the Human Melanoma Biobank provides indeed free 
access for non-commercial users - whereas commercial users have to pay. We have no 
information regarding the conditions associated with either a free access or access 
against payment at the Kryoforschungs- & Demonstrationsbank der Fraunhofer 
Gesellschaft “Eurocroyo SAAR”. All other biobanks provide access to their 
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samples/data only against payment - the ITI DNABank provides access against a fee for 
each sample that just covers some of the costs for DNA isolation. In addition, a co-
authorship of the DNA-Bank manager on publications based on the DNA-bank is 
arranged - or under specific conditions:  
 
- the Patient DNA collection at Institute of Human Genetics Heidelberg provides 
access to  samples only on a collaborative research basis;  
- the KORA-gen biobank only provides access to samples after the KORA-gen 
steering committee has decided on the scientific relevance of the study planed with 
the samples/data;  
- also the Tissue Bank Charité provides access after research groups asking for the 
samples/data have been approved by the local ethics committees.  
 
Only the ITI DNA-Bank and the Kryoforschungs- & Demonstrationsbank der 
Fraunhofer Gesellschaft “Eurocroyo SAAR” are not regulated by a Research Ethics 
Board approval. According to the survey, the DNA-Bank has been approved by the 
local Ethics Board and based on the strict annonimous procedures of the samples no 
further consent is needed.  
 
The current consent form and legal framework allow the following biobanks to share 
samples and data with researchers outside Germany: the ITI DNA-Bank, the ESTDAB 
Biobank, the Kryoforschungs- & Demonstrationsbank der Fraunhofer Gesellschaft 
“Eurocroyo SAAR” and the Human Melanoma Biobank. According to its questionnaire, 
the Patient DNA collection at the Institute of Human Genetics Heidelberg allows 
sharing DNA samples with researchers outside the country. For the Patient DNA 
collection at the Institute of Human Genetics Heidelberg, the ITI DNA-Bank and the 
ESTDAB Biobank, an impediment to a potential networking on European level might 
be the fact that researchers using the samples are not required to feed back results to the 
biobank.  
 
Consent 
The handling of consent is not homogenous. The answers received are not easy to 
understand because several answers have been ticked to one question, and no precision 
added. For the ITI DNA-Bank, the KORA-gen biobank and the Human Melanoma 
Biobank, the donors have to consent to biomedical research. According to the 
questionnaire answers, it can be assumed that there are some trial settings where the 
Patient DNA collection at Institute of Human Genetics Heidelberg, the European 
Searchable Tumour Line Database (ESTDAB) and partly the José Carreras Cord Blood 
Bank Düsseldorf do not need any form of consent from the donors. In addition, consent 
only for a specific study might be requested: this is the case for CB transplant at the 
José Carreras Cord Blood Bank Düsseldorf. As expected, at the Tissue Bank Charité, 
consent is requested for multi-organ donation. We have no information on the consent 
requested from the donors by the Kryoforschungs- & Demonstrationsbank der 
Fraunhofer Gesellschaft “Eurocroyo SAAR”.  
 
In almost all biobanks considered, information arising from biobank studies cannot be 
referred sent back to individuals (personal results). Only at the José Carreras Cord 
Blood Bank Düsseldorf, unusual testing results can be referred back to individuals. For 
half of the biobanks, it is possible for donors to withdraw their consent to store samples 
in the biobank. For the others, it is not. This handling seems to be quite heterogeneous 
Biobanking activity                    
   74
and cannot be associated with whether a biobank is devoted to a specific aim. For the 
ITI DNA-Bank and the ESTDAB biobanks, privacy of donors is protected through 
anonymization but without any type of key code (not surprising, as we already know 
that these biobanks do not refer any results from their studies to the donors). Also the 
Human Melanoma Biobank and the Kryoforschungs- & Demonstrationsbank der 
Fraunhofer Gesellschaft “Eurocroyo SAAR” use either anonymization or coding..  
 
Regulatory aspects  
There is no explicit law up to now exclusively referring to human biobanks. The Federal 
Data Protection Law (“Bundesdatenschutzgesetz”) is, of course, relevant.99 Also, the 
following laws are in force:  
 
— the Embryo Protection Act (Embryonenschutzgesetz) of 13 December 1990; 
— the Gesetz zur Regelung des Transfusionswesens (Transfusionsgesetz) on 1 
July 1998;  
— the Stem Cell Act (Stammzellgesetz) of 28 June 2002; 
— the Federal Data Protection Law of 14 January 2003; 
— the Federal Law on Human Genetic Examinations (GenDG) of 24 April 
2009; 
— the Law on legal protection of biotechnological inventions of 21 January 
2005.100 
 
There is no specific legislation in Germany on the retention, storage or use of umbilical 
cord blood or cells and little discussion on related ethical questions. However, umbilical 
cord cell banks in Germany are licensed under the terms of the German Drug Law 
(Arzneimittelgesetz). Where Cord Blood Units (CBU) are stored, solely for autologous 
use, a licence can be granted by a Local Authority or Regional Council but where CBU 
are stored for related or unrelated third party use, then rigorous cGMP standards have to 
be met and a licence obtained from the Paul Ehrlich Institute, the relevant Federal 
statutory licensing body. In 1999, The German Federal Medical Society issued 
guidelines for the production, storage and use of stem cells from umbilical cord blood. 
The German Government (German Ministry of Health and Social Security) had 
announced to bring a first draft of the long planned law on genetic testing/diagnosis 
(Gendiagnostik-Gesetz) before parliament in June 2004. All relevant ethical issues, 
concerning informed consent, the storage and further use of biomaterials and personal 
data linked to it should be dealt with.101 However, due to political wrangling, the law 
has not been released yet, but announced for 2006.102 Finally the law was enacted in 
Spring 2009 but it does not contain provisions on research anymore. In the first drafts 
research was seen as a key area of regulation but in the later stage of the legislation 
                                                 
99 “Survey on opinions from National Ethics Committees or similar bodies, public debate and national legislation in 
relation to human biobanks”, European Commission Research Directorate-General, Directorate E Biotechnology, 
Agriculture and Food, edited by Line Matthiessen and Kimmo Pitkänen, update October 2004. 
100 Martin Uranga, A., Martin-Arribas, M.C., de Donato, J-H, and de la Paz, M.P., “Outstanding legal and ethical 
issues on biobanks: an overview on the regulation of member states of the EuroBioBank project”, EuroBioBank, 
2006. 
101 “Survey on opinions from National Ethics Committees or similar bodies, public debate and national legislation in 
relation to human biobanks”, European Commission Research Directorate-General, Directorate E Biotechnology, 
Agriculture and Food, edited by Line Matthiessen and Kimmo Pitkänen, update October 2004 
102http://www.gesundheitpro.de/Genetische-Untersuchungen-Gendiagnostik-Gesetz-Forschung-
A050805ANOND018530.html 
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project research was dropped as the legislation was influenced by several constitutional 
rights including the freedom of researchers.   
 
Privacy/Data Protection 
The EU Directive 95/46/EC on the protection of individuals with regard to the 
processing of personal data and on the free movement of such data, was implemented to 
national law in the “Data Protection Act” of 18 May 2001, and entered into force on 
May 23 2001 (“Bundesdatenschutzgesetz (BDSG) in der Fassung des Gesetzes zur 
Änderung des Bundesdatenschutzgesetzes (BDSG)*) vom 18. Mai 2001 (BGBl. I S. 
904)”)103.  
 
Ethics Discussion 
There has been a debate in Germany on human biobanks for years:  
 
• the National Ethics Council began debating the issue of human biobanks in May 
2002. A joint debate with the French National Consultative Ethics Committee 
(Comité Consultatif National d’Éthique) began in late June 2002, in Berlin and led 
to a common declaration on the subject in October 2003. An opinion on human 
biobanks was published by the German National Ethics Council in March 2004;  
• the Central Ethics Commission of the Federal Chamber of Medical Doctors 
(Bundesaertztekammer) published its opinion on the (further) use of human body 
materials for medical research. This opinion refers to the systematic storage of 
biological materials;  
• the Enquete Commission Ethics and Law in modern medicine of the German 
Parliament (Enquete-Kommission Ethik und Recht der modernen Medizin des 
Deutschen Bundestages) has issued a statement at its 8th session on November 11, 
2003 concerning the adoption of a Directive of the European Parliament and of the 
Council on setting standards of quality and safety for the donation, procurement, 
testing, processing, preservation, storage and distribution of human tissues and 
cells (Interinstitutional Dossier 2002/0128). Within this statement, the Enquete 
Commission deals with ethical questions concerning access and benefit sharing 
which it recommends for commercial biobanks. Ethical questions concerning 
informed consent are also dealt with;  
• on March 27, 2003 the Senate Commission on Genetic Research of the Deutsche 
Forschungsgemeinschaft (DFG, German Research Organisation) formulated a new 
statement on predictive genetic diagnostics. It takes the place of the statement 
"Humangenomforschung und prädiktive genetische Diagnostik: Möglichkeiten - 
Grenzen - Konsequenzen", made in 1999, and reaches beyond the latter's content. 
Regarding genetic samples and data banks, the DFG recommends that procuring, 
storing and processing samples and data has to go hand in hand with a reliable 
protection of the respective donors from any abusive use. In addition, the donor has 
to give his self-determined consent to the use of his/hers samples and data. Under 
these conditions, the DFG also holds that a donation of samples or data, with a 
right of usufruct, formulated in broad terms and without being tied to any concrete 
research projects is ethically and legally justified. The emphasis has to be made on 
striking an appropriate balance between the legal protection of the donor's 
personality and the protection of confidence for the researcher104.  
                                                 
103  http://www.berlin.de/datenschutz/infomat/dateien/bdsg/bdsg_01.pdf  
104 http://www.dfg.de/aktuelles_presse/reden_stellungnahmen/2003/download/praediktive_genetische_diagnostik.pdf 
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There was also a public debate on human biobanks as the German National Ethics 
Council held a public conference on this issue on 24 October, 2002. The conference 
papers and discussion received considerable attention in the general media and in 
specialised publications. The opinion on human biobanks, published in March 2004, has 
also drawn considerable attention from the media and other interested parties [ref???].  
 
2.2.3.4 Biobanks in the Netherlands 
 
In the Netherlands 14 biobanks were identified of which 7 public biobanks are devoted 
to public and/or clinical research (the Erasmus MC Tissue Bank, the EORTC VTB 
biobank, the TuBaFrost biobank, the BioBank Maastricht, the LifeLines biobank, the 
Netherlands Brain Bank and the EuroBoNeT biobank); 4 public biobanks not 
necessarily with research purposes (the CONCOR, ECARUCA, the Genomos project, 
The Chronic Kidney Diseases project); 1 public biobank devoted only to clinical 
therapeutic use (the Sanquin Bloodbank), 1 private, commercial cord blood bank (Cryo-
Save): and 1 private stem cell biobank (Cells4Health). 
 
There are many public biobanks for research and also many private biobanks in the 
Netherlands. The first public cord blood bank in the Netherlands was established in 
Leiden by Sanquin (the Netherlands Red Cross) which runs the Dutch blood services. 
Subsequently, three other banks have been established at Groningen, Nijmegen and 
Amsterdam. Leiden acts as the hub for all haematopoietic stem cell activities in the 
Netherlands and is the home of the Europdonor Foundation (the Stem Cell Donor 
Registry of the Netherlands) which acts for EuroCord Nederland, the Dutch Registry 
of Cord Blood Units. The aim of EuroCord Nederland is to collect 5,000 CBU. 
Europdonor is also co-ordinating the STEMNET project which aims to link donor 
registries and stem cell banks in Central Europe with networks and registries in Western 
Europe such as NetCord and BMDW. In this way, the project aims to contribute to 
better therapy in Central Europe and, through the introduction of new ethnic groups, 
better chances for patients world-wide. Bone Marrow Donors World-wide also has its 
headquarters in Leiden. The Leiden Cord Blood Bank is a member of NetCord and a 
partner in EUROCORD. In April 2003, Leiden registered 1,535 CBU with NetCord.  
 
Among the seven public research biobanks, three are devoted to tissue banking: the 
Erasmus MC Tissue Bank is collecting tissues; the EORTC VTB Biobank is collecting 
tissues frozen and paraffin embedded and xenografts, and cell lines derived from bone 
tumours; the TuBaFrost biobank is collecting tissues. 
The other four public research biobanks are the BioBank Maastricht, which is 
collecting DNA, serum, whole blood and also urine, CSF, brestmilk, buccal cells, 
faeces, intra ocular fluid; the LifeLines Biobank is collecting DNA, serum, whole 
blood; the Netherlands Brain Bank is collecting serum, whole blood, tissues, and also 
CSF; and also the EuroBoNeT Biobank whose development has just started and is 
collecting DNA, serum, whole blood, tissues and also xenografts, cell lines all derived 
from bone tumors.  
 
In the following, a biobank of each category will be presented as an example. 
 
Public biobanks with research purposes 
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The overall aim of the LifeLines Biobank is to provide a state-of-the-art infrastructure 
for the study of universal risk factors and their modifiers for multifactorial diseases, by 
means of a common bank for DNA, serum, and other patient-derived samples, medical 
information, and modern and ultra fast ICT solutions to query these data. The biobank 
will be a nation-wide facility, ensuring Dutch collaborating centres and institutes a 
permanent resource for standardised isolation and storage of DNA, serum, plasma and 
urine from large cohorts of healthy volunteers and patients. It provides continued long-
term availability in optimal quality, easy and uniform access to the biological material, 
on an appropriate basis for genotyping and sample analysis, by a network-based 
bioinformatics system accessible from the different participating centres in the medical 
and biological research communities. The facility will incorporate equipment for low- 
and medium-throughput genomics and proteomics, whereas high-throughput genome 
screening will take place in Utrecht and Leiden. It secures a linkage of these human 
tissue samples to high quality medical records and phenotypic databases, with adequate 
protection of patients’ confidentiality, lower costs by requiring less staff, hardware and 
facility space than for individual cohorts. It guarantees higher quality and lower error 
rate by automation, cross-cohort analyses with other European cohorts, by standardised 
genotyping and biochemical sample analysis, enabling independent confirmation as 
well as large-scale studies.  
 
There will be special attention for standardisation of methodology and techniques. This 
will be achieved, in close collaboration, with several existing (European) partners, such 
as ICT companies (LIMS), UK Biobank and companies supplying cryofacility, and 
infrastructure for sample isolation, storage and retrieval, as well as other research 
initiatives such as the P3G consortium (as an associate member in the latter: 
questionnaires and related methodology).105 The biobank will be of strategic importance 
to the identification of genes, vital to the development of health-related biotechnologies, 
diagnostic applications and the quest for new therapeutic targets and drugs.  
 
The LifeLines Cohort will be the first study using the LifeLines Biobank. It 
investigates a representative sample of 165.000 participants from the three northern 
provinces of the Netherlands in a unique three-generation design. LifeLines is 
'hypothesis-driven', i.e. all data collection and analyses are performed on the premise of 
specific research questions. The central hypothesis is that interaction between universal, 
generic risk factors and specific modifiers, e.g. genetic, environmental and complex 
factors, accounts for the development of specific single disorders versus the clustering 
of multiple disorders in individuals.  
 
The TUBAFROST and EORTC VTB projects are central European databases 
collecting the information of frozen tumor tissues with the goal of centralizing the 
tumor tissues information to facilitate the search of doctors/researchers for tumor tissues 
which they need for their cancer research. So far, it is a virtual tissue bank with central 
database and local collection. The goal of these projects is to facilitate cancer 
research.106 Per se, these projects are international and the database information is 
networked. According to the biobanks investigators, it is very difficult to cope with the 
                                                 
105  www.lifelines.nl  
106  www.tubafrost.org  
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various legislations in European countries. In the scope of these two projects, a 
European code of conduct was developed describing how to deal with this.107  
 
Public biobanks with no necessarily research purposes  
The CONCOR registry was initiated in 2002 to make an inventory of the epidemiology 
and specific morbidity of adult congenital heart disease at national level. A rough 
estimate of the current number of adults, with congenital heart disease in the 
Netherlands is between 20,000 to 25,000 patients. This number is growing steadily at a 
yearly rate of approximately 5%, thanks to the development of new operation 
techniques for children with a congenital heart defect who, therefore, have a better 
prognosis and life expectancy. Since it concerns a new, rapidly growing, patient 
population with often substantial (post-operative) morbidity, it is important that 
comprehensive knowledge regarding the specific problems of this category of patients is 
available. Rapid progress is being made in studying the genetic causes of congenital 
heart disease and in identifying which genes are involved in the development of the 
heart. Genetic changes may give rise to congenital cardiac defects and the knowledge of 
the genetics of heart defects is likely to increase strongly in future years. Furthermore, 
most of the patients with congenital heart disease now live into their reproductive age. 
These considerations emphasize the urgent need for intensive genetic research, which 
requires large numbers of patients. The first goal of the registry was to include adult 
patients under treatment at one of the eight academic hospitals in the Netherlands. Data 
entry of patients under treatment at non-academic hospitals was started in 2004. At 
present (January 2006), more than 6,050 patients from 83 hospitals have been included. 
Blood samples for DNA analysis have been collected from 3,000 of these patients.  
 
ECARUCA (“European Cytogeneticists Association Register of Unbalanced 
Chromosome Aberrations”) a European database initiated by the European 
Cytogeneticists Association (ECA) 108and supported by the European Union, collects 
cytogenetic, molecular and clinical data109 of rare unbalanced chromosomal aberrations 
from all (cyto) genetic centres that are member of the ECA110. ECARUCA aims to 
improve patient care and collaboration between genetic centres in the field of clinical 
cytogenetics.111 
 
The aim of the Genomos project is to identify by prospective meta-analysis of 
association studies, susceptibility alleles for parameters of osteoporosis, i.e. BMD and 
fracture risk. Also, to look for the influence of gene-gene and gene-environment 
interaction on the effect of these risk alleles. Over the course of three years, the 
consortium has grown from 18.000 samples to now over 40.000 DNA samples of which 
about 50% is kept and genotyped centrally (at ErasmusMC). Procedures for both 
genotyping (using a reference DNA plate) and phenotyping have been standardized. 
The samples are from well characterized epidemiological study cohorts across Europe, 
as well as from Canada and the USA. The Genomos global consortium is part of the 
                                                 
107  To avoid inter-institutional variability or intrinsic bias in specimen quality in multi center studies, TuBaFrost has 
developed Standard Operating Procedures for sample quality. These Standard Operating Procedures and Quality 
Assurance measures must be implemented in each collecting institute in order to become a collector. 
108  http://www.biologia.uniba.it/eca/  
109  ECARUCA collects the cytogenetic research results and the accompanying clinical features, but does not collect 
the patient material used for the analysis itself.  
110  http://www.biologia.uniba.it/eca/   
111  www.ecaruca.net   
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HuGENET Network of Networks112 113 [14]. The Chronic Kidney Diseases project, 
the Netherlands Twin Register and the Netherlands Brain Bank are further public 
biobanks for research.  
 
Public biobank devoted only to clinical therapeutic use 
The Sanquin Bloodbank of rare bloodgroups of the Council of Europe at the Sanquin 
Blood Bank114 is a public biobank devoted only to clinical therapeutic use, collecting 
red cell concentrates of rare bloodgroups. Sanquin is a nationwide organisation with 
four blood banks, a division R&D, a Fractination Institute and a Diagnostic Lab for 
hospitals. It has some HLA typed donors for bone marrow transplant and or platelet 
transplant. The organisation of searching is done by Europdonor in Leiden. The Sanquin 
Blood Banks in Nijmegen and Rotterdam collect cord blood and keep them in storage. 
All data are sent to EuroCord in Leiden, which organises the matching of the cord blood 
from the donor with the patient. Sanquin has a Blood Bank for rare Blood Groups. The 
bank consists of about 1500 red cell concentrates kept in storage. If blood banks cannot 
find the correct red cell concentrate for a patient with cross matching problems, they can 
look in that blood bank. Since the last 20 years, the Blood Bank in Amsterdam has 
stored samples of all donations, and can go back to donor-identification number, 
donation, date of donation etc. This “serothek” is organised for research reasons. For 
example, a few years ago a research project on rheumatoid arthritis (RA) used this 
serothek. The samples of blood donors, who developed RA after a few years, were used 
to search for markers of the disease in their blood. The goal was to see whether certain 
markers could predict the development of RA, a few years before the donor had 
complaints about his health. No typing of the samples has been done. 
 
Commercial biobanks 
Cells4health BV is a Dutch holding, with affiliates in various European and Asiatic 
countries, specialized in the collection, processing and storage of stem cells derived 
from cord blood. Furthermore, Cells4health is working on advanced cellular therapy 
strategies to achieve effective medical treatments in the fields of vascular repair and 
regeneration, spinal cord injury and regeneration, stroke and regeneration. Partner 
laboratories of Cells4health BV are located in Freiburg (Germany) and Plymouth 
(United Kingdom).115 Cryo-Save is carrying out private commercial research and 
collecting whole blood. It is specialized in the isolation and storage of (adult) stem cells. 
Cryo-Save is a member of the Life-Sciences Group N.V., a Dutch holding with 
affiliates and partnerships in 20 countries and a nominal capital of more than five 
million Euros. Cryo-Save has a central laboratory in Brussels and a cooperation partner 
in Germany, and is one of the largest service providers in the world in the field of stem 
cell storage with more than 30,000 stem cell samples.116 
 
Sample collections 
                                                 
112  http://www.hugenet.org.uk/networks/list.html Human Genome Epidemiology Network, or HuGENet™ is a 
global collaboration of individuals and organizations committed to the assessment of the impact of human genome 
variation on population health and how genetic information can be used to improve health and prevent diseases. 
113  Private communication from André Uitterlinden, coordinator of the GENOMOS Project.  
114  http://www.sanquin.nl/Sanquin-eng/sqn_DiagnosticServices.nsf/p-
WebFSStart!OpenPage&h=0&body=9350EB325EBA2F97C12568AB00445FD9 
115  www.cells4health.nl  
116  http://www.cryo-save.com/  
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At the EuroBoNeT Biobank, the Erasmus MC Tissue Bank, the EORTC VTB Biobank 
and the TuBaFrost biobank, the selection of donors is made on the basis of whether they 
have a specific disease. At the BioBank Maastricht, the selection of donors is random as 
well as based on whether they have a specific disease or fulfil a specific condition. As 
this biobank is devoted to clinical research diagnostics, it can be assumed that the 
donors selected at random build the control group in the trial settings.  
 
The donors at the LifeLines Biobank and at the Netherlands Brain Bank are selected on 
a random basis. This is also the case for the Cryo-Save Biobank, which is not 
surprising, as this biobank is a private company and profit oriented, storing whole blood 
against payment. At the BioBank Maastricht, the LifeLines Biobank and the 
Netherlands Brain Bank, samples are collected by primary care workers and also by 
services and staff especially employed for this purpose. At all other biobanks, samples 
are collected by associated hospital staff or primary care workers.  
 
The Erasmus MC Tissue Bank, the LifeLines Biobank and the Netherlands Brain Bank 
are the only biobanks which do not collect any samples from different countries, 
whereas the others do. The EuroBoNeT Biobank, the EORTC VTB Biobank and the 
TuBaFrost biobank, which are all settled at the same institution117, argued that the 
various regulations in different countries are an impediment to collecting samples from 
different countries; therefore, a European code of conduct was developed for these 
biobanks, describing how to deal with this118. The biobanks considered can be divided 
into two groups of sample size: the Sanquin Bloodbank of rare bloodgroups of the 
Council of Europe, the EORTC VTB Biobank, the TuBaFrost biobank and the 
Netherlands Brain Bank with more than 1000 samples, but less than 5000. In contrast, 
the other biobanks have a large samples collection with more than 5000 samples. The 
Cryo-Save Biobank even mentioned 38,000 samples, but it cannot be ruled out, that this 
number refers to Cryo-Save’s samples in all European countries where Cryo-Save has 
activities and not only in the Netherlands119. 
 
All biobanks have in common that they also collect medical/phenotype information 
about the donors. Some biobanks collect additionally demographic information and/or 
ethnicity information and/or environmental/lifestyle information and/or genetic data. 
The Sanquin Bloodbank of rare blood groups of the Council of Europe also collects red 
cell antigens and the LifeLInes Biobank information about the medication used.   
 
Access availability and sharing of samples 
The Erasmus MC Tissue Bank, the BioBank Maastricht and the Netherlands Brain 
Bank are all stand-alone biobanks. No biobank provides open public access to its 
samples/data through internet. In case of existent networking with other biobanks, 
access to samples and data is always restricted120. Samples and data of the BioBank 
                                                 
117  University Medical Center Erasmus MC established in the city of Rotterdam: www.erasmusmc.nl  
118  www.tubafrost.org  
119This might be underpinned by the fact that, although the Cryo-Save Biobank in the Netherlands was addressed, the  
questionnaire returned came from Belgium.  
120 Interpretation of the answers to the question on the database connectivity is quite difficult because the definition of 
the “stand-alone” and “networked-intranet concepts” are not consistent for all. For instance, if one supposes that 
“stand-alone” means that the biobank is not networking with any other team in the institution where it is settled, the 
answer “stand-alone” and “networked-intranet” does not make sense. In contrast, one can suppose that “stand-alone” 
means “not networking with any other institution”. Due to this inconsistency, we cannot be sure that the respondents 
understood the question in the same way and, therefore, the answers must be interpreted very carefully. 
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Maastricht, a stand-alone biobank, are only used by researchers on-site. In contrast, 
samples and data from the Erasmus MC Tissue Bank and the Netherlands Brain Bank 
are mentioned to be used also by researchers from other institutions in the same country, 
by researchers from different European countries and even from the rest of the world. It 
may be assumed that these biobanks can indeed send their samples to other researchers 
from outside countries that need them for research but cannot send any data through an 
internet connection121. Indeed, the Netherlands Brain Bank has already been involved in 
some international projects. All others biobanks, not cited yet, are used by researchers 
on-site and also by researchers in the same countries, in other European countries and 
even in the rest of the world (LifeLines Biobank). However, among them, only the 
EORTC VTB Biobank and the TuBaFrost Biobank have been already involved in 
international research projects. The reason why the Erasmus MC Tissue Bank has not 
been involved in international projects already might be the problem mentioned from 
the investigators of the biobank as occurring when cooperating with researchers in other 
countries: the legislations in the European countries are too various. The Cryo-Save 
Biobank though not having been involved in international projects already mentions the 
fact that “non commercial samples” is a problem thereby. Although this answer is not 
quite clear, one can assume that this private for-profit biobank would not cooperate with 
biobanks only using "non-commercial samples” for their research. Finally, samples and 
data of rare bloodgroups of the Sanquin Bloodbank of the Council of Europe are used 
by other therapeutical medical doctors in other European countries. 
 
According to the Cryo-Save’s questionnaire, samples and data collected are only used 
by other researchers in other European countries. (However, this questionnaire was 
returned from Belgium, where the legislative situation is not clear, e.g. it is unclear 
whether private cord blood banks are allowed or forbidden, which might be the reason 
for Cryo-Save samples and data not being used currently in Belgium.).  
 
No biobank surveyed provides free access to its samples and data. The following 
biobanks provide access only against payment: the Sanquin Bloodbank of rare 
bloodgroups of the Council of Europe, the Cryo-Save Biobank, the BioBank Maastricht 
and the Netherlands Brain Bank. The others only provide restricted access to their 
samples and data: the EuroBoNeT Biobank, the Erasmus MC Tissue Bank and the 
TuBaFrost Biobank after negotiating reimbursement of costs, cooperation and co-
publication; the EORTC VTB Biobank only provides access to trial related institutes 
and the LifeLines Biobank provides access to samples/data only to approved research 
projects. By whom these projects have to be approved is not mentioned. The Cryo-Save 
Biobank is the only biobank which indeed performs research not regulated by a 
Research Ethics Board approval.  
 
The current consent forms and legal frameworks allow most of the biobanks to share 
samples and data with researchers outside the country, but only data are allowed to be 
shared at the Lifelines Biobank. The LifeLines Biobank and the Netherlands Brain Bank 
are the only biobanks devoted to research to which researchers using the samples are 
required to feed back results of their research to the biobank., This is not the case for all 
other biobanks.  
 
                                                 
121 It is also possible that this apparent contradiction can be put down to the lack of definition of the “stand-alone 
biobank” concept. 
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Consent 
The handling of consent is not homogenous, even among all public biobanks devoted to 
research. The EuroBoNeT Biobank, the EORTC VTB Biobank and the TuBaFrost 
biobank from the Erasmus Medical Center request a special consent procedure defined 
in their code of conduct. The Erasmus MC Tissue Bank uses blanket consent with an 
opt-out option i.e.donors can object the use of their tissues for medical research 
purposes. They have also developed a code of conduct for secondary use of residual 
tissue122. Cryo-Save, the private cord blood bank, requests informed consent as 
specified in the contracts signed with the donors/clients.  
 
Information arising from biobank studies can be referred back to individuals (personal 
results) if they have given their consent at the Cryo-Save Biobank, the EuroBoNeT 
Biobank and at the BioBank Maastricht. The LifeLines Biobank may also refer 
information, arising from studies, back to individuals, even if the donors did not give 
their consent. At other biobanks, information arising from biobank studies cannot be 
referred back to individuals (personal results). However, at the Erasmus MC Tissue 
Bank, if this information is “beneficial the proper medical treatment routes will be 
found, if findings are of influence on diagnosis it will be told to the treating physician 
who has the best judgement how to deal with the information.” 
 
For all biobanks considered, it is possible for donors to withdraw their consent to store 
samples in the biobank. Also, a common feature to all biobanks: privacy of donors is 
protected through coding with a key code.  
 
Regulatory aspects 
The following laws are relevant for human biobanks in the Netherlands: 
 
• in February 2004, a new law was passed on “Safety and quality of human tissues”, 
in force since 1 July 2004. The law states that, in principle, all human material that 
becomes available to a medical professional must be offered to an ‘Organ Bank’. 
The bank then decides whether to accept it or to dispose of it as medical waste. 
When the relevant parts of the Act come into force, the Organ Banks will only be 
able to operate with a Government permit and will be inspected regularly. This 
means that all cord blood banks, whether public or private, will have to apply for a 
permit to operate as an Organ Bank. It has been specifically stipulated that no-one 
may profit from the storage of cord blood for later personal use. This means that, as 
long as profits are invested in the bank, there will be no problem and the law 
allows commercial corporations to apply for an Organ Bank permit as long as they 
keep their cord blood storage activities administratively and financially separate 
from their other (e.g. pharmaceutical) activities and within the intentions of the 
law.  
• the “Decree concerning Requirements for the handling of Human Tissue” in force 
since 1 July 2004, specifies requirements for Organ Centers (under the Organ 
Donation Act) and Organ banks (under the Safety and Quality of Human Tissue 
Act).  
• still in preparation is the Bill on the right of determination concerning human 
tissue.  
 
                                                 
122  www.fmww.nl  
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Privacy/Data Protection 
The EU Directive 95/46/EC on the protection of individuals, with regard to the 
processing of personal data and on the free movement of such data, was implemented to 
national law in the law from July 2000 which entered into force on 1 September 2001.  
 
2.2.4 Biobanks in Southern Europe 
 
In the context of this study, Southern Europe comprises the countries: Cyprus, France, Greece, 
Italy, Malta, Portugal and Spain. The search for biobanks in this region of Europe turned out to 
be difficult, mainly due to the lack of publicly available information. However, several small 
university based collections which are disease-specific do exist. Some of these were identified 
through Eurobiobank, a consortium of European Rare Diseases Biobanks, and are discussed in 
the following sections. Biobanking activities in Cyprus, Portugal, Greece and Malta were scarce 
(or difficult to identify), and are thus not discussed in this report .  
 
2.2.4.1 Biobanks in Italy 
 
Eight biobanks and one consortium of biobanks were identified in Italy. Although it can 
be assumed that some small scale biobanks for research exist in many hospitals, it was 
only possible to retrieve a few of them, for which information was available. Though an 
initiative to set up a large scale biobank was announced in June 2003, it was only set up 
in December 2005 and has been constituted within the Center of Transfusion Medicine, 
Cellular Therapy and Cryobiology, in Milan. The following biobanks were identified: 
 
⇒ GEHA 
⇒ GENESKIN 
⇒ IMPROVE 
⇒ Istituto Nazionale Neurologico Carlo Besta 
⇒ NHMGB - Naples Human Mutation Bank of the Cardiomyology and Medical 
Genetics 
⇒ Ospedale Maggiore Policlinico,  
⇒ University of Milano, 
⇒ University of Padova, Department of Neurosciences 
⇒ CNRB - Centro Nazionale per le Risorse Biologiche 
⇒ European IgA nephropathy Biobank 
⇒ Center of Transfusion Medicine, Cellular Therapy and Cryobiology 
At the University of Padova, Neurosciences123 Department a neuromuscular bank, was 
started in 1980 and collects most muscle pathologies. The bank was first officially approved by 
Telethon in 1994. The neuromuscular bank contains more than 6000 tissue samples stored 
frozen (5600 muscle, 240 nerve, 122 thymus, 18 heart, 54 skin, 9 chorion villi) and about 400 
new samples are collected every year. The bank stores the slides of stained sections of about 
6500 muscle biopsies, and 2300 muscle specimens embedded in epoxy resin for electron 
microscopy. About 1950 DNA samples from patients and relatives with inherited 
neuromuscular disorders are stored. A standard protocol for collection of biopsies is followed: 
at the arrival in the laboratory, each sample is subdivided in several fragments, stored both in a 
bank of frozen tissues for morphological and biochemical studies, and in a bank for tissue 
culture, where more than 2300 muscle biopsy samples are kept in liquid nitrogen. An informatic 
database records the clinical data, diagnosis, muscle biopsy code number and location of each 
sample. The Bioethical Committee of University of Padova, approved the consent form for 
                                                 
123  http://telethon.bio.unipd.it/NMTB 
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patients muscle biopsy and DNA sample collection, analysis and storing. The "Neuromuscular 
Tissue Bank" is supported by Telethon Italian Foundation124 since 1996. The bank is part of 
Eurobiobank. 
 
The Neuromuscular Biobank of the Dpt. di Scienze Neurologiche, Ospedale Maggiore, 
Milan125 has been operative for 27 years and received the ISO 9001 Certification in 2002 by 
DNV. It consists of four different laboratories (morphology, biochemistry, genetics, tissue 
cultures) with two specifically equipped storage rooms, all related to a Department for the 
clinical evaluation of patients and their follow-up. The laboratories examine biological 
specimens obtained from hospital patients, or sent by other hospitals/laboratories after signing a 
legal agreement with the Unit. All specimens are obtained from patients, affected with 
neuromuscular disorders, after informed consent –.This bioank is also part of the Eurobiobank 
Consortium. 
 
The Integrated Project (IP) GEHA has been instituted to identify genes involved in healthy 
ageing. The plan of this project is to: (i) collect 2650 long-lived (90+) sibpairs from 11 
European countries; (ii)  perform a genome scan by microsatellites in all the sibpairs (a total of 
5300 individuals) (iii) case studies (i.e. the 2650 probands of the sibpairs) and controls (2650 
young people), the three genomic regions  (chromosome 4, D4S1564, chromosome 11, 
11.p15.5, and chromosome 19, around APOE) which were identified in previous studies to be 
involved in ageing and life longevity. 
 
The Naples Human Mutation Gene Bank (NHMGB)126 was established in 1994. Its main aim 
is to collect samples from patients with neuromuscular diseases and primary cardiomyopathies, 
showing the Mendelian mode of inheritance. Each sample set in the bank includes the DNA 
sample from the affected individual, a sample from his/her first-degree relatives where 
necessary (depending on the mode of inheritance) and the result of the molecular investigations. 
A comprehensive pedigree and a clinical profile are also recorded. The bank also contains DNA 
samples from normal people, useful in the study of polymorphisms in the population. The 
"Naples Human Mutation Gene Bank" has been supported by Telethon Italian Foundation since 
1996; it is a member of the Eurobiobank consortium. 
 
The National Biological Resource Centre (Centro Nazionale per le Risorse Biologiche-
CNRB)127 is a non profit consortium, which groups a network of biotechnological Italian 
Institutes of excellence that are strongly representative at local and national level within the 
field. The CNRB's legal seat is the Italian Institute for Industrial Promotion (Italian Ministry of 
the Productive Activities) The CNRB is a network, aiming at fostering and coordinating the best 
operative programs linked to technology transfer and innovation policies. It also thrives at 
creating stable links between research and industry, within the national and international 
biotechnological, bionanotechnological and bioinformatics research and production circuits. 
 
The Center of Transfusion Medicine, Cellular Therapy and Cryobiology128 is composed of 
two banking Units. The first, is the Milan Cord Blood Bank operational since 1993 which 
stores and supplies placental cord blood from and to the whole world. The second, is the newly 
set up (December 2005) Biobanca Italiana, an Italian biobank. This bank has been set up with 
the intention of collecting random biological samples of the Italian population. In addition it 
also holds disease specific samples.  
 
 
                                                 
124  http://www.telethon.it/ 
125  http://www.centrodinoferrari.com/sito/en/servizi/diagnostica_banca.html 
126  http://cardiomiologia.it 
127 http://www.cnrb.it/index.htm 
128  http://www.policlinico.mi.it/ 
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Regulatory aspects 
The Constitution of the Republic of Italy (Art. 32 par 2) set the ethical basis, upon which 
informed consent for the deposition of biological samples is based. In addition, amendments to 
the Italian Medical Code (art 38) of the Italian Medical Federation and the European Charter of 
Fundamental Rights (2000/ C354/01) have reaffirmed the need for proper informed consent. 
More specifically, the Italian Society of Human Genetics and the Telethon Foundation have set 
up guidelines for the proper running of Human Biobanks. The local ethics committees within 
the health facilities or authorised research institutes were given legal status in 1992 by a 
Ministerial Decree and, subsequently by another Decree in 1997. The EC Directive 2001/20/EC 
was implemented by the Legislative Decree No. 211 of 23 June 2003129. Regional Bioethics 
Committees (REC) were created in 2000 and act as co-ordinators for local research ethical 
committees, as well as providing a link between them and the National Bioethics Committee. In 
regions where only a regional REC exists, they review research proposals. The National 
Bioethics Committee was established in 1990 by a Prime Minister's Decree. It acts as a 
consultative body of the Council of Ministers. The National Ethics Committee for Research and 
Clinical Trials established 1992, advises the Ministry of Health on ethical and scientific issues 
and is in charge of co-ordinating ethical and scientific review of multi-centre clinical trials of 
substantial national interest. 
 
Privacy/Data Protection 
The Italian Data Protection Act was enacted in 1996130 and fully implements the EU 
Data Protection Directive. The act covers both electronic and manual files, for both 
government agencies and the private sector. As a member of the Council of Europe, 
Italy has signed and ratified the Convention for the Protection of Individuals, with 
Regard to Automatic Processing of Personal Data (ETS No. 108) and the European 
Convention for the Protection of Human Rights and Fundamental Freedoms. The 
OECD Guidelines on the Protection of Privacy and Transborder Flows of Personal Data 
have also been adopted.  
 
2.2.4.2 Biobanks in France 
 
Similar to the Italian situation, though small/medium scale biobanks for research should 
exist in many centres, very little information was publicly available (in English). 
However, two biobanks were identified in France: Généthon DNA and Cell Bank131 
was created in 1990 and its main aim is to promote progress in genetic research, in the 
interest of patients and their families, by making high quality cells and human products 
available to the scientific community; Généthon's DNA and cell bank is devoted, 
primarily, to genetic research on rare genetic diseases. The relationship between the 
DNA and cell bank, and those using its services is regulated by a charter. The bank's 
relationship between donors and users is regulated by ethical principles governing the 
receipt of human products, its removal, processing, storage and any associated 
information. Every project intending  to use the DNA and cell bank, must be requested 
to the arbitration committee of the Bank and formerly the Collection Department in 
writing. This arbitration committee is assisted by experts if necessary. On acceptance of 
the project, a contract is prepared specifying the rights and obligations of the parties. 
This bank is part of the EuroBiobank Consortium. 
 
                                                 
129  https://oss-sper-clin.agenziafarmaco.it/normativa/decreto_24062003_inglese.pdf? 
130  http://www.dataprotection.it/codice_privacy_english.htm 
131  http://www.genethon.fr/?id=82 
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In 1990, the Picardie Regional Council and the Somme General Council launched the 
Biobanque de Picardie132. Both Councils invested in the project by providing grants 
for the construction, functioning and equipment of the biobank. The biobank accepts 
cellular tissues, DNA, RNA and serum. The DNA and cell bank collects and conserves 
biological samples in accordance to the protocols requested by the partners.  
Both biobanks are certified Biological Resource Centres (BRCs) thus carrying out 
activities in accordance with the BRC definition of the OCDE working group: 
"specialized resource centres that acquire, validate, study and distribute collections of 
cultivable organisms (micro-organisms, plants, animals, or human cells), replicable 
parts of these organisms (genomes, plasmids, DNA libraries) and viable but not 
cultivable organisms". In France, official BRCs have to be certified by the AFNOR 
normalization body.    
In addition, some cohort studies are also storing biological elements for long term 
research and should be considered as biobanks, such as the “Elfe” cohort involving 
20.000 children or the “Constance” cohort involving more than 200.000 adults.     
 
Regulatory aspects 
In France, there is a specific law applicable to collections of Human biological material, 
from their removal to their storage, including their transformation and their distribution 
(“Décret n°2007-1220 du 10 août 2007” 133. and “Arrêté du 16 Août 2007” introducing 
the new articles L. 1243-3 and L. 1243-4 of the Public Health Code). If samples are 
being processed for internal use only, a notification to the French Ministry of Research 
of the existence of such sample collection is sufficient; an authorization will be needed 
is the samples are to be distributed to other institutions. It is interesting to notice that 
this regulation shall not apply on sample collections hosted outside of France. 
Nevertheless, an authorisation to export or import Human samples is required to allow 
samples to cross the French borders (Public Health Code article R.673-22).  
 
In addition, a complex legal framework is applicable in relation to issues on data 
protection, medical research and informed consent133. Here, the protection of the person 
and his/her personal data, in case of medical research, is regulated by different 
authorities with different roles: 
 
 the Committees for the Protection of Persons (CPPs): the committee issues an 
opinion to the biomedical research investigator, for the protection of individuals 
and for any subsequent amendments to the research protocol; the CPP can also 
issue an opinion about a collection of biological samples, especially when 
Human biological material is planned to be used for purposes different from 
those described in the initial clinical research protocol or for scientific research 
projects not requiring the approval of a protocol;  
 the French Health Products Safety Agency (AFSSAPS, “Agence Française de 
Sécurité Sanitaires des Produits de Santé”)aaa must be consulted before starting a 
clinical trial in order to authorize the protocol and the sites;  
 
                                                 
132  http://www.biobanque-picardie.com/ 
133 http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000829163&dateTexte= 
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 the CNIL (Data Protection Supervisory Authority)134is responsible for the 
supervision of any use of personal data including biomedical research data and 
its authorisation is required prior to the collection or the processing of health 
personal data; 
 
 the CNIL (Data Protection Supervisory Authority) is responsible for the 
supervision of any use of personal data including biomedical research data and 
its authorisation is required prior to the collection or the processing of health 
personal data; 
 
 the CCTIRS (consultative committee on health data processing in research) 135 
must be consulted prior to the CNIL in order to provide the CNIL with an 
opinion on the lawfulness of the processing of personal health data; 
 
 the French medical board (“Conseil de l'Ordre des Médecins”) reviews each 
contract engaging a doctor in a clinical trial in order to verify that the conditions 
settled in the contract are aligned with the reality of the study; both the protocol 
and the case report form (CRF) must be included in the submission dossier to 
allow this evaluation; 
 
 the CCNE (National Consultative Ethics Committee)134 is an independent 
committee which missions are defined in the Bioethics law of August 6, 2004; it 
gives general opinions on ethical issues related to biology, research or health but 
do not review research protocols (e.g., see CCNE Opinion n°77 on Ethical 
problems raised by biological material collections and biobanks issued on March 
20, 2003)136; 
 
 additional local and institutional Ethics Committees exist within some 
institutions such as hospitals; they issue specific and general decisions on ethical 
issues but rarely review research protocols; their opinion is not required by the 
law but they contribute to the definition of ethical best practice.  
 
The approval for biomedical research requires various procedures. If the research 
involves personal data processing, then full approval requires both an approval for the 
research protocol and a separate legal procedure for data processing. 
 While CPP considers the patients protection within the research protocol, the French 
Health Products Safety Agency is focusing on the patient safety (AFSSAPS)137 and the 
French medical board checks if the relation binding the doctors to the sponsors are 
ethically acceptable, especially regarding the financial agreements. Approval of the 
protocol by the AFSSAPS, the CPP and the French medical board is compulsory, 
except if the study does not involve patients (only data), in which case the CPP opinion 
is not needed. AFSSAPS approval is not needed so far for studies which are not 
considered as biomedical research (which do not involve the use of a drug, e.g., 
epidemiological studies) but the new law proposition called “Jardé” might change this 
in the near future. Research projects involving samples from embryos or deceased 
                                                 
134 http://www.cnil.fr/ 
135 http://www.enseignementsup-recherche.gouv.fr/cid20537/cctirs.html 
136 http://www.ccne-ethique.fr/docs/fr/avis077.pdf 
137 http://www.afssaps.fr/ 
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persons are subject to specific regulations (e.g., an authorization issued by the “Agence 
de la biomédecine”138 is needed when banking or conducting research projects on  
embryos or embryonic stem cells);           
The legal procedure regarding the data processing depends on the type of study. If the 
study is in the scope of the CNIL guideline for biomedical research (MR-001)139, then a 
unique declaration to the CNIL is sufficient and covers all other future studies which are 
in the scope of this guideline. If the study is not in the scope of MR-001 (e.g., 
epidemiologic studies or studies in which samples are collected for purposes not defined 
in the study protocol), then a specific authorization should be gathered from the CNIL 
for each study. In such case, the CCTIRS should be contacted first to issue an opinion 
and then refers to the Data Protection Supervisory Authority (CNIL) for approval (if the 
study does not aim to improve scientific knowledge the CCTIRS opinion is not needed 
and the CNIL should be notified directly). It is important to notice that data that have 
been anonymized (for which the link between the subject and the data has been 
permanently broken) are not subject to personal data protection regulations anymore, 
thus the CNIL does not need to be involved. 
 
2.2.4.3 Biobanks in Spain 
 
Two biobanks were identified in Spain:  
 
• the Instituto de Investigación de Enfermedades Raras IIER is located inside an 
institute, namely "Instituto de Salud Carlos III", with more than 10 centres dedicated to 
Health Research, including basic research, epidemiological research and applied clinical 
research. The IIER (former CISATER) was designated by the World Health 
Organization Regional Office for Europe, as a Collaborating Centre for the 
Epidemiology of Environmental related Diseases. A number of rare diseases are 
included within this framework. It is a foundation member of the International Society 
for Biological Environmental Repositories (ISBER), created by large American and 
European research agencies. Following this Society instructions and collaborative 
agreement with CDC, the CISATER created a DNA and biological samples bank for the 
Toxic Oil Syndrome cohort and is now establishing the Spanish bank of biological 
samples for Rare Diseases. As it is a partner of Eurobiobank, IIER collections and 
methods are published in the EBB website  
 
• the Banco Nacional de ADN140 is a service of the University of Salamanca. It 
receives, processes and stores samples of DNA, plasma and cells of voluntary 
donors, as well as basic information on the health and socio-demographic data of 
the donors. One of the bank’s objectives is to try and obtain a representative 
sample of the resident population in Spain, and more than 1,000 voluntary 
donors have already provided blood for this bank. These samples are at the 
disposal of the scientific community, in order to facilitate, promote and develop 
national and international scientific investigation on human evolution and the 
genetic diversity in relation to the health and genesis of the disease. The bank 
was officially inaugurated in 2004, by a contract between the Foundation 
Genome Spain, the Department of Health of the region of Castilla and Leon, and 
                                                 
138http://www.agence-biomedecine.fr/professionnels/recherches-sur-l-embryon-et-les-cellules-souches-
embryonnaires.html 
139http://www.cnil.fr/en-savoir-plus/fiches-pratiques/fiche/article//une-procedure-simplifiee-de-declaration-pour-les-
recherches-biomedicales 
140  www.bancoadn.org 
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the University of Salamanca. Recently, a new call for tenders has been published  
to create four new banks for high prevalence diseases. These four new banks 
will be nodes of the DNA National Bank network and they are focusing on 
neuropsychiatric, metabolic, cardiovascular and oncologic diseases141.  
 
Regulatory aspects 
 
Biobanks in Spain are regulated under the law 14/2007 on biomedical research. Every 
health centre that intends carrying out research and clinical trials must have an REC. 
The health authority of each autonomous community authorises these REC’s. As a 
member of the EU, the Spanish data protection law is in conformity with the EU 
directive. The 41/2002, of 14 November law, regulates the autonomy of the patient, the 
rights and duties of providing information and clinical documentation. The Royal 
Decree of 65/2006, of 30 January regulates the activities relating the import/export of 
human tissues. The Royal Decree 65/2006 regulates international circulation of samples 
for use in vivo, no in vitro. The international circulation of samples for in vitro use is 
going to be regulated by the government, as a development of the law 14/2007. In 
Spain, data protection is guaranteed in the Constitutioin.   Organic Law 15/1999 of 13 
December on the Protection of Personal Data142 and the Royal Decree 994/1999, of 11 
June, on Safety Measurements Rules for Computerized Personnel Data, constitute the 
most updated regulation in this issue. More importan than the Royal Decree 944/1999, 
is the Royal Decree 1720/2007, that aproves the Reglament that develops this Organic 
Law. 
 
 
 
 
2.2.5 Biobanks beyond Europe 
 
Some major biobanking initiatives outside Europe are discussed in this section. Due to 
the challenging geographical area to cover, the main focus of this section focusses at the 
first level of large biobanks. However, a more diverse sample of biobanks was gathered 
for the United States showing different models of biobanking activities143.  
 
2.2.5.1 United States of America 
 
In a report prepared by the RAND organization, following an extensive mapping of 
human biobanks in the United States in 1999, the conservative estimate number of 
tissue collections was a staggering 307 million tissue specimen, accumulating at a rate 
of more than 20 million samples per year [15]. Given the frantic race towards scientific 
developments and improvement of health, we can only imagine today’s actual numbers. 
Thus, this section does not pretend to provide an exhaustive mapping of all biobanks.  It 
will focus on the range of tissue banks which can be used for research and that provides 
a potential for collaboration or interesting models of biobanking.   
                                                 
141  http://www.bancoadn.org/imagenes/noticias_web/samples_of_prevalent_diseases_in_the_spanish_population.pdf 
142  https://www.agpd.es/upload/Ley%20Org%E1nica%2015-99_ingles.pdf 
143  P3G is a not-for-profit (shouldn't this be "profit-making") organization aimed at facilitating collaboration in the 
field of population genomics.  P3G maintains a website with descriptive information. on population based research.  
For this section, information made available through the P3G Observatory (www.p3gobservatory.org) was used to 
complete the information collected through the ESTO questionnaire. The HUMGEN website was used to identify 
applicable legislation and guidelines (www.humgen.qc.ca). 
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Biobanks identified 
The tissue banks vary according to purpose, size, and nature of the tissues collected. For 
the purpose of this section, we have classified the biobanks identified according to the 
following categories:  
 
• nature of the material collected: tissue (pathology, brain, heart tissue, etc); stem 
cell; blood; 
• purpose of the collection: specifically for research,, clinical, or transplant 
purposes; 
• funding: private, public/non-profit, hybrid.  
 
Tissue Banks 
o Penn State Cancer Institute (PSCI) Tissue Bank 
o TARPS Tissue and Research Pathology Services (University of Pittsburgh) 
o Pediatric Rheumatology Tissue Repository (PRTR) is a national resource 
o Early Detection Research Network Exchange (EDRN) -NCI 
o Cooperative Family Registry for Breast and Colorectal Cancer (NCI) 
o Tissue Bank Shared Service/Greenbauhm Cancer Center/Maryland 
o Children Oncology Group (NCI funded) 
o Armed Force Institute of Pathology-National Pathology Repository 
National Institute of Child Health and Development (NICHD), Brain and Tissue 
Bank for Developmental Disorders 
o Kathleen Price Bryan Brain Bank 
o Stanley Foundation Brain Collection 
o Harvard Brain Tissue Resources Center 
o New York Brain Bank 
o National Parkinson Foundation Brain Endowment Bank 
o Human Brain and Spinal Fluid Resource Center 
o McKnight Brain Institute Brain Bank 
o National Alzheimer Coordinating Center 
 
Pathologists in the hospitals and health Institutions are collecting human tissue for 
clinical diagnostic purposes.  By law, they are required to keep these tissues for 
validation for a period of time ranging from 2 to 10 years144. These collections or the 
leftovers from clinical procedures have an important potential for research purposes, 
however, their use for research must comply with legal and ethical requirements 
(including a proper consent process). For instance, the National Pathology Repository 
housed at the Armed Force Institute of Pathology (AFIP) currently stores: ‘over 50 
million microscopic slides, 30 million paraffin tissue blocks, and 12 million preserved 
wet tissue specimens’145. According to their website, this resource is currently ‘under 
utilized’ and collaboration with AFIP is encouraged. Moreover, many hospitals have 
organized their own local tissue bank/registry, ranging from a relatively modest to a 
large scale.   
 
The NIH is the main Federal focal point for medical research in the United States.  It is 
composed of 27 research institutions and centers.  The NIH is supporting various 
                                                 
144 CLIA Regulation, sub-part J: tissue retention (493.1105  Standard: Retention requirements).  
145  http://www.afip.org/Departments/repository/npr.html.  Date Accessed: April 1st 2006 
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infrastructures for tissue banking across the United States. In the field of Cancer 
Research, the NIH National Cancer Institute is the lead organization for funding and 
coordinating research efforts to find a cure for cancer. The availability of high quality, 
well annotated tissue is pivotal to the success of such research, thus the NCI is one of 
the key players in the development of biobanking research tools. The pooling of 
biological resources is an important strategic asset in a highly decentralized collection 
model. Various strategies to virtually or concretely pool biobank resources together 
have been put in place and are supported by the NCI. The pooling of these resources can 
take various forms:  
 
"There are three main models of collection and storage operations: 
decentralized collection with centralized storage, centralized collection and 
storage, and decentralized collection and storage " [16] 
 
An example of decentralized collection and storage of tissue is the Cooperative 
Human Tissue Network. Through a management system, the CHTN can coordinate 
the procurement and distribution of tissues from routine surgical resections and 
autopsies.  
 
"CHTN provides biomedical researchers with access to human tissues. Six 
member institutions coordinate the collection and distribution of tissues across 
the United States and Canada in six regional divisions. The CHTN specializes in 
the prospective procurement, preservation, and distribution of human tissues for 
research. In addition to normal, benign, and malignant tissues, tissues from 
patients with specific diseases such as ulcerative colitis, a premalignant state, 
are provided"146 
 
CHTN was established in 1987 and claim to have provided ‘more than 500,000 high 
quality specimens from a wide variety of organ sites to over a thousand investigators’. 
Tissue is offered, in priority, to peer-reviewed funded investigators, including 
investigators from Federal and National laboratories. However, the priorities list goes 
all the way down to include private funded research. Access to tissue is conditional 
upon IRB review and other requirements set by the Network. Canada is the only foreign 
country for which tissues are provided (via the Midwestern Division)147. 
 
The NIH-NCI Early Detection Research Network is another example of an effective 
collaboration, where research centers can virtually pull together the specimen collected 
in a decentralized way. The EDNR members seem to be all American. The EDNR 
claims to have access to almost 92 000 samples.148 
 
The NIH-NCI Clinical Trial Cooperative Group Program funds various research 
platforms collecting tissue for research.  For instance, the Cooperative Oncology 
Groups (COG) collects tissue from paediatric clinical trials. It maintains a tumour bank 
and cell lines for research. It is a joint effort from Canada and USA, however, 
applications for membership from the international community are also considered.   
 
                                                 
146  National Biospecimen Network Blueprint, (2003) appendix N. 
147  http://www-chtn.ims.nci.nih.gov/require.html 
148  http://edrn.nci.nih.gov/resources/erne-specimen-summary 
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TARP is an example where tissues are collected in various hospitals but are centrally 
banked at one location, namely the University of Pittsburgh.  In operation since 1991, 
TARPS ‘serves as the central support for UPCI research programs needing tissue 
materials from patients seen at the University of Pittsburgh Medical Center (UPMC)’149. 
It collects neck cancer tissue and is being broadened to include gastrointestinal and 
pancreatic cancers, haematological malignancies, and melanomas.  Specimen 
distribution is based on a defined priority order of usage for investigators involved in a 
particular research field. The Tissue Utilization Committee (TUC) establishes priorities 
and handles any conflicts. Based on a similar approach, the PennState Cancer 
Institute (PSCI) is collecting tissue within the hospital for the primary use of 
researchers within their Research Center or affiliated institutions150. As of 2006, the 
bank contains 2855 fresh frozen 278 OCT embedded and 2246 paraffin fixed normal, 
tumour and non-tumour samples. The Tissue Bank Shared Service/Greenbauhm 
Cancer Center/Maryland has a similar ‘in-house’ service for its members and 
affiliates.  
 
Besides cancer research which is an important area of activity when it comes to tissue 
banking, other disease-focused sectors of research are establishing similar organized 
resources at a small or large scale. Brain, heart, bone and other tissues collected in local 
hospitals, can be used for research purposes. These biobanks can be supported by 
private foundations, dedicated to fighting a particular disease or through public research 
funds in research centers. They are usually housed in hospitals and other health 
institutions. ,We have focussed our attention, for this project on brain banks. Our 
research revealed more than 20 brain banks throughout the country. For instance, the 
Kathleen Price Bryan Brain Bank located at Duke University, contains 1200 brains 
for research. These brains are collected by pathologist in a local institution: the Memory 
Disorders Clinic (North Carolina). It is a member of the International Brain Banking 
Network whose goal is to improve the acquisition and distribution of quality 
neurospecimens to qualified neuroscientists from anywhere in the world. The Stanley 
Foundation Brain Collection is located at the Uniformed Services University of the 
Health Sciences (USUHS) in Bethesda, Maryland. It collected around 600 brains from 
1994 to 2005.  This biobank will ship tissues to foreign countries.   
 
NCI is leading a large-scale initiative to improve what has been identified as the most 
difficult problems that will drive 21st century cancer research: the limited availability of 
carefully collected and controlled, high-quality human biospecimens annotated with 
essential clinical data and properly consented for broad investigational use: 
 
‘Although many existing tissue repositories in the United States collect and store 
millions of specimens for many types of scientific investigations, the contents of these 
repositories are frequently collected and stored under varying conditions, making it 
difficult for scientists to compare or pool genomic and proteomic results from 
biospecimens across institutions. Because many of these samples were initially 
collected for a broad range of uses, the amount of clinical information associated with 
these biospecimens also varies widely, and is rarely detailed or longitudinal. In 
addition, many of these biospecimens may not have appropriate donor authorization for 
genetic studies. Finally, current access to existing specimens is often uneven, further 
                                                 
149  http://www.upci.upmc.edu/facilities/tarps/index.html 
150  http://www.hmc.psu.edu/cancer/research/tissue/allocation.htm 
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impeding scientific progress. The heterogeneity among existing repositories poses a 
challenge to support genomic and proteomic research, particularly concerning the 
ability to conduct and compare large numbers of biospecimens to capitalize on genomic 
and proteomic technologies.’151 
 
To change this situation, the NCI has created the Office of Biorepository and 
Biospecimen Research in 2005. The OBBR serves as the coordinating and management 
center for overarching biospecimen-related policies, practices and other related issues 
across the NCI’s biorepositories. One of the key initiatives of the OBBR is the creation 
of the National Biospecimen Network.   
 
National Biospecimen Network Blueprint152 lays the foundation to provide a solution to 
this situation.  The solution lies not in the creation of a mega biobank but rather a solid 
network of high quality biobanks, in the pure tradition of NCI cooperation. : 
‘The NBN (http://biospecimens.cancer.gov/nbn/blueprint.asp) is a concept for a 
common biospecimen collection and biorepository infrastructure that promotes 
resource building and sharing for team science. Such an infrastructure would harness 
the potential of new technologies for cancer research, while ensuring that the privacy 
interests of biospecimen donors are preserved. The NBN would support a 
comprehensive framework of policies and technology to increase the number and 
quality of biospecimens available for research. It would include deployment of a robust, 
flexible, scalable, and secure bioinformatics system that supports the collection, 
processing, storage, annotation, and distribution of biospecimens and data using 
standard operating procedures based on best practices.’153 
Such a National Biospecimen Network could change the landscape of biobanking in the 
United States currently faced with multiple parallel efforts to create networks of virtual 
or real tissue repositories.   
The BRN has active collaborations with other NCI programs such as The Cancer 
Genome Atlas and Clinical Proteomic Technologies for Cancer. Through these 
partnerships, the BRN serves as a resource for project grantees and presents new 
opportunities for biospecimen research. 
 
Stem Cells 
⇒ University of California, Human Embryonic Stem Cell Line 
⇒ WiCell Research Institute 
 
Human Stem Cell research is a leading field of research. In 2001, the Bush 
Administration limited research using public funding to a limited number of authorized 
cell lines already collected. Stem Cell Research conducted on other lines or for purposes 
prohibited by legislation can only be funded privately. The University of California 
and WiCEll Research Institute are amongst the ‘authorized’ Federal Government cell 
lines eligible for public research funds154. It should be noted that Stem Cell lines are 
also used for research in the private sector.   
 
                                                 
151http://biospecimens.cancer.gov/nbn/blueprint.asp 
152National Cancer Institute (NCI) - National Dialogue on Cancer (NDC), National Biospecimen Network Blueprint, 
Washington, September 2003. 
153http://biospecimens.cancer.gov/nbn/blueprint.asp 
154  http://stemcells.nih.gov/research/registry/eligibilityCriteria.asp 
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Blood Specimens and DNA Research Banks  
 
Research collecting blood and DNA 
 
⇒ Healthy Aging in Neighbourhoods of Diversity across the Life Span study 
⇒ Nun Study 
⇒ Bogalusa Heart Study, (NHLBI) 
⇒ National Health and Nutrition Examination Survey (NHANES) (CDC) 
⇒ Women’s Interagency HIV Study. 
⇒ Framingham study (NHLBI) 
⇒ Jackson Heart Study (NHLBI) 
⇒ ARIC study (NHLBI) 
⇒ Physicians’ Health Study, (NIH) 
⇒ Nurses’ Health Study (Original cohort) (NIH) 
⇒ Nurses' Health Study II (NIH) 
⇒ Women's Health Initiative - Observational study (NHLBI) 
⇒ Iowa Women's Health Study 
⇒ Cancer Prevention Study - 3 (CPS-3) (American Cancer Society) 
⇒ Cancer Prevention Study - II Nutrition Cohort (CPS) 
⇒ Marshfield Clinic Personalized Medicine Research 
⇒ Study of Women Across the Nation (SWAN) 
⇒ Cardiovascular Heart Study (CHS) (NHLBI) 
⇒ National Chidren Study 
⇒ Genomic Medicine Program 
⇒ GAIN (Genetic Association Information Network)155  NIH 
 
Blood collected specifically for research purposes is mainly collected during clinical 
trials, or longitudinal studies. The number of biobanks collecting blood for research 
purposes is staggering. In the post Human Genome era, the need for well characterized 
DNA banks seems almost inexhaustible. Any given research initiative is susceptible of 
creating a small biobank for research purposes, stored in a public or private research 
center. We did not attempt to retrieve all these studies and focussed our attention on 
large biorepositories. However, we have identified a few representative ones to show 
the diversity of such biobanks.  
 
NHLBI supports many of these clinical research initiatives and longitudinal studies. 
Framingham Heart Study, funded by the NIH-NHLBI, collects blood samples and 
data since 1948. Three generations of participants (for a total of almost 15 000 
participants) contributed to the Framingham Heart study, with continued monitoring of 
participants over a long period of time.  Researchers can apply to the Framingham Heart 
Study, through a well defined process, to obtain material and data for research. The 
philosophy seems to be one of openness towards collaboration; however, no specific 
mention is made on the sharing policy with respect to international collaborators156.  
                                                 
155 http://www.fnih.org/GAIN/GAIN_home.shtml 
156  ‘The NHLBI and Boston University seek to encourage use of these data and materials by investigators not 
affiliated with the Framingham Study or Boston University, to foster collaborative relationships where appropriate, 
and to ensure that the Framingham investigators are appropriately acknowledged. Collaboration with Framingham 
investigators (past or present) is not required as a condition of receiving DNA and/or genetic data. The NHLBI and 
Boston University further seek to promote the development of valuable discoveries and inventions beneficial to the 
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NHLBI supports other large scale projects around the United States.  Often, these tissue 
banks are hosted in hospital centers or affiliated research centers.  The ARIC Study 
includes a Cohort Component which began in 1987 and includes a cohort sample of 
approximately 4 000 individuals between the ages of 45 and 64 from a defined 
population in their community. A total of 15792 participants received extensive 
examination, including medical, social, and demographic data every 3 years. While use 
of the resource is well organized and seems almost encouraged, the Material 
Distribution Agreement (available online) seems to limit distribution within the United 
States.   
 
"Promoting use on a national scale of such a resource will require a large and 
concerted effort which may involve investigators not currently part of the ARIC Study. 
The NHLBI and the researchers it supports have a responsibility to the public and the 
scientific community to encourage as rapid scientific progress as possible using these 
resources, subject to appropriate terms and conditions".157   
 
The use of such material is well regulated in the MDA. Among the topics covered, it 
includes the need for IRB approval, the duty of the researcher not to share or use the 
tissues for other research purposes, not to try to identify participants and to return to 
ARIC the data generated from his study to benefit the biobank.   
 
The Jackson Heart Study is an expansion of one of the study sites of the ARIC 
project. The JHS ‘plans to include up to 6 500 African-American men and women 
between the ages of 35 and 84 and will invite all previous ARIC participants 
(approximately 59 to 78 years of age in 2000) along with younger and older men and 
women from a larger geographic area’158. The process and forms for requesting material 
is available on the website.   
 
The NHLBI Biologic Specimen Repository maintains a blood bank for research on 
blood donor and blood recipient. Since the mid-1970s, the Institute's Blood Division has 
established and supported several large blood specimen repositories to perform 
prospective and retrospective studies of blood donors and recipients.  ‘From 1991-2004, 
a total of 148 667 specimens from the NHLBI Biological Specimen Repository were 
sent to various investigators.’159  Other important NHLBI studies include: Bogalusa 
Heart Study, Women's Health Initiative - Observational study, etc.  
 
The Nurse Study collected more than 51 000 blood samples in phase I and 30 000 in 
phase II.  The SWAN study collected an important repository of blood samples.  ‘The 
repository includes approximately 510 000 samples from the first 7 years of specimen 
collection.  This included more than 300 000 samples from the annual visits and 206 
000 samples from the Daily Hormone Sub-study (DHS)’160.  The Swan study has a 
detailed policy and process for accessing the resources for further research.  Contrary to 
                                                                                                                                               
public health based upon use of this Framingham Study repository of valuable materials and data.’ Framingham DNA 
and Genetic Data distribution policy available on NHLBI website:  
http://www.nhlbi.nih.gov/about/framingham/policies/index.htm#purp. 
157  http://www.cscc.unc.edu/ARIC/datadist/download/UNLICOMM. 
 ExternalDataDistributionAgreementForMaterialsAloneorforMaterialsandDataCombined06012005.doc 
158 http://www.nhlbi.nih.gov/about/jackson/2ndpg.htm 
159 http://www.nhlbi.nih.gov/resources/medres/reposit/reposit.htm.   
160 http://www.swanrepository.com/ 
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the Framingham study where participation of an ‘in-house’ investigator is encouraged, 
here it is mandatory.  We could not come to a firm confirmation about the potential for 
international collaboration from reading the policy available on the web.  Other 
important studies include: Healthy Aging in Neighbourhoods of Diversity across the 
Life Span study, Nun Study, etc.  
 
The Center for Disease Control’s (CDC) mandate is to protect the health and safety of 
the population.  It supports the National Health and Nutrition Examination Survey 
(NHANES) program.  Since 1960, the National Center for Health Statistics has been 
conducting NHANES surveys, nationally representative survey of the population.  Since 
1999, it is a permanent program of the CDC.  The NHANES III Study led to the 
creation of an important DNA bank resource (about 7000 specimens from 
participants161) at the Division of Laboratory Sciences (DLS) at the National Center for 
Environmental Health (CDC)162 that is made available for research purposes.  More 
precisely, 7500 cell lines and about 17000 samples are stored in the laboratory.  CDC is 
also leading many other research initiatives entailing the collection of biological 
samples, including the National Birth Defect Prevention Study.  It also serves as a 
reference laboratory and thus collects various biological samples, cells, bacteries and 
other biological agents.  
 
Marshfield Clinic Personalized Medicine Research Project is a new ambitious 
longitudinal research initiative.  This is a 20-year project that hopes to recruit 40 000 
participants.  Started in 2002, the project has so far collected over 18 000 samples.  
Nothing seems to preclude International collaboration with the Marshfield Clinic 
project.  The resource has already been used for Alzheimer and glaucoma research 
projects.   
 
Physicians’ Health Study II of the Brigham and Women’s Hospital is the second 
phase of a study that started in 1981.  This NIH funded research is aimed at testing the 
effect of supplements in the primary prevention of cardiovascular disease, cancer, and 
age-related eye disease--vitamin E, vitamin C, and a multivitamin.  The physicians were 
asked to provide blood samples for research.  Seventy-six percent (76%) of the 
participants accepted and thus the sample size is around 12 000 samples.  This project 
indicated its interest for international collaboration.  As it is increasingly the case with 
repositories, researchers who use the resource are required to return data back to the 
resources once the research is completed.   
 
In 2000, the US Congress authorized the planning and implementation of the National 
Children Study163.  This study is a coordinated effort between the National Institute of 
Child Health and Human Development and the National Institute of Environmental 
Health Sciences, the Centers for Disease Control and Prevention, and the Environmental 
Protection Agency.  This study will ‘examine the effects of environmental influences on 
the health and development of more than 100 000 children across the United States, 
following them from before birth until age 21164’. Children willl be followed throughout 
the different stages of their development and growth, with in-person visits with the 
research team and questionnaires.  Collection of samples began in January 2009. 
                                                 
161 http://www.cdc.gov/genomics/activities/ogdp/2003/chap01.htm 
162 http://www.cdc.gov/nceh/dls/dna_bank.htm: 17 000 specimen and 7500 cell lines 
163 Children's Health Act of 2000 (Public Law 106-310 Sec. 1004  
164 http://nationalchildrensstudy.gov/ 
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The Department of Veterans’ Affairs announced in March 2006 the launch of a 
Genomic Medicine Program that could lead to the creation of large-scale research 
program165.  The NIH is also considering creating a large scale project.  A compelling 
case for such a large-scale population project was made by Francis Collins in Nature in 
2004166.   
 
The GAIN (Genetic Association Information Network)167 is an NIH initiative aimed at 
providing research resources for the scientific community.  On March 15, 2006, this 
public-private partnership invited investigators at Universities and research centers 
world-wide to submit applications to have existing disease-specific samples from case-
control (or similar) studies genotyped at no cost168.  In exchange, the data will be made 
available to the research community in general.  In 2008 the Genetic Association 
Information Network (GAIN) completed its work, posting genotypes and phenotypes 
from the 18,000 samples it mapped to a National Library of Medicine database (dbGaP) 
that was also funded by the program. 
 
 
Tissue Bank/Blood Bank Resources 
⇒ Angioma Alliance 
⇒ AIDS and Cancer Specimen Resource (ACSR) -NCI  
⇒ Division of the Acquired Immunodeficiency Syndrome (DAIDS), Specimen 
repositories 
⇒ Coriell Institute for Medical Research (NIH) 
⇒ National Disease Research Interchange 
⇒ PathServe Autopsy and Tissue Bank Inc. 
⇒ SeraCare Life Science Inc. /BBI Biotech 
⇒ Asterand 
⇒ US Biomax Inc. 
⇒ LifeSpan Biosciences 
⇒ NHLBI Biologic Specimen Repository 
 
The main purpose of some biobank is to offer easy access to tissues as a resource per se.  
They are centered more around a research infrastructure than a project per se.  They 
specialize in the procurement, preservation and distribution of tissue samples.  These 
banks could be privately funded or supported by national organizations.  Asterand, or 
PathServe are good examples of private companies offering these types of services.  
They all offer a range of human tissue and researchers can order their tissue even 
through internet169.  Privately funded tissue resources are usually opened for 
international collaboration.   
 
Other repositories are publicly funded resources for researchers.  We have already 
mentioned various collaborative initiatives earlier in the section on Tissue bank (NCI-
                                                 
165News Release,’VA Forms Committee to Advice on Genomic Medicine’ March 16, 2006:  
http://www1.va.gov/opa/pressrel/docs/GenomicMedCmte.doc  
166 The Case for a US Prospective Cohort Study of Genes and Environement, Nature 2004, 429, 475-477. 
167 http://www.fnih.org/GAIN/GAIN_home.shtml 
168 http://www.fnih.org/GAIN/Solicitation_press_release.shtml 
169See the Ardais online submission process at Harvard University:  
http://www.research.bidmc.harvard.edu/Corelabs/BIGRDetails.asp 
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related initiatives).  These biobanks resources can serve a single hospital or offer a 
nation-wide or world-wide service. In addition to be a leading research center, the 
Coriell Cell repository holds the world’s largest collection of cell cultures.  This NIH 
funded institution, offers a human genetic cell repository, an Aging cell repository, 
privately funded diabetes collection and cancer collection.  It offers services to private 
or public institution, in the USA or abroad.   
 
The National Allergy and Infectious disease (NIAID) of the NIH supports multiple 
repositories for research and reference purposes.  DAIDS, a division of the NIAID, 
supports research initiatives on HIV.  Researchers supported by DAIDS are clearly 
encouraged to establish collaboration and shared the resources with the larger scientific 
community.  The NIAID National Disease Research Interchange offers a catalogue of 
human cells, tissues and organs for research.  Finally, the AIDS and Cancer Resource 
is a multi-site repository source for ‘well documented tissue and biological samples 
serving investigators working in the fields of HIV/AIDS and related cancer, virology, 
immunology, pathology, epidemiology, tumour biology, assay development, as well as 
others’170.  ACSR is coordinated at University of California but has collaborators 
throughout the US and internationally.   
 
Finally, repositories can be constituted by a given disease foundation to support and 
stimulate research on this specific disease.  For instance, the Angioma Alliance (a 
volunteer network created in 2002) recently centralized its tissue and DNA bank to 
facilitate research in cavernous angiomas.   
 
Regulatory Aspects 
The legal framework for biobanking activities is a complex one. In the United States of 
America, there is no single legislation governing biobank at the Federal level. However, 
a web of legislations governing research activities, privacy and human tissues form the 
basis of the regulatory framework.  Also, many health-related activities are governed by 
States legislation: offering a patchwork of different approaches.  
 
Federal Regulation applies to research funded by a federal agency. Title 45 CFR 46: 
‘Protection of human subjects’ regulates all aspects of research with human subjects 
including IRB review of research and consent process.  The NBAC report 
recommended that anonymized tissue NOT be considered research with human subject 
and thus be excluded from the application of the legislation. However, all other types of 
research with human tissues are covered by this legislation.  Other articles of the 
Common rule could apply to human tissue banking depending on the context in which it 
takes place.  
 
Stem cell research and banking is subject to a specific legislation: United States House 
of Representatives, Stem Cell Therapeutic and Research Act of 2005171. Also the recent 
DHHS Health Insurance Portability and Accountability Act of 1996 (and regulation: 45 
CFR Parts 160, 162, and 164) have brought profound changes to the research activities 
(including biobanking).  In contrast, there are quite a significant number of guidelines 
for biobanks and repositories.  For Instance, the International Society for Biological and 
Environmental Repositories (ISBER), a United States-based international organization 
                                                 
170http://acsr.ucsf.edu/aboutUs.aspx 
171H.R. 2520, 109th Congress, 1st Session, December 20, 2005 
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has recently adopted: Best Practices for Repositories I: Collection, Storage, and 
Retrieval of Human Biological Materials for Research172. This document covers all 
aspects from record management, facility, quality assurance, and safety.   
 
In view of a certain lack of clear legislative guidance in the field, various professional 
organizations have sought to offer guidance to their members with respect to research 
with human tissue and banking activities.  For example, the College of American 
Pathologists also have a policy on the use of human tissue,173 and is almost entirely 
dedicated to research with human tissue.  The American College of Medical Genetics 
adopted guidance on the storage of human tissues some time ago174.  More recently 
(2002), the American Medical Association adopted a policy on the Safeguards in the 
Use of DNA Databanks in Genomic Research175  Private corporation in the field of 
banking have also adopted code of ethics (for instance Ardais Code of ethics).  Over the 
course of the HapMap project, Coriell has adopted its own policy for the Responsible 
Collection, Storage, and Research Use of Samples from Named Populations for the NIGMS 
Human Genetic Cell Repository176. 
 
Finally, the Office of Human Research Protections (OHRP) has adopted a ‘Guidance on 
Research Involving Coded Private Information or Biological Specimens’177.  This 
document clarifies the application of the federal code of regulation and reiterates the 
application of principles elaborated in the 1997 Guidance Repositories, Tissues Storage 
Activities and Data Banks.  
 
Privacy / Data Protection 
The Health Insurance Portability and Accountability Act (1996)178 and the Standards 
for Privacy of Individually Identifiable Health Information (designated as the ‘Privacy 
Rule’)179 govern the protection of individually identifiable health information that is 
held or maintained by an entity designated in the legislation.  The Privacy Rule 
generally requires authorization from the person to use their protected health 
information for research purposes.  However, the Privacy Rule provides for some 
exceptions.  
 
Privacy Act of 1974 applies to certain personally identifiable information held by 
federal agencies in a “system of records” and thus applies to any research record held by 
HHS. Under this law, an agency must provide an individual access to his or her record. 
Still the legal situation in the USA is influenced by the federal system. Important 
privacy regulations differ from state to state.   
 
Ethics Discussion 
                                                 
172CELL PRESERVATION TECHNOLOGY, Volume 3, Number 1, 2005 
 http://www.isber.org/Pubs/BestPractices.pdf 
173College of American Pathologists, Use of Human Tissue, August 1996,  
http://cap.medical.org/Ethical_Use_of_Human_Tissues_guideline.pdf 
174Statement on Storage and Use of Genetic Materials, 1995, http://genetics.faseb.org/genetics/acmg/pol-17.htm 
175American Medical Association (AMA), E-2.079 Safeguards in the Use of DNA Databanks in Genomic Research, 
Chicago, June 2002,  http://www.ama-assn.org/ama/pub/category/print/11989.html 
176http://ccr.coriell.org/nigms/comm/submit/collpolicy.html 
177Department of Health and Human Services (DHHS) - Office for Human Research Protections (OHRP), Guidance 
on Research Involving Coded Private Information or Biological Specimens, Rockville, August 8 2004 
178 Public Law 104-91, August 21, 1996 
179 45 CFR Part 160 and Subparts A and E of Part 164 
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In 1999, the National Bioethics Advisory Commission of the United States of America 
published a report on Research Involving Human Biological Material: Ethical Issues 
and Policy Guidance180. This report examines quite extensively the situation with 
respect to biobanking in the United States, including the RAND report, which is a 
comprehensive mapping of biobanks in the United States.  It also offers 23 
recommendations on ethical issues and policy guidance with respect to biobanking 
activities.   
 
Given that many actors have showed expressed their interest, the question of the 
creation of a large-scale population-based project is being debated in the United States.  
Investments have already been committed to develop the National Children Study.  
However, there are discussions about the need for other large scale project(s), and 
debates about the format such a project should take and how ELSI issues could be 
appropriately addressed before a final decision is made.  Hearings in front of the 
Secretariat Advisory Committee on Genetic Health and Society suggested different 
avenues for such a large scale project181.  Representatives from the CDC, Department of 
Veteran’s Affairs, NHGRI, P3G and National Institute of Child Health and Human 
Development suggested were among the organization who testified.  The Draft Report 
on Policy Issues Associated with Undertaking a Large US Population Cohort Project 
on Genes, Environment and Disease182, is currently available for comments.  ELSI 
questions such as public engagement and legal framework for such projects are being 
examined.  
 
 
2.2.5.2 Canada 
 
Tissue collection 
⇒ Procure Cancer 
⇒ Cancer Research Network of the FRSQ/ Reseau de recherche sur le cancer 
(FRSQ) 
⇒ Alberta Research Tumor Bank  
⇒ British Columbia Cancer Agency Tumour Tissue Repository 
⇒ Manitoba Breast Tumor Bank 
⇒ Ontario Cancer Research Network 
⇒ Children's Oncology Group 
⇒ Tissue Bank of the Respiratory Health Network of the FRSQ 
⇒ The Brain Tumour Tissue Bank 
⇒ Douglas Hospital Brain Bank 
⇒ LIFEBANC/Arthur and Sonia Labatt BTRC   
⇒ Capital Health/Regional Tissue Bank 
 
Pathologists in all hospitals and health Institutions are collecting human tissues for 
clinical diagnostic purposes.  The Canadian Association of Pathologists (CAP) 
                                                 
180It should be mentioned that all the legislative research was made possible through the help of the HUMGEN 
research tool. NBAC Report, Rockville, Maryland, August 1999,  
http://www.bioethics.gov/reports/past_commissions/nbac_biological1.pdf 
181http://www4.od.nih.gov/oba/SACGHS/meetings/Feb2005/SACGHSFeb2005postmeeting.htm, March 1st, 2005.   
182http://www4.od.nih.gov/oba/SACGHS/public_comments.htm 
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recommends various periods of retention for validation (up to 20 years)183.  However, 
their use for research purpose requires a proper consent.   
 
Cancer registries are present in all provinces and regulated provincially.  Some 
provinces created not only registries but also tumour banks (with consent).  For 
instance, the Ontario Cancer Research Network coordinates the collection, storage, 
analysis, annotation, and distribution of tumour and blood samples obtained from 
hospitals across Ontario184.  In Quebec, the Cancer Research Network of the FRSQ 
can count on 4 major health institutions in the province to collect tumour and blood for 
research purposes.  Recently, Alberta has set up a centralized tumour and blood bank 
available for research185. All these organizations are open for collaboration.  These 
initiatives offer many scientific advantages including fair and equitable access to high 
quality and well annotated tissue samples.   
 
To coordinate and pool resources procurement for research throughout Canada, the 
Canadian Tumour Repository Network (CTRnet) was formed in 2004 with the 
financial assistance of the Canadian Institutes of Health Research (CIHR) under the 
direction of the Canadian Association of Provincial Cancer Agencies (CAPCA).  
Through this innovative network,  tissues are collected and kept under the authority of 
their local institutions.  Decisions to share tissues rest solely with such institution.  
Through this alliance, researchers have access to more than 7000 samples186.   
 
‘CTRNet operates as a not-for-profit consortium of leading provincial tumour banks 
and programs that furthers Canadian health research. CTRNet provides interested 
researchers with a streamlined process to obtain quality human tissue and human tissue 
products from member tumour banks.’187 
 
In other fields of research, similar efforts are being put into place to pool locally 
collected research material together.  At a provincial scale, other networks are being 
organized to link local biobanks for research purposes.  For instance, a virtual network, 
the Tissue Bank of the Respiratory Health Network of the FRSQ, facilitates the 
procurement of tissue for research in respiratory diseases.  This virtual bank stores the 
sample information on a central server, while the samples are preserved in each 
respective centre.  ProCURE is a not-for-profit organization whose mission is to fund 
and structure over time a bank of biological materials and data on men with prostate 
cancer as well as those at risk of developing the disease.  This Alliance is currently 
under development.  Once fully operational it will collect prostate tissue and blood from 
patients in four hospitals across the province of Quebec.  This project is also funded by 
the FRSQ.    
 
Any tissues collected for clinical diagnosis or following surgery can potentially be used 
for research (with appropriate consent).  Tissues can also be collected post mortem, for 
research purposes.  The Brain Tumour Tissue Bank of London Ontario collects 
                                                 
183The Retention and Use of Human Biologic Material (2005). http://cap.medical.org/guide_retention-human-
biologic-material.htm 
184http://www.ontariotumourbank.ca/public/about.jsp 
185http://www.cancerboard.ab.ca/pdf/media_desk/05-09-19_tumour_bank.pdf 
186 Press release: Le Québec participe à la création d'un nouvel outil de recherche dans la lutte contre le cancer à 
l'échelle canadienne, March 15 2006 ; https://fqc.qc.ca/infopro2.asp?id=755 
187 https://www.ctrnet.ca/index.php?pid=11000 
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leftovers from pathology analysis in local hospitals (with appropriate consent).  The 
Douglas Brain Bank actively recruit post-mortem brain donor for research purposes188.  
 
Blood Specimens and DNA Research Banks 
⇒ Canadian Study on Health and Aging 
⇒ Genizon BioSciences 
⇒ Interheart 
⇒ Healthy Aging Study 
 
The Canadian Institute of Health Research, Genome Canada, provincial public funding 
agencies and private funds support many biobanks created in the specific context of 
research projects.  These biobanks vary in size from the traditional small individual 
research purpose to longitudinal large scale repositories, and are kept in hospitals, 
university research centers and various health institutions.  There is no formal and 
centralized registration process for biobanks created for research purposes.  Thus, it is 
difficult to assess the number of such banks.  Also, not all biobanks created in the 
context of a research project can be used for other research purposes, either because of 
lack of proper consent or lack of research infrastructure and funding.  When multiple 
research use is possible, the decision to collaborate is at the discretion of the 
investigator. 
 
Major research centers across Canada hold multiple biobanks created for research 
purposes.  For instance, Michael Smith Genome Science Center runs many of these 
research projects, including the Healthy Aging Study which collects blood from 
participants 85 years old or older.  Another good example is the InterHeart Study, a 
Canadian led research project, which has enrolled 14 000 cases of acute myocardial 
infarction and 16 000 matched controls from 55 countries.  Blood collected during this 
study was centralized in the Canadian laboratory at McMaster University.  Finally, 
genetic/genomics research is thriving, stimulated by a dedicated funding organization: 
Genome Canada, and although we could not formally assess the number of DNA banks, 
we suspect it is quite impressive.   
 
Private pharmaceutical companies also collect tissue and blood samples during clinical 
trials.  However, the existence and size of these biobanks are difficult to track.  It is 
perhaps seen as commercial privileged information.  Genizon Bioscience is a private 
corporation leading various types of research in the field of genomics189.  Their website 
indicates the creation of a biobank for research purposes which is maintained by the 
company. 
 
Longitudinal studies are of increasing interest in the context of human genome research.  
The Canadian Study on Health and Aging is one of the important population-based 
studies performed in Canada. The data collection is now ended and blood samples have 
been collected for more than 9 000 participants of 65 years of age and more. Regular 
follow-ups of the participants have been completed between 1991 and 2001.  The Public 
Health Agency of Canada has built and maintains a level 4 security laboratory in 
Winnipeg, responsible for identification, control and prevention of infectious disease.  
This facility serves as a reference center for infectious disease and various research 
                                                 
188 http://www.douglasrecherche.qc.ca/brainBank/about.asp 
189http://www.genizon.com/html/content.asp?node=22 
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projects are on Genetic, bacteriology or virology.  The genetic laboratory has a capacity 
of 250 000 samples.  The samples of the third phase of the longitudinal study of risk 
factors for dementia in elderly Canadians (Canadian Study of Health and Aging)190 are 
currently stored there. 
 
The Canadian Institute of Health Research has recently launched a Canadian 
Longitudinal Study on Aging (CLSA).  This study would follow 50 000 men and 
women 40 years and older for 20 years and collect blood from every participants.191 
CLSA will collect information on the changing biological, medical, psychological, 
social, and economic aspects of their lives. These factors will be studied in order to 
understand how they have an impact on aging.  The recruitment of the first 20,000 
participants in collaboration with Statistics Canada began in January 2009. 
 
A few important population-based studies are emerging in Canada and are creating 
research infrastructures open to multiple future research uses.  Statistics Canada, 
Canada’s central statistical agency, is responsible for the national census. It is currently 
planning the realization of a study including extensive physiological measures and 
biological sampling among a random sample of 5 000 Canadians. Canadian Health 
Measurement Survey involves Canadians from 6 to 79 years old192. The survey 
includes two phases: an interview at the household to administer questionnaires about 
health and lifestyle, and a visit to a nearby health clinic to collect blood and urine 
samples and to perform various physical measurements.  A pilot survey took place in 
Calgary in 2004. The full collection began in spring 2007. 
 
The CARTaGENE project targets the recruitment and follow-up of 1% of the Quebec 
province population aged between 24 and 75 (50 000 participants).  All participants will 
be asked to provide a blood samples for DNA research and basic clinical analysis.  
Health, lifestyle and genealogical information will also be collected.  The blood and 
DNA samples will be kept for future researches193. The recruitment of participants 
began in 2008.194 
 
Genome Canada is the primary funding and information resource relating to genomics 
and proteomics in Canada.  Together with the 5 genome centers across Canada, Genome 
Canada funds and manages large-scale projects and platforms.  For instance, multiple 
research platforms are funded through Genome Canada and its centers such as the 
Genome Quebec and McGill University Innovation Center who played a key role in the 
HapMap project.  Genome Canada recently funded another population-based initiative 
in the Atlantic Region: the Atlantic Medical Genomic and Genetic Initative, but this 
project is only in very early stages of preparation.   
 
Regulatory Aspects 
There is no specific legislation governing biobanking activities specifically.  However, 
recently, the Federal Government adopted the Assisted Human Reproduction Act (2004, 
c. 2) which governs the collection and research with reproductive material.   
 
                                                 
190http://www.nml-lnm.ca/english/hostgenResearch_e.htm 
191 http://www.cihr-irsc.gc.ca/e/22982.html 
192 http://www.statcan.gc.ca/pub/82-003-s/2007000/article/10363-eng.pdf 
193 www.cartagene.qc.ca 
194 http://www.cartagene.qc.ca/images/stories/pdf_en/pressrelease-06-01-2008.pdf 
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The 3 major Canadian Funding Agencies, the Canadian Institutes of Health Research 
(formerly, the Medical Research Council of Canada), the Natural Sciences and 
Engineering Research Council of Canada, and the Social Sciences and Humanities 
Research Council of Canada, have adopted a common guidance document for research 
with human subjects and human tissues: the Tri-Council Policy Statement — Ethical 
Conduct for Research Involving Humans.195  All federally funded research as well as 
the institutions that hope to receive Federal funds must be in compliance with the 
principle therein described.  Section 10 of this document is about human tissue 
collection.  It stresses the importance of a free and informed consent process as well as 
respect for privacy in any biobanking activity.   
 
Health is a matter of provincial competence.  Provinces have specific and different 
legislations on many aspects of health activities but there is a no specific legislation on 
biobanking activities for research purposes per se.  However, there are multiple 
guidelines that can be applied.  For instance, in the province of Quebec, the main 
research funding agency has adopted guidelines on research with human subjects and 
human tissues196.  
 
Privacy / Data Protection 
The Personal Information Protection and Electronic Documents Act (PIPEDA) was 
adopted in 2000197 but came into full effect in 2004.  The legislation set rule for how the 
private sector organizations may collect, use or disclose personal information in the 
course of commercial activities. The law gives individuals the right to access and 
request correction of the personal information these organizations may have collected 
about them. It also governs the protection of personal information and exchange or 
disclosure outside a province.  It should be mentioned that provinces that have enacted 
equivalent legislation will not be subject to PIPEDA (Quebec, Alberta, British 
Columbia). Health legislations and other privacy legislations have been adopted at the 
level of provinces.  
 
The Privacy Act took effect on July 1, 1983. This Act imposes obligations on federal 
government departments and agencies to respect privacy rights by limiting the 
collection, use and disclosure of personal information. The Privacy Act gives 
individuals the right to access and request correction of personal information about 
themselves held by these federal government organizations.  
 
Ethics Discussion 
The CARTaGENE project, in preparation for several years, stimulated public debate 
about population-based biological resources.  Over the course of the preparation phase, 
CARTaGENE initiated various activities of public consultation and public information 
and discussion.  The reports are available on their website.   
 
Ethics is developed on a decentralized model in Canada.  There is no national bioethics 
committee.  The Province of Quebec, Commission on Ethics, Science and Technology, 
                                                 
195Interagency Advisory Panel on Research Ethics (PRE): 1998 (with 2000, 2002, 2005 amendments), Ottawa, 
October 2005.  http://www.pre.ethics.gc.ca/english/pdf/TCPS%20October%202005_E.pdf 
196FRSQ, Guide d’éthique de la recherche et d’intégrité scientifique, 2003.  
http://www.frsq.gouv.qc.ca/en/ethique/ethique.shtml 
197PIPEDA, 2000, c. 5 
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published a position paper in 2003 about Genetic DNA databases.198  The Canadian 
Biotechnology Advisory Committee, who provides expert advice on ELSI to the Federal 
Government, commissioned several research papers on biobanks and population-based 
research in 2003199.  The Interagency Advisory Panel on Research Ethics is a body of 
experts to ensure the evolution of the ethics policy statement of the funding agencies 
(Tri-Council Policy Statement).  Although the Interagency did not publish a position 
paper on this topic, it is part of the mandate of the group. Finally, Canadian 
Biotechnology Secretariat of Industry Canada (Government of Canada) has funded 
several survey of public opinion research into biotechnology issues.  The 2005: ‘A 
Canada - US Public Opinion Research Study on Emerging Technologies - Report of 
Findings’ provides a picture of Canadian opinion on several issues including gene 
bank200.  
 
It should also be mentioned that Canada hosts several internationally recognized 
research center on ELSI.  The vitality of academic discussion about population-based 
biobanks has stimulated several academic published papers and forums of discussion.   
 
2.2.5.3 Asia 
 
The geographical area of Asia is wide and the organizational structure for research is 
not easy to map.  More importantly, given that one key component of the methodology 
for this research was desk research and internet contact, the language barrier proved to 
be a real challenge.  Even once a biobank was identified; trying to find contact 
information proved to be difficult.  Some websites are translated (or partially translated) 
in English, but not all.  
 
Even direct communication was complicated by the time zones (phone calls had to be 
made late in the evening or night time, Montreal time). All these elements constituted a 
challenge for this survey, but they assuredly could also constitute a challenge for plans 
towards collaboration.    
For this part of the survey we kept the research at the first level (large biobanks) or key 
components of the biobanking network. 
 
Many countries in Asia have launched or are about to launch ambitious population 
biobanks.  In fact, some of the biggest projects (in terms of number of samples) can be 
found in Asia.   
However, there are important ELSI challenges that must be examined taking into 
account the different cultural context than the European or North American approaches.   
 
JAPAN 
⇒ Health Science Research Resources Bank/Japan Health Science Foundation 
⇒ Biobank Japan - Riken Institute 
⇒ Japanese collection of research bioresources (JCRB Genebank) 
⇒ Japan National Cancer Center 
                                                 
198Commission d’Éthique du Québec, Les enjeux éthiques des banques d'information génétique: pour un 
encadrement démocratique et responsable (2003). http://www.ethique.gouv.qc.ca/eng/publications.html 
199http://cbac-cccb.ca/epic/internet/incbac-cccb.nsf/en/h_ah00128e.html.  See CBAC (2004), Protecting Privacy in 
the Age of Genetic Information, ; CBAC (2005) Human Genetic Materials: Making Canada's Intellectual Property 
Regime Work for the Health of Canadians .   
200http://www.biostrategy.gc.ca/english/View.asp?pmiid=720&x=721 
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⇒ Brain Bank Project 
SINGAPORE 
⇒ National University of Singapore Tissue Repository 
⇒ Singapore Consortium of Cohort Studies 
⇒ ES Cell International Inc. 
⇒ Singapore Tissue Network 
CHINA 
⇒ Kadoorie Study of Chronic Disease in China (KSCDC) 
KOREA 
⇒ MizMedi Women Hospital Research Center 
⇒ Biobank for Health Sciences  
TAIWAN 
⇒ Taiwan Biobank 
 
 
Japan 
 
Japan has currently many large-scale biobanking initiatives.  This dynamic development 
is the result of a planned and concerted effort, deployed by the Japanese Government to 
stimulate the growth of the biotechnology industry.  In 1999, the Government 
announced massive investments in various sectors of activities including the 
biotechnology to stimulate the economy201.  Sixty-four (64) Billion ¥ were allocated to 
genome analysis and various research projects.    
 
One of the most ambitious projects is ‘Biobank Japan Project on the Implementation 
of Personalized Medicine’ which aims to create a large-scale DNA repository, with 
blood samples from some 300,000 individuals linked to a database containing clinical 
information [17]. This initiative started in 2003 and is funded by the Government’s 
Ministry of Education, Culture, Sports, Science and Technology.  It is a collaborative 
effort from the Human Genome Center, the Institute of Medical Sciences (Tokyo 
University)-IMST- and the Japan Science and Technology Agency (JST).  The project 
is collecting samples from 66 hospital centers across Japan.  In 2005, 150 000 DNA 
samples and clinical data had been collected202.  The team is led by Dr. Nakamura of 
RIKEN (the Institute of Physical and Chemical Research).  It is not clear whether this 
biobank is opened for international collaboration.   
 
In addition to high-profile Japan Biobank, it is estimated that there are large numbers of 
State sponsored bioinformatics and biobank projects in an estimated 40-50 research 
institutions203.  However, as noted in a report to the UK Parliament Select Committee 
on Science and Technology, these ‘private collection’ tend not to distribute their 
samples beyond their groups or institutes204.  An example is the Bio-sample bank set up 
in 2002 by the Clinical Laboratory Division of the National Cancer Center.  This 
                                                 
201 National Science Foundation,  ‘The Government of Japan Special Millenium Project Budgetary Framework’ Jan. 
26, 2000Tokyo Regional Office, http://www.nsftokyo.org/rm00-03.html 
202 Press Release: RIKEN and Perlegen Begin Collaboration to Conduct High-Resolution, 
Whole Genome Studies of up to 47 Common Diseases 
 http://www.perlegen.com/newsroom/pr/2005/2005_07_21_Riken_Press_Release.pdf 
203 Gerard Porter, ‘Regulation of Human Genetic Databases in Japan’ Report prepared for the AHRB research Center 
for Studies in Intellectual Property and Technology Law, Sept. 2004, p. 497. 
204 C. Stuart, ‘Human Genetic Databases in Japan’ Memorandum by the Science and Technology Section of the 
British Embassy, Tokyo, tabled UK Parliament Select Committee on Science and Technology (2000) 
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resource is aimed at in-house doctors and researchers from the Research Institution of 
NCC (as mentioned in their annual report)205. 
 
Providing appropriate material for research is a concern that is addressed by a web of 
organizations supported by the Government.  The Japanese Collection of Research 
Bioresources (JCRB) is an example of such biorepository.  In 2005 the JCRB, created 
under the auspices of the National Institute of Infectious Diseases was transferred under 
the responsibility of National Institute of Biomedical Innovation (NiBio), Osaka, Japan.  
JCRB collects samples from a number of cell and gene banks.  However, the 
distribution of the material to researchers is entrusted to a public research resource 
bank: the Human Science Research Resource Bank (HSRRB).  The HSRRB was 
created in 1995 and is managed by the Japan Health Sciences Foundation, and funded 
by the Ministry of Health and Welfare.  Genes and cells are made available to 
researchers both locally and internationally.  The use of the samples is subject to strict 
ELSI conditions and procedures established by HSRRB.  
 
Singapore 
 
The biomedical science industry has been identified as one of the four pillars of 
Singapore’s economy and it is thriving.  
 
In 2002, the Singapore Bioethics Advisory Committee prepared a report on Tissue 
Banking for Research.  According to the report, a significant portion of tissue bank 
consists of tissues taken for clinical purposes and held in hospitals, health institutions or 
even doctors’ offices.  The SBAC took the position that tissue collected by private 
individual should not be encouraged and that biobanks should be held by institutions 
(whether private or public) and be subject to statutory supervision and appropriate 
governance . This translated into the implementation of a well coordinated system for 
tissues supply for research.   
 
National initiatives for coordinated tissue collection began with the establishment of the 
Singapore Tissue Network (STN) in 2002. The Singapore Tissue Network is a not-for-
profit organization housed at Biopolis, the nation’s biomedical hub established by the 
Agency for Science and Technology and Research (A*Star), which also funds the 
project.   
 
The Singapore Tissue Network is a nation-wide network repository for clinicians in 
Singapore to archive tissue, sera, and DNA, RNA and other derivative products of both 
normal and disease origins for research purposes.  
 
‘These samples collected by the Singapore Tissue Network under strict informed 
consent and confidentiality ethical processes, will be used by public research efforts to 
further the advance of the medical sciences while ensuring strictest standards for 
maintaining donors’ privacy.’  
 
Such coordinated program offers multiples advantages including: ensuring standardized 
ethics procedures, proper funding for biobank resource, and equitable distribution of 
                                                 
205 See 2003 annual report of the NCC Clinical Laboratory Division: www.ncc.go.jp/en/ncch/annrep/2003/clin.pdf 
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high quality tissues available.  On the topic of collaboration, one of the benefits 
underscored by the organization is:  
 
‘Active participation between clinicians and researchers will promote multi-center 
research collaborations and serves as a nucleating force for attracting overseas 
collaborations from academia and industries R&D.’  
 
One example of collaboration is the STN’s collaboration with the National University 
of Singapore/National University Hospital Tissue Repository which is a hospital-based 
central collection system aimed at collected tissue leftover from surgical procedure and 
assures a coordinated and high quality supply of tissue for researchers.  This tissue 
repository is the result of collaboration between three departments: the NUH Office of 
Biomedical Research (OBR), the NUH/NUS Department of Pathology and the NUS 
Office of Life Sciences. Funding comes from NUH and NUS, as well as the Singapore 
Cancer Syndi-cate.  The tissues are intended for researchers of the NUH/NUS Center.  
 
Another example is STN’s collaboration with the Singapore Consortium of Cohort 
Studies.  In 2005, the A*Star Institute has proposed 4 research consortium to pool and 
focus the re-search efforts and resources.  One of these consortiums is the ‘Singapore 
Consortium of Cohort Studies’.  This project consists of a prospective cohort of 10 000 
diabetic patients and an amalgamated cohort of 12 000 participants.    
 
Stem Cell research is also very active in Singapore. Funded by A*STAR, The 
Singapore Stem Cell Consortium (SSCC) will serve as the primary coordinating body 
for stem cell-related research activities in Singapore with the aim to build strong 
linkages between basic science and clinical research groups.  
 
Activities 
The SSCC plans to focus its efforts in three areas: 
 
• R&D: Basic stem cell biology research will encompass the characterization, 
validation, differentiation and expansion of stem cells. Translational & clinical 
research will include the derivation of clinically-compliant stem cell lines, the 
differentiation and modulation of stem cells into various tissue types, and the 
development of cell-based therapies.  
• Resources & Infrastructure: Two examples include a cell processing facility to 
produce cGMP-grade cells, and an SSCC core lab that will focus on the derivation, 
characterization and expansion of stem cell lines.  
• Training and Education: The SSCC plans to increase the pool of local stem cell 
scientists by organizing training courses and workshops, as well as stem cell-
related conferences and journal clubs. Public education will also be an important 
function of the SSCC, to improve public knowledge and understanding of stem cell 
research.  
 
China 
 
In China we were able to identify 1 major biobank: the Kadoorie Study of Chronic 
Disease in China (KSCDC).  KSCDC is a collaborative project between the Clinical 
Trial Service Unit of Oxford University and the Chinese National Centre for Disease 
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Control.  The project is funded by the Kadoorie Charitable Foundation in Hong Kong 
and is aimed at collecting blood samples and various lifestyle and medical data from 
500 000 adults from 10 geographic areas of China206.  However, we anticipate this is 
just the tip of the Iceberg.  There are important research centers, in Beijing, Shanghai 
(National Human Gene Research Center, Shanghai) and in Hong Kong, but 
unfortunately, we had difficulty finding the appropriate information.   
 
Taiwan 
 
Taiwan has launched the ‘Taiwan Biobank’ initiative. So far, the leading group from 
Academia Sinica has collected 3 000 samples.  Funding announcement by the highest 
authority in the Government, on April 2005 (15 million NT), confirmed the expansion 
of the pilot study into a large-scale DNA bank207.  The group plans to collect blood 
plasma samples and genetic information from 200 000 participants between the ages of 
40 and 60208.  However, apparently, the Taiwan Biobank raises criticisms in the 
literature for lack of transparency and public consultation.  
 
So far, a Feasibillity Study has been concluded209.It is expected that an on-going pilot 
research plan will provide a solid foundation for its biobank development [18] 
 
South Korea 
 
In South Korea, we found a biobank resource under the responsibility of the Korea 
Center for Disease Control and Prevention: ‘The BioBank for Health Sciences 
preserves biological resources including cells, sera, plasma, urine, tissues, DNA, 
lymphocytes, peripheral blood as well as BAC clones of human and microorganisms 
that have been collected by various national projects such as the Korean Health and 
Genome Study (KoHGES), the National Survey of Health and Nutrition, and Genome 
Research Centers for 12 disease groups’210  Our research indicates this biobank is of an 
important size, but we were unable to confirm the number of tissue collected.   
 
Stem Cell research in South Korea caught the media attention in unfortunate 
circumstances recently.  However, South Korea remains a key player in the field of 
stem cell research.  In fact, there are 3 institutions from Korea that can provide cell lines 
for research eligible for Federal funding in the United States211.  These include the Miz-
Medi Women Hospital which is amongst the Stem Cell banks.  This center provides 
human embryonic stem (hES) cells to researchers in academic and industrial science all 
around the world.   
 
 
                                                 
206http://www.ctsu.ox.ac.uk/~kadoorie/public/ 
207Chiu Yu Tzu, ‘Biomedical project aims to establish a top research center’ Taipei Time, April 7, 2005. 
http://www.taipeitimes.com/News/taiwan/archives/2005/04/07/2003249445 
208 Basic information for the project can be found on the official Taiwan Biobank website but no translation is 
available in English: http://www.ibms.sinica.edu.tw/biobank/biobank.htm.  Through secondary sources we were able 
to collect basic information.  Chou Kuei-Tien, ‘Risk Governance of Biobank’ August 8th 2005 power point 
presentation. Liu Ching-Yi, ‘Explain database plan to the public’, Taipei Time, Jan. 11, 2006. 
http://www.taipeitimes.com/News/editorials/archives/2006/01/11/2003288507 
209 www.twbiobank.org.tw/nsc/ 
210 http://www.cdc.go.kr/webcdc/english/en09/dbhs.jsp 
211 http://stemcells.nih.gov/research/registry/eligibilityCriteria.asp 
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2.2.5.4 Other Large Scale Biobanks Initiatives 
 
⇒ Howard's Genomic Research in the African Diaspora (GRAD) 
⇒ The Western Australian Genome Health Project (WAGHP) 
⇒ Melbourne Collaborative Cohort Study (HEALTH 2000) 
⇒ Indian Genome Variation Consortium 
⇒ Prospective blood-based study of 200,000 individuals in Mexico 
⇒ Genomic variability and haplotype map of the Mexican population 
⇒ National Laboratory for the Genetics of Israeli Populations (NLGIP) 
 
 
There is an international enthusiasm towards the creation of large-scale biobanks.  We 
have surveyed a few selected large-scale biobanks from other countries outside EU and 
not covered so far in this report212.  All these large scale initiatives are more repositories 
for multiple research uses than research projects per se.  Large scale biobanking 
initiatives are underway in several countries (Australia, India, New Zealand, Mexico, 
etc.), including blood and tissues banking for research as well as non-research purposes.  
 
In developing countries some projects are present, like the African Center for health and 
population, and often focus investigation of HIV or infectious diseases. However, major 
population-based or cases-controls studies including blood banking for genetic research 
are more rare, possibly due to scarce resources.  
 
The National Laboratory for the Genetics of Israeli Populations (NLGIP) is a 
population-based biobank in Tel Aviv University that is collecting over 4000 samples.  
DNA and cell lines are being collected for future uses.  This biobank is opened for 
international collaboration.  The fact that the tissues are collected with a blanket consent 
certainly makes such collaboration more easy, which tends to be the case in most of the 
population based project (unless prohibited by law).   
 
GRAD study is hosted at the Howard University.  Researchers plans to gather blood 
samples or cheek swabs from 25,000 African-Americans to create the Genomic 
Research in the African Diaspora (GRAD) Biobank, the largest repository of DNA from 
Blacks. 
 
World-wide, the Western Australian Genetic Health Project (WAGHP) of the 
Western Australia Institute for Medical Research is probably one of the most ambitious 
population-based initiatives. Efforts to build this project started in 2004 and it targets 
the recruitment of 2 000 000 participants.   
 
The Indian Genome Variation Consortium, initiated in 2003 [19] aims to provide 
data on validated SNPs and repeats, both novel and reported, along with gene 
duplications, in over a thousand genes, in 15,000 individuals drawn from Indian 
subpopulations.  DNA will be collected following the Indian Council of Medical 
Research Guidelines213.  
 
                                                 
212 In addition to the ESTO Questionnaire, we reffered to the P3G Observatory as a source of information for this 
section.   
213 Ethical Guidelines for Biomedical Research on Human Subjects (2000), http://icmr.nic.in/ethical.pdf 
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In South America, Mexico has just created an important pole of genomic research with 
the Institute of Genomic Medicine of Mexico (INMGEN).  The Center is currently 
conducting a Genomic Mapping of the populations of Mexico.  Mexico has been the 
place for previous large scale projects such as the prospective blood-based study of 200 
000 individuals in Mexico (1999-2001.  However, this biobank is kept with CTSU of 
Oxford University.  Several of those projects could be open to potential collaboration. 
However, collaboration will be limited by the difficulty to harmonize the data collected 
through various tools, study designs and cultural contexts.   
 
To achieve such harmonization and create opportunities for future collaboration, the 
P3G Consortium214, a not-for-profit organization, is committed to facilitate the sharing 
of expertise and catalyze efforts to develop research strategies and tools for a 
meaningful collaboration between biobanks and population projects.  Many population-
based projects around the world are active members of P3G.  P3G also disseminates this 
knowledge in the public domain so as to support the international scientific community 
in improving the health of populations through its web-based Observatory. 
 
Regulatory aspects 
In Asia, some countries have a different perspective on some ELSI questions, including 
the consent process, than the traditional, more individual centered perspective prevalent 
in North America and Europe.  The discussions level varies from one country to 
another, and from an external point of view, the governance of human research seems 
uneven from one country to another.   
 
Singapore and Japan have deployed extensive efforts towards the development of an 
ELSI framework for biomedical research.  The ‘Human Tissue Research Report’ of the 
Bioethics Advisory Committee (Appointed in 2000 by the Government) is extremely 
useful to map the current legal and ethical landscape in Singapore215.  In fact, the 
committee concluded that there was very little guidance on tissue banking activity 
outside of the Human Organ Transplant Act.  However, the report offers general 
guidance on the conduct of biobanking activities.   
 
In Japan, two sets of guidelines have been adopted to offer a timely framework for the 
current increase in biobanks and biomedical research activities.  The ‘Fundamental 
Principles of Research on the Human Genome’216 (2000) proposed by the Bioethics 
Committee of the Council for Science and Technology is Japan and the ‘Ethical 
Guidelines for Analytical Research on the Human Genome/Genes’217 (2001) Issued by 
the Japanese Ministry of Health, Labour and Welfare, the Ministry of Education, 
Culture, Sports and Technology and the Ministry of Economy, Trade and Industry.  
Both documents stress the importance of privacy and informed consent.   
 
In South Korea, the Government adopted the ‘Bioethics and Biosafety Act’ in January 
2005218.  This legislation covers many aspects of biomedical research, including 
                                                 
214 www.p3gconsortium.org 
215 Report of the Singapore Bioethics Advisory Committee,  Human Tissue Research, 2002, http://www.bioethics-
singapore.org/resources/reports2.html 
216 http://www.mext.go.jp/a_menu/shinkou/shisaku/principles.htm 
217 http://zobell.biol.tsukuba.ac.jp/~macer/eghgr.htm 
218 http://www.ruhr-uni-bochum.de/kbe/Bioethics&BiosafetyAct-SouthKorea-v1.0.pdf  
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biobanking activities.  It creates a National Bioethics Committee and includes principles 
such as free and informed consent for biomedical research.   
 
Our research did not enable us to find legislation in China or Taiwan.  However, this 
does not mean that bioethics is not the subject of discussion [20].  The only relevant 
document we could find was prepared by the Ethics Committee of the Chinese National 
Human Genome Center of Shangai [21].  
 
Privacy / Data Protection 
China has limited protection on Privacy. Article 40 of the Constitution of the People’s Republic 
of China provides for the freedom and privacy of correspondence of citizens of China. 
However, HongKong has adopted a Personal Data Ordinance (Chapter 486). The 
implementation of the ordinance is under the authority of a Privacy Commissioner for Personal 
Data. This legislation is into force since 1996, in response to the EU directive, in order to 
maintain the free flow of information with countries that have equivalent legislation.  Taiwan 
has adopted the Computer-Processed Personal Data Protection Law, enacted in August 1995219. 
The Act governs the collection and use of personally identifiable information by government 
agencies and many areas of the private sector The constitution also provides for a limited right 
of privacy (similar to the article 40 of the People’s Republic of China).  
 
South Korea offers a contrasting legislative picture than the Chinease situation.  The 
privacy is protected both in the Constitution and in privacy legislations.  Article 17 of 
the Constitution clearly states that the ‘Privacy of no citizen may be infringed’220. We 
found two legislations of relevance: the 1994 Act on the Protection of Personal 
Information Managed by Public Agencies and the 1996 Act on Disclosure of 
Information by Public Agencies  
 
We could not find privacy legislation in Singapore.  However, there are ‘satellite’ 
legislations such as the Electronic Transactions Act 1998, which offer some limited 
protection over personal information.  
 
Japan has adopted the Law on the Protection of Personal Information in 2003. The law 
applies to personal information handling enterprises that constitute databases.  It sets 
rule for the collection, storage and use of personal information.  It came in full effect in 
2005.221  However, the law only applies to data collectors that store data on 5000 
individuals or more.  
 
Ethical Discussion 
The creation of population biobank resources are accompanied by ethical discussions:  
• Israel’s Bioethics Advisory Committee, Population-Based Large-Scale 
Collections of DNA Samples and Databases of Genetic Information  (2002) 
• Australia Law Reform Commission, Essentially Yours, Part E: Human Genetic 
Databases (2003) 
 
 
International Regulatory Initiatives 
                                                 
219 http://www.privacyexchange.org/legal/nat/omni/taiwan.html 
220 Article17, Constitution of South Korea, http://www.oefre.unibe.ch/law/icl/ks00000_.html 
221 For information about the legislation see: http://www.bakernet.com/ecommerce/japaneseprivacylaw.pdf 
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Given the global enthusiasm for population based biobanks and for birepositories, many 
international organizations have recently examined questions related to biorepositories 
or large-scale databases, and issued guidelines or discussion papers:  
 
• Council for International Organizations of Medical Sciences (CIOMS), 
International Ethical Guidelines for Biomedical Research Involving Human 
Subjects (2002); 
• World Medical Association (WMA), Declaration on Ethical 
Considerations regarding Health Databases (October 2002); 
•  Human Genome Organization (HUGO), Statement on Human Genomic 
Databases (December 2002); 
•  UNESCO – General Conference, International Declaration on Human 
Genetic Data, Geneva (2003) ; 
•  World Health Organization (WHO), Genetic Databases – Assessing the 
Benefits and the Impact on Human Rights and Patient Rights (2003). 
 
Currently, other initiatives are underway.  WHO is conducting a project called: Human 
Genetic Database: towards a global ethical framework: 
 
‘With the support of the Geneva International Academic Network (GIAN), the Ethics 
and Health Unit of the World Health Organization (WHO/DGO/ETH) and the Bioethics 
Unit of the Medical Faculty of Geneva University (Unité de recherche et 
d'enseignement en bioéthique) have joined together to study the conditions under which 
genetic databases can be established, kept, and made use of in an ethically acceptable 
way.’222 
 
The team will be looking into the current scientific literature and conduct interviews.  
The ultimate goal is to produce draft practice guidelines.  
 
OECD is also working on Human Genetic Research Databases.   
 
‘An expert working group of delegates from the OECD's Working Party on 
Biotechnology and the Working Party on Information Security and Privacy has been 
established to study the challenges raised by the interactions between genomics and 
informatics. The group will review how well existing privacy and data security rules 
and practices, including the OECD Privacy and Security Guidelines, might be applied 
to data from genetic testing. It will also consider the social dimensions raised by the 
growth in availability and use of individuals' genomic data.’223 
 
It was hoped to complete the research by May 2006 and that a final document would be 
submitted to OECD members in 2008. Finally in 2009 the OECD Guidelines on Human 
Biobanks and Genetic Research Databases were finalised and published. A background 
report on the issues addressed in the guidelines has also been published. Within the 
guidelines the OECD defines top- and mid-level principles and endorses best practices 
which are aiming to translate the principles into practice. The document covers also the 
highly contested areas such as consent, benefit sharing and return of information 
procedures.  
                                                 
222 http://www.who.int/ethics/topics/hgdb/en/ 
223 http://www.oecd.org/document/6/0,2340,en_2649_34537_1911942_1_1_1_1,00.html 
Biobanking activity                    
   114
 
OECD is leading another initiative related to biorepositories including cells and material 
from micro-organism, plan, animal and human: ‘the Global Network of Biological 
Resources’.    
A global BRC would:  
 
‘… Connect national BRCs and provide the framework within which co-ordination, 
harmonisation and quality assurance could be provided. This would enhance the 
services provided to the global community by BRCs beyond what the existing 
international frameworks could achieve.’224 
 
Global Biological Resource Center Network would help face the challenges of 
maintaining and exchanging biological resources.  According to the OECD website, 
efforts to establish a Global Biological Resources Network have been endorsed by 
OECD Science and Technology Ministers.  
                                                 
224 Biological Resources Centers, Underpinning the Future of Life Science and Biotechnolgy, OECD, 
http://www.oecd.org/dataoecd/55/48/2487422.pdf 
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3 BIOBANK NETWORKING IN EUROPE: CHALLENGES AND 
OPPORTUNITIES 
 
The study has identified several biobanks across Europe and world-wide which range 
from small disease-based to large population-based collections. Undoubtedly these offer 
a great resource for research on disease mechanisms and for the development of 
appropriate therapies and diagnostics. In this context, the sharing of samples and data 
gains immense significance but also implies a need for better interaction and 
networking among existing and emerging biobanks.  
 
Several initiatives towards this direction already exist or are currently emerging 
including EU-funded projects such as BBMRI, PHOEBE and DanuBiobank, and 
international projects such as P3G which have been discussed in the study. In addition, 
some of the survey's findings point to the potential opportunities provided by existing 
biobanks for improved networking at least at the EU level. Firstly, the surveyed 
biobanks have already a strong tradition of collaboration (over 88% collaborate with at 
least another group) and the majority of them have been involved in international 
projects. Moreover, a large number of repositories exist across Europe and some 
infrastructure (e.g. labs and personnel) is already in place. However, many challenges 
also exist due to the different biobanking practices on data collection, processing and 
storage. An additional barrier to harnessing the full benefit of biobanks may be 
presented by the different legal, regulatory and ethical frameworks that are applied 
across MS.  
 
This chapter discusses these challenges (as identified by the survey and our desk 
research) and identifies the options for improving biobank networking. In this context, 
the prospects for developing a potential European Biobank Networking Platform, the 
potential for funding of such activities, the insurance of appropriate benefit sharing and 
public engagement in biobanking activites and the promotion of legal and technical 
harmonization (samples, data, etc) are also discussed. 
 
 
3.1 Challenges 
 
 
3.1.1 Technological challenges 
 
IT infrastructure and bioinformatics: data comparability and standardisation 
The collection of various biological samples and associated information is central to 
biobanking. Bioinformatics and IT have become critical tools in life-sciences research 
allowing data acquisition, processing, analysis, management and reporting. However, 
these approaches vary widely in the different biobanks examined. For example, the way 
one repository collects, processes, and stores its specimens may be very different from 
that of another repository, which may complicate comparisons of research results 
obtained using biospecimens from different repositories. The quality and the extent and 
type of clinical information collected with the specimens also vary from repository to 
repository. In addition, the type of informed consent obtained from many of the tissue 
sources of these specimens is not always sufficiently robust to allow the use of these 
specimens in research that requires long-term follow-up of clinically relevant data. Such 
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variability is likely impeding comprehensive data analysis, and could potentially pose a 
greater challenge for data sharing and networking among biobanks. 
 
One of the biobank managers interviewed in the course of this project said: 
 
"One of the main barriers which really hampers large scale multicenter transnational 
research and sharing of tissues is the lack of freely available safe coupling standard 
operating procedures or applications of databases with safeguards approved by 
juridical and IT specialists on privacy issues. It would be ideal to couple data of tissue 
specimen of population banks with systematic disease banks; so both could access each 
other’s samples if needed. Moreover, including registry data would allow a better view 
on the donor’s history. Also it is crucial for the outcome of experiments to offer means 
to acquire follow up data and add these data to the sample record in a way that the 
privacy of the donor is not compromised just by extracting anonymously the data from 
existing clinical databases, of course only in those cases it is experimentally needed. 
Furthermore, it is in everybody’s interest (patient (donor and patients to come), treating 
physician, health lawyers and scientists) to find ways to improve the balance between 
all stakeholders".  
 
 
Data associated with research samples and donors must be structured in a comparable 
way. Yet, in today’s healthcare environment, the relevant clinical data are rarely in such 
a form and practices for data collection depend on the mission of the repository. 
Collections of biospecimens used primarily by basic researchers may only require 
minimal associated clinical data, such as demographic data and pathology reports. 
Biospecimens collected for translational research (e.g., target identification or 
validation) may require more in-depth associated clinical data, such as medical and 
family histories, treatment, and clinical outcomes data [16]. Inconsistencies of format, 
depth, and vocabulary are significant challenges even within one single site.- 
 
Comparability of specimens and of the associated clinical and biomedical data should 
be a key feature on next generation biobanks and will be critical for the development of 
a European biobank. Specifically, researchers will require the ability to utilize 
specimens and the associated annotation collected within a multi-site network to build 
data sets of sufficient statistical power. This creates a need for a collection process 
management and a quality assurance system. Moreover, the informatics infrastructure 
for biobanking will have to include standardized software225.  
 
Standardization of biobanking procedures as well as adherence to these practices by all 
participating organizations is necessary to ensure the scientific quality of data generated 
downstream. One of the ways to achieve this is through the establishment of biobanking 
good laboratory practice (GLP) and good clinical practice (GCP) that could be enforced 
by regulatory authorities226. Some biobanks, such as Tubafrost, which are already based 
on the association of several local biosamples collections in different European 
countries made available through a central database have chosen to develop such “Code 
                                                 
225 IBM Releases Six Critical Issues for the Success of Biobanks:  
http://www.ibm.com/news/be/en/2005/06/14.html 
226 IBM Releases Six Critical Issues for the Success of Biobanks:  
http://www.ibm.com/news/be/en/2005/06/14.html 
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of Conduct”227 on their own. A similar approach may be applied across Europe. In this 
context, a proposal recently funded by the EU for developing a Biobanking and 
Biomolecular Resources Infrastructure (BMRI), is putting emphasis on providing best 
practice-based standard protocols for different types of sample and data collections with 
a view to facilitating their long-term use [22].  
 
In the USA, the National Biospecimen Network (NBN) Design Team, a subset of the 
Tissue Access Working Group (TAWG) convened by the National Dialogue on Cancer 
(NDC) to address “access to appropriately collected, consented, and annotated tissue,” 
drafted in 2002 a blueprint for a national biospecimen network. The NBN Design Team 
envisioned a network of geographically dispersed tissue repositories to collect, process, 
store, and distribute appropriately consented diseased and normal tissue and other 
biological specimens with associated clinical data supported and coordinated by an 
accessible, user-friendly bioinformatics system networked across the country. The 
biospecimens would be collected, processed, annotated, stored, and distributed in a 
highly standardized manner to minimize experimental variability and accelerate 
scientific progress [16]. 
 
However, the challenge remaining would be to devise internationally approved criteria, 
standards, laws, regulations, systems, and professional practices for controlling physical 
and computerised access to data, managing personal identifiability, and securing 
informed consent - while at the same time, facilitating justified access for research 
purposes.  
 
The conclusions from the meeting of the EU-funded biobanking projects stessed once 
again the need for "federated databases with robust IT communication for secure and 
effective data integration, storing and sharing (data submission, data integration 
searching standards for getting data in and out " [23]. 
 
3.1.2 Legal, Regulatory and Ethical Requirements 
 
The conditions for biobanking and scientific use of biobanks are affected by laws and 
regulations in different ways. First, there are a number of important issues, more or less 
associated with each other. Many of them are of an ethical nature or somehow related to 
ethical considerations such as: consent, autonomy and personal integrity; privacy 
protection and safety; access to stored samples and data; transfer of samples and data 
across national border; “ownerships” and disposition of samples and data; intellectual 
property rights; commercialization; feedback of results to sample providers; information 
to the public/public engagement. Second, there are different types of legal and 
regulatory mechanisms used by policy-makers. On the one hand, there are “hard 
instruments” such as specific biobanks or human tissue acts and other relevant laws that 
apply to biobanks and medical research in general. On the other hand, the use of 
biobanks is also affected by “soft instruments” such as joint standards and guidelines, 
used for example by various monitoring bodies, or even softer governing mechanisms 
like incentives or sanctions.  
 
Yet, currently, there is no uniform regulatory system applying to human biobanks used for 
genetic research purposes and the way existing regulations and guidelines are interpreted and 
                                                 
227 Cf. Tubafrost Biobank.  
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implemented extremely varies across biobanks in different countries which might create an 
impediment to research collaboration and coordination [24]. The main question dealt with here 
is to what extent, and how, these national differences actually influence the establishment of 
joint research projects where different national biobank resources are effectively pooled228. The 
analysis is based on desk research and interviews with biobank researchers and law/ethics 
specialists, as well as on data collected through the survey, and discussions at the two meetings 
with experts organized in the context of the study.  
 
In this context, IPTS (in collaboration with Dr. Jane Kaye from the University of 
Oxford and the Public Health Genomics European Network PHGEN229), organised a 
workshop in Mach 2007 with experts from academia and industry, lawyers, national 
data protection authorities, and representatives from the European Commission and the 
European Data Protection Supervisor. The main objective of the meeting was to take an 
in-depth view at the existing legal bottlenecks and future needs of biobanking with 
special regard to the collection, exchange and linkage of samples and data in Europe. 
The scope of the workshop captured the linkage of data and samples, both the internal 
linkage of data and samples stored in a biobank and the external linkage of biobanks 
and secondary information resources such as cancer registries. The need for standard 
terminology but also the increasing role of ethics committees in the interpretation of 
existing regulation and guidelines were seen as some of the most important factors 
influencing global collaboration in biobanks-based research [60].    
 
In January 2010, experts from academia, industry and the European Commission 
convened in Sevilla again to discuss the development of the field in the last 3 years. In 
the meantime, both biobanking and the basic sciences which use biobanks have made 
substantial progress. New disease-specific and population based biobanks are set up in 
Europe and around the globe. While the need for biobanks was still debated in 2007 
there is now an overall mutual agreement in the research community that biobanks are 
important tools for modern health research. This research in the field of genomics and 
systems biology is by nature a global enterprise which needs a global research 
infrastructure. 
 
Privacy protection and security issues 
Biobank legislation seeks to balance the interests of individuals (especially sample 
donors and their families) and the research interest. Therefore, it is logical that privacy 
and security issues are addressed by biobank-related legislation and regulation. An 
important aim of the regulation is to protect the donors against harm that can arise due 
to the handling of sensitive information. Much of the focus, both in the debate and in 
the actual regulation, has been directed at DNA analysis – although unauthorised 
diffusion of other type of medical information can be as harmful.  
 
Data protection requirements in Europe are laid down by the Directive 95/46/EC on the 
protection of individuals with regard to the processing of personal data and on the free 
movement of such data230. However, currently, significant variability still exists with 
                                                 
228 It should be noted that collaboration usually takes place between researchers or research groups, not between 
0biobanks. That is, researchers may engage in international collaborative projects where different teams contribute 
samples and data stored in their own biobanks (or in joint biobanks). 
229 www.phgen.eu 
230 Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of 
individuals with regard to the processing of personal data and on the free movement of such data. Official Journal L 
281, 23/11/1995 P. 0031 - 0050 
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regards to privacy and data protection requirements for biobanks. Experts suggest that 
such differences may be partly attributed to the varied interpretation and 
implementation of the Directive covering aspects of biobanking by national authorities, 
and its translation into administrative procedures. As a market directive the directive 
95/46/EC is by definition fully harmonising; still the Art. 8 (3) and 8 (4) which cover 
Public Health issues are allowing exemptions from this harmonisation. According to Art 
8 (4) of the Directive, Member States “may, for reasons of substantial interest, lay down 
exemptions in addition to those laid down in paragraph 2”. The design of Art 8 of the 
Directive gives Member States substantial discretion in the field of Public Health. Still, 
Member States shall set up nations regulations which are not in conflict with the overall 
aim of the Directive to facilitate the exchange and flow of data in the EU Member 
States. The existing information does not allow the conclusion that the Member States 
have explicitly used the exemption of Art. 8 (4) to develop divergent regulations for 
biobanks. Within the transposition of the Directive Member States may have rather 
focused on the national Public Health setting, such as monitoring and surveillance 
systems, as they transformed the discretion of Art. 8 (4) into policies.  
 
One of the main complications being that although the field of data protection is 
harmonised through the EC directive on data protection, the collection, storage and 
sharing of samples for research purposes is not [42]. Furthermore, in countries that have 
enacted special biobanks acts it is not always clear where the borderline goes between 
the scope of these acts and that of the Directive. For example, how biobank materials 
are looked upon in various jurisdictions is not always the same. Furthermore, in 
countries that have enacted special biobanks acts it is not always clear where the 
borderline goes between the scope of these acts and that of the personal data acts [8]. 
There may, for instance, be uncertainty regarding which law should give precedence in 
case the rules differ.  
 
Different demands on coding or anonymizing of data are often used by the authorities as 
a complement to requirements on consent. For example, research on biosamples without 
informed consent can sometimes be permitted if the identity of research subjects is 
protected by high-security data-handling systems. In this context, there seems to be a 
broad agreement among researchers that biobank-based research should be carried out 
on samples and data that are coded (or double-coded), and that the code should be 
broken only in exceptional cases (this is in line with requirements from UNESCO). It 
can be in the following types of situation: cases where there is suspicion about cheating; 
when there is need for new data; when carrying out longitudinal studies; and in the 
context of metaanalysis (in order to avoid counting individuals twice). This means that 
generally researchers do not want samples and data to be anonymized in the sense that 
there exists no code key that can be used to break the code, if necessary.  
 
As discussed in a recent publication, coding has major advantages over anonymization 
in the context of using research samples for secondary purposes: “… Anonymization, 
while often ethically and legally expedient, undermines the scientific usefulness of the 
samples over time since no further clinical data can be added to the database because 
tracing the sample back is impossible. Likewise, the individual can never benefit from 
any results. International bodies have yet to support the obvious personal and scientific 
advantages of double-coding.” [43] 
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It should be noted that anonymization here means that samples or data contain no 
information what so ever that could reasonably be used by anyone to identify the 
individuals who donated the samples [43]. This is what the Medical Research Council 
(MRC) in the UK calls “unlinked anonymisation”231. MRC in its ethical guidelines also 
uses the term “linked anonymized samples or data”, meaning that samples and data are 
fully anonymous to the people who receive and use them but contain information or 
codes that would allow others (e.g., the biobank operator) to link them back to 
identifiable individuals. There are others who would describe these samples as being 
coded][8]. Thus, there is no consensus on the terminology used in this field. This lack of 
clarity “undermines possible harmonization due to the resulting complexity, especially 
when new concepts such as reasonable or proportional anonymity are introduced” [27]. 
However, some biobanks have already taken initiatives to improve this lacking232 and  
the EMEA has published a note for guidance on definitions on genomic data and sample 
coding categories which  came in operation from May 2008233.  
 
In the biobanks acts and the guidelines adopted by various countries a common 
provision is that coding is recommended or even prescribed. The answers that were 
received through the questionnaire also show that a large majority of biobanks apply 
coding (including “linked anonymization” according to the terminology of MRC). Thus, 
such a practice seems to be spreading in Europe, whether imposed by regulation or not. 
The development of such a standard in Europe should facilitate international 
collaboration where biobanks are involved. There are of course many ways in which the 
coding/decoding can be carried out technically. There is also the possibility of involving 
a third party responsible for holding the key. However, the regulatory authorities rarely 
specify which solution to use. It is up to the biobank operators to decide how to do the 
coding so that the authorities’ requirements can be met. In the context of individual 
research projects, it may then be a task for the research ethics committee to judge if the 
methods applied are appropriate, given other circumstances at hand (e.g., what type of 
consent the researchers have obtained). 
 
The handling of privacy protection and data security in accordance with emerging 
standards, which usually means some kind of coding, makes biobank-based research 
more complicated and costly. There is no indication that differing regulation between 
countries per se, in this particular regard, would constitute an obstacle to international 
research collaboration, even when there is a need to share samples across borders. There 
are well-established techniques that can be used. However, lack of agreement on the 
nomenclature can be an obstacle.  When collaborating biobanks use different types of 
techniques and security standards this may of course complicate the pooling of samples 
and data. One possible solution to facilitate harmonisation and collaboration would be 
the creation of a “safe” and “trusted” third party to be used for all researchers as a 
trustee for the names and identity of participants. Moreover, in the absence of a uniform 
standard level, commercial biobanking activities may potentially flock to countries 
setting the lowest requirements on privacy protection.The European Medicines Agency 
(EMEA) proposed specific terminology in pharmacogenetics through a position paper 
                                                 
231 Medical Research Council (in the UK), "Human tissue and biological samples for use in research: operational and 
ethical guidelines", MRC Ethics Series, 2001 (p. 2). 
232 In Sweden, the KI Biobank has developed a Biobank Lexicon with the purpose of paving the way for consensus 
on terms within the field of biobanks. 
233 Note for guidance on definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data, 
and sample coding categories (EMEA/CHMP/ICH/437986/2006)  
http://www.emea.europa.eu/pdfs/human/ich/43798606en.pdf 
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in 2002234. This nomenclature could fit the needs for current research practice and is 
line with different harmonising efforts to optimise privacy [36]. Nevertheless a deeper 
international understanding of these issues still needs to be reached.  
 
Access to stored samples and data 
Small collections of biosamples are often used only by the local researchers who 
collected the samples. Larger biobanks are often open to be used also by other 
researchers in the same country or from other countries. However, this does not mean 
that these external researchers have unconditional access to samples and data. The 
access is almost invariably restricted and is normally controlled by the biobank operator 
itself (no national regulation exists for access, but rather for transport)235. Typically, 
there must be collaboration with researchers linked to the biobank in some way. 
Furthermore, it is very common that the planned research project, besides the ethical 
review carried out by appropriate authority, must be approved also by a steering 
committee or similar body that has responsibility for the biobank (in extreme cases only 
one person, such as the principal investigator). This type of review is usually based on 
scientific principles aiming at making the best use of stored samples. Finally, it varies 
greatly whether researchers using the biobank need to pay or not, although it seems that 
payment is becoming more common. This is understandable since running biobanks as 
an infrastructural resource is costly, and such costs can rarely be covered by normal 
research grants236. 
 
Transfer of samples and data across national borders 
Sending samples abroad may in some countries require a special consent from the 
donors. With the principal aim of protecting donors, the biobanks acts in Sweden and 
Norway, for example, only permit samples to be analysed abroad, not stored for a 
longer period of time237. The Swedish Biobanks Act also requires that samples be coded 
or anonymized before shipping. Moreover, to get the approval for sending samples is in 
these countries associated with some bureaucracy, which the researchers perceive to be 
irritating and constituting an obstacle to international cooperation. However in most 
European countries, as it seems, apart from the time-consuming ethics review process 
researchers do not experience any legal barriers to sending biobank material abroad. A 
large majority of the researchers who answered our questionnaire state that they face no 
problem in this regard – provided that appropriate permission for the projects has been 
obtained from the research ethics committee and others concerned (such as the board or 
steering group of the biobank). 
 
If biobank legislation is to be harmonized within Europe, the barrier to sending samples 
abroad that obviously exists in some countries is one of the more important aspects to 
deal with. To effectively carry out research projects it may often be advantageous to 
centralize the handling and analysis of samples. While the requirements for sharing of 
data is pretty much harmonized in Europe, thanks to the implementation of the 
Directive 94/46/EC on data protection, the legal situation with regard to biosamples is 
                                                 
234 http://www.emea.europa.eu/pdfs/human/press/pp/307001en.pdf 
235 Following the HAPMAP project, there is a whole trend towards the sharing of data in a pre-competitive fashion. 
This is supported by funding agencies for publicly funded research. 
236 Previous research on biobanks in Sweden showed that it was often relatively easy to get project funding for 
collection of samples and data. But it was more difficult for the researchers to finance the operation of the biobank 
itself. 
237 This means that researchers from these countries cannot participate in projects where samples are to be stored in a 
central biobank located abroad. 
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far from being clear. Therefore, it was suggested that legal experts from different 
countries should make an analysis. For example, by making a legal observatory or 
clearing-house they could help the researchers to deal with the regulatory uncertainties. 
Such an observatory is needed to facilitate bilateral and trilateral contracts between 
researchers and biobanks. An increasing number of stakeholders seem to favour an 
analogous application of the Data Protection Directive to achieve an equivalent level of 
harmonisation for both domains, data and samples. It also needs to be further 
investigated whether the regulations as such are posing problems or whether the 
interpretation and application through ethics committees and IRBs is causing adverse 
effects due to the heterogeneity. These committees may also set standards which are 
stricter than the law; in this case the role of ethics committees and the rule of law need 
to be studied. So far there is no literature or evidence available which explores the field. 
Further research needs to be launched in this field.     
 
To enhance the legal certainty for researchers and to reduce the administrative 
complexity a permanent European hub for the exchange of samples and data might be 
considered. Information on particular countries are increasingly accessible on the 
internet, e.g. through the work of BBMRI. Still, the national rules need to be tailored for 
international multi-centre studies and consortia and a facilitator is needed to streamline 
this process.     
 
The issue of consent 
Human bodily substances and, to a minor extent, the personal data are proprietary in 
many EU Member States and can only be processed with the explicit and informed 
consent of the data subject concerned. The existence of informed consent is a standard 
ethical requirement in all kinds of medical research, and therefore applies also to 
biobank-based research. In such a context, informed consent concerns the process in 
which a potential sample donor receives the relevant information and decides whether 
or not to authorize storage and various uses of the sample, based on that information 
and his or her own values  [25]. In this sense the informed consent of the donor consists 
of different ethical and legal layers. In practice the consent process is often seen as one 
domain and the different subsections of the consent process are not clearly defined. The 
consent encompasses the (invasive) retrieval of the sample, in some countries the 
transfer of property rights regarding the sample, the processing of sample and secondary 
personal data and the consent to the research which is carried out in a later stage. The 
different layers of consent need to be reflected in the information and disclosure duties 
of the biobank as the consent would be invalid otherwise.   
 
Although the basic principle of informed consent for approval of biobank-based 
research is applied in most countries, there are national differences regarding the 
strictness and the procedures, as imposed by national laws and guidelines. Such 
discrepancies in the regulation of biobanks may create problems for international 
collaborative projects. In this context, one interviewee expresses the following concern: 
“the interpretation of the consents is currently discussed in the legal and ethics 
advisory bodies. Until those questions have been sorted out, no wider sharing of 
samples and data can take place”. 
 
The «informed consent» requirement could, additionally constitute a problem if a pre-
existing data collection is being used, or if a research project moves in a different 
direction from the one originally assumed. Thus, whenever data and biological samples 
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are introduced into a biobank for the first time, the question arises of how precise the 
consent of the data subject should be238. Especially, for an optimum use of European 
biobanks, it may be appropriate to link data and information from a variety of sources. 
With modern electronic techniques and the internet, biobank data can be exchanged and 
pooled across networks. This may yield information of a quantity and quality beyond 
those envisaged when the donors gave their consent. Consideration must be given to the 
rules for limiting the arbitrary transfer and linkage of samples and data collected for 
biobanks239. 
 
A number of different solutions have been proposed, and some are already being 
applied. Traditionally, in research, the object of consent must be quite precise and the 
participant must be informed of all potential procedures and risks. However, some are 
questioning whether this traditional view is applicable in biobanking activities. 
Depending on the focus, these solutions give priority to either the autonomy of the 
donor (in the sense of the right to informational self-determination) or the research 
interests for practicality and implementability of the research projects. Like the UK 
Biobank, the German National Ethics Council and the Swiss Academy of Medical 
Sciences (SAMS) have indicated their support for a blanket consent system for 
biobanks, and do not have any ethical reservations provided that consent can be 
withdrawn at any time240, 241. 
 
One can distinguish two types of situation, which put different demands on the handling 
of the consent issue. The first is when a study is going to use existing biobanks 
containing samples that have been collected previously for some purpose (e.g., 
diagnostics, a clinical trial or a specific research project). The second situation is when 
building new research biobanks from scratch, for the purpose of a particular study or 
with other more far-reaching aims – such as creating repositories that can be used for a 
number of different studies.  
 
The first situation is probably the most problematic one. Before starting an international 
collaborative project where samples and data stored in different countries are to be used, 
each research group needs to obtain an ethical approval from concerned authorities in 
the respective country (irrespective if biological material is to be transferred or not). So 
far there seems to be no mutual recognition process for ethical approvals from third 
institutions.  The authorities have to review, inter alia, the existing consents and decide 
if these are sufficient or if there is need for some kind of action (such as getting renewed 
informed consent from the donors or applying some kind of opt-out solution).  
 
For international projects, there are two types of problems. First, there may be 
differences between the biobanks in terms of what kind of consent that exists for the 
stored material. When it comes to old biobanks it is common that the donors’ original 
consents, if there are any, do not coincide with the purpose of the planned research. 
Very often samples stored in clinical biobanks have been collected without any explicit 
consent for research from the patients. Second, the review carried out in each country 
                                                 
238 Claudia Mund, Biobanks – Data Sources without Limits?, in: Jusletter 3. Oktober 2005 
http://www.weblaw.ch/jusletter/Artikel.asp?ArticleNr=4211, 
http://www.privacyconference2005.org/fileadmin/PDF/mund_e.pdf 
239 ”Biobanks for Research”, Opinion of the German National Ethics Council, Berlin, 2004  
240 Cf. German National Ethics Council, Biobanks for Research, opinion of 17 March 2004, Berlin 2004, p. 55 ff., 
especially p. 61 f. (www.ethikrat.org/_english/publications/Opinion_Biobanks-for-research.pdf). 
241 The guidelines can be found at www.samw.ch/docs/Richtlinien/d_RLBiobanken.pdf (in German). 
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will of course be carried out based upon each country’s domestic laws and rules. The 
current provisions of existing regulations concerning information and consent may vary 
from country to country. Depending on these circumstances the review process may 
thus take shorter or longer time, and the outcome in terms of the requirements may vary.  
 
Further complication may be added when considering the requirements for sample 
transfer. As the survey brought about, in practice, different handlings exist with regards 
to the sharing of samples. For example, researchers asking for DNA samples at the 
National Laboratory for the Genetics of Israeli Populations (NLGIP) need to declare 
they would not be transferred to others. In contrast, the EORTC VTB Biobank can share 
its samples (tissues and data) with researchers in the other countries, as soon as the 
donors and patients have expressly permitted it242. Another barrier to an unproblematic 
transfer of samples is also the fact that the consent obtained from the donors might 
depend on the clinical trial setting and not be universally valid, as it is the case for the 
EORTC VTB Biobank. 
 
With regard to archived medical care samples, there is a trend where ethically approved 
research on such material is permitted without re-consent. The condition is that samples 
are either anonymized or exceptionally coded, provided there are important health 
interests, there is notification of such practice, no objection, and research ethics 
approval [26] . 
 
Although informed consent is the norm in medical research, an opt-out solution is 
sometimes regarded as acceptable in biobank research, since there is no physical risk to 
the subjects. But this requires that strict security measures are taken in order to 
safeguard the privacy of donors and that there is widespread support of medical research 
in the population. In Iceland, for example, according to the law on the Health Sector 
Database, people will have the possibility to opt out from the database [27]. Opting-out 
is considered by some as detrimental to research without real benefits for the autonomy 
of the donors [28].  
 
The observation that the routines used for obtaining consent may vary greatly between 
existing biobanks involved in international projects has been taken as starting point for a 
study carried out at the Centre for Bioethics at Karolinska Institutet and Uppsala 
University. It addresses the selection of appropriate information and consent procedures 
when previously collected samples are used in international collaboration. The 
researchers behind the study argue that although informed consent is a standard 
requirement in the ethics literature, the circumstances for research on existing biobanks 
are sufficiently different to motivate a special practice. Moreover, they present a special 
ethical framework that can be used to solve the problems and challenges that 
international biobank researchers encounter with regard to the consent issue [[26].  
 
In the second situation (i.e. creation of new research biobanks), new samples are going 
to be collected in different countries for the purpose of a new international research 
project or the creation of new infrastructures for future collaborative research. 
Obviously, there are strong incentives to use, if possible, the same type of consent in all 
participating countries – since this would enable flexible uses in the future as it is often 
impossible to know in advance how the researchers will like to use the material. It 
                                                 
242 Cf. returned Questionnaire.  
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would be a great advantage if common grounds for review of consent, and other ethical 
aspects on biobank research, could be established in different countries.  
 
As illustrated in Figure 3-1, consent procedures can be thought of as a continuum from 
highly specific consent to blanket consent [29] . A much debated topic is whether broad 
consent to future biobank research can be acceptable, or if a renewed consent must be 
asked for each new study. Broad consent means that donors give permission to use 
samples and data for multiple purposes of future biomedical research. Several 
arguments against broad consent have been put forward. For example, the Icelandic 
ethics professor Vilhjalmur Arnason, referring to the principle that consent should be 
based on information relevant to an assessment of benefits and risks associated with the 
research, argues that “the more general the consent is, the less informed it becomes” 
[30] . He means that the standard meaning of informed consent cannot accommodate 
broad consent (sometimes also called “authorization”). 
 
 
Figure 3-1:  Categories of consent 
Blanket consent
Consent to biomedical research
Consent to research on specific
disease (eg, cancer research)
Consent to a
specific study
Autonomy Specificity
 
Source: Hansson, et al.  [29] 
 
 
The question of what is appropriate information has been raised, considering that 
blanket consent can indeed provide all relevant information if the risks and benefits are 
appropriately informed. For research that involves less risks for research participants, 
less-strict information and procedures are appropriate [29]. In the same way, if these 
risks and benefits are common to several studies, then general information on these 
studies might be sufficient [29]. Of coursse, in assessing risks and benefits associated 
with a proposed study the ethics review boards must take into consideration how 
personal data is handled and other potential risks for the donors. They might also 
consider to what extent donors are willing to take the risk of being not fully informed on 
all aspects of the future use of a biobank.  
 
It has been suggested that the key to broad consent is that participants are not 
consenting to a specific study, but a specific process and a given governance structure 
that ensures that future uses are within acceptable and agreed parameters. In other 
words, the donors should be offered a whole package that includes a number of 
procedures for handling of samples and data. By having good procedures and structures 
in place people will feel confident that their integrity will not be violated. In this 
context, a recent study concludes that (“well-informed generalized”) consent to future 
research has not yet become the norm in international regulation [27]. But for certain 
types of research there is a gradual move towards allowing biobanks to obtain a broad 
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consent for future research using either anonymized or, preferably, coded samples and 
data. Especially for large-scale longitudinal studies on genomic variation such a practice 
may be accepted provided it is justified both scientifically and ethically. 
 
It seems that scientists involved in large population-based biobank projects, such as the 
UK Biobank and the Estonian Biobank, favour a solution with an explicit broad consent, 
which is documented through the donor’s signature on a special consent form. The 
existence of such a clear consent undoubtedly makes it easier to use such biobanks for 
various scientific purposes.                        
As commented by a clinical researcher working in a hospital, such a practice is 
convenient for this type of research biobanks, but it is not a good solution for 
healthcare-based biobanks. To require a practice where a written consent has to be 
obtained from patients is impractical and costly. Thus should be enough to inform the 
patients on notice boards – and that the research ethics committee should have the right 
to permit research without consent. Such a practice is already applied in several 
countries. It also needs to be noted that the existience of a consent document does not 
per se prove the validity of the consent. From a legal perspective rather the appropriate 
information of the patients/donors should be stressed and not necessarily the sheet of 
paper which is finally signed.  
 
The view of actual and potential donors in various countries has been examined in a 
number of studies. Although there is no consensus of opinion among these studies, most 
actual donors seem to favour a procedure of broad consent given on the occasion of 
recruitment. Blanket conset was amongst the "persistent disagreement" issues in a 
public deliberation group exercise carried in 2007 [41]. Some of the public's alternative 
as an alternative to the blanket consent was, as an example, a consent form with 
specified preferences for different research uses. By giving the right to withdraw the 
consent later, regretful donors can be protected243. It can be added, though, that the right 
to withdraw necessarily requires some kind of public accessible information about the 
uses. Therefore, many are arguing that uses of biosamples should be publicly known in 
some sort of registries. 
 
While there are those defending both explicit and specific consent [30, 31] or a muli-
layered more specific consent which allows for prospective research [32-34] many 
experts seem to be in favour of a well-informed blanket consent [18, 35-40] .  Their 
arguments are mainly economical feasibility (to create a large biobank for to study just 
one particular issue would have a tremendous   cost and would make it impracticable).  
Moreover, from a scientific point of view,, if the informed consent is too strict, future 
research may be hindered because most of the studies will not be planned or even  
conceptualised when the consent is given.This however should not suggest a policy 
where anything goes. Even the Council of Europe seems to be more open to a broader 
consent for future research244. A working group at UNESCO concluded in 2002 that 
blanket consent might be more appropriate to allow future research in biobanks245. 
                                                 
243 Our questionnaire data shows that the right to withdraw previous consent is almost invariably practised in 
European biobank research. 
244 CM(2006)21 Addendum, Council of Europe, Steering Committee on Bioethics (CDBI): Draft Recommendation 
Rec(2006) of the Committee of Ministers to member states on research on biological materials of human origin Draft 
explanatory memorandum . https://wcd.coe.int/ViewDoc.jsp?id=961137 
245 UNECO SHS-503/01/CIB-8/3 (Rev.2): Human Genetic Data: Preliminary Study by the IBC on its Collection, 
Processing, Storage and Use, May 2002 
http://portal.unesco.org/shs/en/files/2138/10563744931Rapfinal_gendata_en.pdf/Rapfinal_gendata_en.pdf 
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Those defending the use of blanket consent also stress the importance of the right to 
opt-out or withdraw consent. Maintaining the right to withdraw consent preserves 
personal integrity and autonomy of the donors [19]. In addition, consent for future 
secondary research, requires public notification of such research and ongoing ethics 
reviews [27]. 
 
The role of Ethics Review Boards 
It has been argued that broad consent for use of human blood and tissue samples in 
future biobank research in epidemiology is legitimate. The arguments include the great 
value of such research, the respect for the autonomy of the donors, and the current 
regulatory practice in many countries. It is concluded, inter alia, that provided the 
security level is high and donors and families are protected from harm, no limitation on 
autonomy is necessary246. The third argument (on the regulatory practices) is of 
particular interest in the context of the present study. According to current practice in 
the UK, Estonia and Sweden, ethics review boards have a mandate to approve a biobank 
study without requiring informed consent. In Iceland, the National Bioethics Committee 
can do the same. Furthermore, Germany, Norway, the Netherlands, and the USA, 
existing regulations permit biobank research without consent provided that the samples 
are not identifiable (furthermore, there must be a consent for taking the sample, and the 
anonymization must be assessed by an IRB). It is concluded that if ethics review boards 
might grant permission to carry out research without consent, there is no reason why the 
participants themselves should not be allowed to give broad consent if they are clearly 
informed about the underlying factors which determine the need for a broad consent. 
 
The view of Ethics Review Boards can be challenged from the perspective of the 
European Data Protection Directive. According to Art. 8 (2 a) of the Directive the 
processing of sentive data is not prohibited if the data subject has given his or her 
“explicit consent to the processing of those data”. Member States are even empowered 
to put further restrictions on the right to consent. Biobanks and ethicists may rightfully 
argue that this regulation is paternalistic but it fits into the overall regulatory rationale of 
the Directive. It is the explicit aim of the Directive to prevent mass data preservation as 
the Directive has a rather narrow understanding of the concept of purpose. In Art. 2 (h) 
of the Directive the informed consent is defined as “the data subject’s consent shall 
mean any freely given specific and informed indication of his wishes by which the data 
subject signifies his agreement to personal data relating to hime being processed”. In 
line with the argument of Arnason and open or broad consent may not be in line with 
the definition of the Directive as the data subject seems not to have the right to take a 
risk. The wording of the Directive has been influenced by a decision of the German 
constitutional court which                        
ruled that the German law on population’s censuses was partly unconstitutional as it 
infringed the “right to informational self-determination”247. This fundamental right 
includes a right to know who is processing what kind of personal information for which 
purpose. Due to the political situation at the time of the decision, the fundamental right 
does not include a right not to know or a right to take a risk. Following this rationale an 
"uninformed" or partially informed consent can be seen as invalid as the data subject is 
not empowered to assess the long-term consequences of his or her consent.  
 
                                                 
246 It can be questioned though whether the current regulatory frameworks are efficient enough to enable broad 
consent. 
247 BVerfGE 65, 1, Decision from the 15 December 1983 1BvR 209, 269, 362, 420, 440, 484 / 83 
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Feedback of personal results to sample providers 
Analyses carried out on samples in the course of research may reveal information that 
has implications for the donors’ future health or healthcare, or affect their interests in 
other ways. This raises the question whether such information should be reported back 
to the donors. This question is often addressed in ethical guidelines for biobank 
research. The Medical Research Council (MRC) in the UK, for example, states that 
“researchers should assume that participants have a right to know information that may 
affect their interests, but that they might choose not to exercise this right” [12]. MRC 
advises researchers to decide in advance what their strategy will be regarding the 
feedback and whether any linkage of research results to individuals will be possible. 
This must be set out in their submission to the ethics committee and the chosen policy 
must be explained clearly to the donors before they consent to take part in the study. 
 
In the UK Biobnak, participants have access to general information about the project’s 
progress, but are not to be given any individual information relating to the project’s 
finding. This is in contrast to the proposed US Biobank project whose volunteers will be 
given the option of being told about findings that could affect their health, such as 
whether they are developing cancer [45]. 
 
Maybe, this is an issue that is of higher relevance to individual research projects than to 
biobanks as infrastructure. But biobanks can of course have a policy regarding this 
issue. A general feedback policy may also have implications on the communications 
infrastructure of the biobank as the biobank might have to handle a large set of 
complicated data. Therefore, a question on this was included in the questionnaire. The 
results show that approximately 40 percent of the biobanks surveyed state that they give 
such feedback, but on the condition that the donors have consented to it. The two 
genome projects in Estonia and Latvia are two examples. However, the option to give 
feedback in all cases is rarely used. One exception is Generation Scotland. 
 
General information about research results of a biobank study is made available through 
publication in scientific journals.  However, giving specific information to individual 
donors is discouraged by some because of the high levels of responsibility assumed by 
the researcher [36].  If clinically relevant information is expected from the study, 
collaboration with clinical experts is then advised [32]. 
 
Giving feed back of analysis results is only possible if the data is coded (i.e. not 
anonymized in a strict sense). But, in line with the researchers’ reluctance to use the key 
to break the code, there is a preference not to report back any individual results. In this 
context, one professor says that "if there is a proposed partner for a new project who has 
such a requirement, that partner’s biobank would not be regarded to be useful. At the 
same time he says that such requirements are unusual in Europe. It is mainly when 
discussing collaboration with American researchers that ethics committees sometimes 
come up with this kind of demand". It should be noted though that according to our 
questionnaire data feedback of personal analysis results is not so uncommon in Europe 
(Figure 2-16).  
 
“Ownership” and right of disposal over samples and data 
The issue of who “owns” biosamples, or biobanks, and has the right of disposal over 
them is very complex. In a study on intellectual property (IP) and biobanks carried out a 
few years ago it was concluded that in an IP context, biobanks are regarded as 
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protectable compilations, that is, databases [46]. This means that biobanks may be 
protected by intellectual property in the form of copyright or sui generis protection. The 
study recommends that the intellectual property rights be regulated by contracts among 
the various actors involved in creating the biobank. These IP rights do not infringe the 
IP rights of researchers who use the materials of the biobank to create their own 
inventory step which enables them to seek, e.g., patent protection. The commercial 
exploitation of biobanks might be a huge ethical and political issue as it also affects the 
public trust in the biobank. In contrast the commercial exploitation does not affect the 
legal framework for biobanks to the same extent. Property and Intellectual Property 
rights regimes are in place to structure the process. The exisiting international 
framework seems to be appropriate to govern the domain. It seems to be rather a 
political question to ensure the equitable access to biobanks and to organize a fair 
distribution of financial gains which have been achieved by using the (public) 
infrastructure of a biobank.   
 
There is a trend to consider samples and data in a biobank as a public or community 
good so that donors cannot claim any property rights [18, 47, 48].  The business value 
derived from the biobank would then belong to those conducting the research, not the 
individual donors [18]..  In terms of property rights,  the open source model as well as 
the benefit-sharing proposed bu UNESCO 248 have been claimed by some [48]. 
 
There is no doubt that the issue of ownership and disposal is important for effective use 
of biobanks, generally. There are at least a few cases where long-lasting disputes 
concerning the ownership have had negative effects on the use of specific biobanks for 
research. One such case, which has got a fair amount of publicity, concerns the Medical 
Biobank in Umeå where some of the researchers involved are opposing the university’s 
and the county council’s attempts to take control over the biobank. Especially, this 
dispute effectively hindered the use of this biobank in commercial research [49]. The 
case revealed that at least in Sweden the legal situation is not entirely clear. However, it 
remains to be seen how this issue will be handled in other countries. In Singapore, for 
example, the National Ethics Committee suggests that biobanks should be owned by 
“institutions” and not private individuals. The situation is even more complex in legal 
systems which do not use the property rights regime for samples obtained from donors. 
Still, the collection of the samples (the bank) constitutes a substantial value and may 
need to be protected by property rights. The economic value of a biobank may also 
constitute a legal problem if the biobank or the institution behing the biobank goes 
bankrupt. There is no clear position yet how the rights of donors shall be fully protected 
in such a case.    
 
In the present study we have not come across any case where international collaboration 
has been hindered by IP-related factors. However, it cannot be excluded that such 
problems have occurred or will occur in the future. This is an issue that needs to be 
further investigated. 
 
 
 
Benefit sharing 
                                                 
248UNESCO International Declaration on Human Genetic Data, 16 October 2003  
http://portal.unesco.org/en/ev.phpURL_ID=17720&URL_DO=DO_TOPIC&URL_SECTION=201.html 
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The individual participant in a biobank study will not typically benefit by participating 
[50]. The outcomes of the research on these data bases improve our knowledge of the 
genetic and non-genetic factors contributing to disease and therefore facilitating 
treatment or prevention strategies.Therefore, biobanks are established base on the 
altruism of individual donors.  Inevitably, this good-will is based on trust [40]. 
 
With the argument of public benefits, even the right to withdrawal has been questioned 
based on the notion of solidarity [51]. 
 
3.1.3 Funding and Financial Maintenance 
 
While it is desirable that biobanks eventually become financially self-sufficient, in the 
short-term they will require a substantial infusion of capital for the establishment, 
development and maintenance of the necessary infrastructure249. In private biobanks the 
costs are typically borne by the depositor; in public biobanks the costs are charged to 
the user and paid either through medical insurance (principally in the USA) or by public 
health services. However, sample storage is rarely a fully recognised activity, except in 
some pharmaceutical groups or biotechnology companies. Even for bigger banks, 
continuity of funding is not always assured. For those involved, regrouping of the 
biobanking activity could enable economies of scale and cut costs. However, it has to be 
compatible with simplicity of use [52].  
 
There are different kinds of funding actors involved in biobanks (Figure 3-2). While 
health care-based biobanks are formally financed internally by the county councils, 
special funding is in most cases needed in order to build, administer, and use research-
based biobanks. Obviously, funding provided by public entities are usually short term 
where the funding for biobanks infrastructures would need to be on a long term - hence, 
there seems to be a need to shift from funding projects to funding long term 
infrastructures. 
 
Return-on-investment models or a sustainable public funding will be critical for the 
successful funding and development of a biobank approach on EU level. Biobanks that 
make their samples available to other researchers might want to participate at the profit. 
This has been confirmed by a survey respondent who “would be willing to share 
samples with other biobanks provided that a system for fair revenue sharing is set”250. 
Furthermore, a critical attribute of a shared resource is that the distributed resource be 
what it is supposed to be251. The issues of quality control and quality assurance for 
shared samples or sample repositories are of major concern, because these activities 
might be a major contributor to the costs of some public research institutions. 
Commercial competitors willing to employ less stringent measures on a smaller 
selection of resources can and do offer apparently similar products at cut-rate prices. 
High-quality research depends on high-quality materials, and the scientific community 
will have to recognize that it must pay for quality control, through subsidy if not 
                                                 
249 IBM Releases Six Critical Issues for the Success of Biobanks: ttp://www.ibm.com/news/be/en/2005/06/14.html 
250 Cf. returned Questionnaire. 
251 Resource Sharing in Biomedical Research, Committee on Resource Sharing in Biomedical Research, Division of 
Health Sciences Policy, Institute of Medicine, 1996. 
http://bob.nap.edu/html/biomed/#contents. 
Networking: Challenges and Opportunities 
   131
through user fees. Precise handlings might be necessary to state that has to defray these 
costs. 
 
Figure 3-2:  Different types of actors involved in biobanks 
 
 
Adapted from: Laage-Hellman, J., “The industrial use of Biobanks in Sweden: an overview” [7] 
 
 
However, the mode of sample allocation between biobanks is not guided by market 
relations. In the language of welfare economics, there are “externalities”, benefits and 
costs transmitted among individuals for which compensation in price terms is not and 
perhaps cannot be obtained. In the dynamics of scientific production, biological samples 
are research intermediary products when final products are publications or patents. Even 
if the research material is a critical resource, the necessity to corroborate results by other 
teams using the same biological material or to reach a critical mass of samples can 
partly explain the importance of the sample flows between laboratories [52].  
 
When developing a European biobanking structure, handlings must be set up for sharing 
samples among several biobanks which take the costs of transport and quality control 
into account. Otherwise, this point might be an impediment to the willingness of 
biobanks to cooperate. The questionnaires returned from the Erasmus MC Tissue Bank, 
the Tubafrost Biobank and the just-started EuroBoNeT biobank have confirmed that 
these biobanks are indeed willing to share their samples with others, but only after a 
negotiation on reimbursement of costs252. 
 
 
3.1.4 Public involvement, information, acceptance 
 
The success of any research project has a direct relation with the trust of participants 
that will voluntarily accept to provide samples and, usually, private information about 
their health and living habits. To secure the trust of all partners, including participants 
and the larger community to which they belong, public information, consultation and 
public participation seems one of the most important factors influencing success [53]. 
                                                 
252 Cf. returned Questionnaires 
Networking: Challenges and Opportunities 
   132
The more recent literature goes one step beyond and states that trust is earned through 
the establishment of an ongoing relationship with the participants [54] .  
Most available data on public trust in relation to the use of genetic information suggest 
that individuals do have some confidence in the privacy and confidentiality of the use of 
their data and are willing to allow to the use of this information [55]. However, any 
single violation can easily break this trust and lower the support.  
 
While all biobanking projects can raise concerns because of the pooling of sensitive 
information from a group of individuals, large-scale projects raise issues and concerns 
in an acute way and, the question of public participation has recently received of 
attention in this context. There is now general recognition that large-scale projects need 
to engage the public, at the stage of its conception and on an ongoing basis, in order to 
draft and implement a project that will be viewed as legitimate and as an overall a 
positive scientific initiative. Engaging the public supposes first that it be informed. It 
also requires a dialogue about all aspects of the research project. Finally, the object of 
discussion should not only be the project itself. When making a decision about 
participation in a project, potential participants must understand the overall context. 
They must have trust not only in the project itself by in the overall process and 
regulatory system governing biotechnology and research activities in general.  For 
example, even if donors might be willing to accept blanket consent, such a practice 
might jeopardize public trust in biobanking and make it more difficult to collect 
samples. Second, the application of broad consent on the sampling occasion is not the 
same thing as letting research ethics review boards, and other authorities involved, grant 
once-and-for-all permission for broad research proposals. 
 
A meta-analysis of more than 30 studies of research participants from around the world 
was published in 2006. The researchers concluded that of the 20 studies that assessed 
willingness to donate samples for research purposes, 17 found that at least 80% of 
respondents would donate a sample if asked [38]. However, the limits of these apparent 
positive findings must be acknowledged. The polls show a range of various responses 
and we can anticipate these responses are intrinsically linked to the cultural, scientific 
and political context. For instance, in a pool of Singapore population, 49% were willing 
to donate samples of blood for genetic research [56]. A group of Canadians and 
Americans were asked if they would donate a genetic sample and health history 
information to a genebank to be used for health research, provided that their identity 
would be stripped. ‘Three in ten Canadians and a third of Americans would be very 
willing to do so, while four in ten would be somewhat willing’253.  
 
This general willingness to donate blood samples for research must be put in contrast 
with some of the concerns raised by participants.  There is a range of concerns that have 
been identified in the literature especially in the context of DNA banking: appropriate 
consent, confidentiality, future uses, nature of the research, etc254. These concerns must 
be identified and addressed by the scientific community and policy-makers in order to 
create a positive climate for blood and tissues donation for research.   
 
                                                 
253Report prepared for the Canadian Biotechnology Secretariat, ‘First Impression Understanding Public Views on 
Emerging Technologies’(2005) p. 18  http://www.bioportal.gc.ca/CMFiles/CBS_Report_FINAL_ENGLISH249SFD-
9222005-5696.pdf 
254See for instance: Voss, Report to the Human Genetic Commission on the Public Attitudes to the Use of Genetic 
Information (2000) p. 11-12. 
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Having a better understanding of the public’s opinion about biobanks in general is 
especially important in the context of rapid scientific changes and capacity.  In 2003, the 
French National Consultative Bioethics Committee (CCNE) recommended that a large 
consultation of the public take place on the question of pooling of databases and 
biobanks to understand their views on the question255. It is certainly a good practice to 
have an independent and credible organization to conduct polls to better understand 
publics’ views about biobanking. Public education program to address the fear and 
concerns, and to raise awareness about the need for biobanks in the research process and 
improvement of health, is also a good objective towards building and maintaining trust 
with the public.   
 
Faced with such challenging issues, almost all the emerging large-scale population-
based biobank projects have invested time, energy and efforts towards public 
communication and consultation.  Various models to approach the public have been 
experimented by these large-scale projects. ‘The Iceland Health sector database and 
Estonian Genome Project have followed a ‘communication approach’ in order to 
address public concerns, whereas UK biobank and Quebec CARTaGENE have chosen 
a ‘partnership approach to involve the public in decision-making processes’ [57]. Any 
public consultation must be a well-integrated process that will really feed, influence and 
shape the research proposal rather than a parallel process. The House of Common Select 
Committee on Science and Technology criticized the UK Biobank project for having 
‘bolted-on’ the public consultation process. It was strongly suggested that establishing a 
dialogue with the public should be an integral part of the science process. It is suggested 
that public consultation should aim to: (1) Enhance protection, (2) enhance benefits, (3) 
legitimacy, (4) shared responsibility [58].  
 
Wellcome Trust and the MRC have funded many public consultation processes and 
various experts’ papers on the development of UK Biobank256.  The most recent round, 
in 2003, covered most aspects of the proposed project, from recruitment, consent, to 
financial gains257. Generation Scotland has also developed and extensive public 
consultation program. A reflection on defining an appropriate model was initiated early 
in the process258. Ten focus group discussions formed the basis of a ‘Preliminary 
Consultation Exercise’ in 2003-2004259. This consultation covered topics such as: 
participation, recruitment, withdrawal, access, consent, feedback, public engagement, 
and confidentiality and participants were also encouraged to raise issues. CARTaGENE 
(Canada) also conducted focus groups about the project260. These focus groups were 
informed about the proposed project and were invited to express their willingness to 
participate in such project or not, and to discuss about various topics from the protocol, 
to consent, confidentiality, future uses, etc.  
 
                                                 
255Comité consultatif national d’éthique pour les sciences de la vie, (CCNE), ‘Problèmes éthiques posées par les 
collections de matériels biologiques et les données d’information associées : ‘biobanques’, ‘biothèques’. Avis no 77, 
p. 7.   
256See the UK Biobank website for a complete list of consultation.  
257People, Science and Policy Ltd, ‘UK Biobank Framework for the Consultation of the Ethics and Governance 
Framework’, (2003), http://www.ukbiobank.ac.uk/docs/people-science-policy.pdf  
258T. Wakerford, F. Hale, ‘Generation Scotland : Towards Participatory Models for consultation’ 
http://129.215.140.49/gs/Documents/Consultation.pdf  
259G. Haddow and al., October 2004. http://www.generationscotland.org/ 
260CROP, ‘Project Cartagene: Faits saillants des rencontres du groupe’ (2003), http://www.cartagene.qc.ca/focus.cfm 
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There is an increasing recognition that participants should not only be consulted, they 
should partake in the implementation and long-term development of the project. Finding 
an appropriate way to involve the public in such a project is quite a challenge. 
Establishing a long-term dialogue with the public is an essential component of this 
partnership [54].  A reflection, already initiated by the projects mentioned above and 
others should be pursued to define the parameters of appropriate models such a long-
term involvement should take in Europe. Funding agencies should also recognize the 
need to hold such consultations and fund public engagement activities as integral part of 
any large-scale initiative funded in the future.  
 
The right to withdraw consent is considered important for the public trust in research 
and consequently to people's willingness to participats and to consent to research [19]. 
 
 
3.2 Options for a European Biobank Networking Platform 
 
In the current era of genomics based medicine, large-scale genetic epidemiological 
studies have become a key tool in elucidating disease and designing improved and more 
personalised therapies. However, such studies require large numbers of cases and 
controls so that statistical significance of results is ensured261. In this context, biobanks 
constitute a critical resource. Yet, the existing collections vary widely in several aspects 
which maybe in turn hindering their collaboration and effective use in research. There is 
a recognised need for increasing networking and harmonisation among biobanks in 
Europe (and world-wide).  
 
In the following sections, we address first the issue of networking large population-
based biobanks and then focus on smaller, disease-specific biobanks and the need for 
pooling such resources within Europe.   
 
In several European countries, initiatives have already been taken to build national 
population-based biobanks (e.g. decode, EPIC, Estonian Genome Project, IBBL 
Luxembourg) (Chapter 2.2). Given these ongoing or planned biobanking activities, 
creating a completely new European biobank0 project would be a costly and not very 
efficient operation (e.g. it would take years to reach the number of cases needed for the 
prospective research). In this context, one expert from the UK explains why there is a 
need to network and “harmonize” biobanks internationally:  
 
“For example, it would take UK Biobank 17 years to achieve 10 000 cases of breast 
cancer, which would be needed in order to effectively study the genetic effects on this 
disease. In order to reduce this time lag, the expert pointed to the need of 4-6 “UK 
Biobank equivalents” around the world. By pooling samples and data from these 
biobanks, which would thus be based upon 2-3 million recruits, the researchers would 
                                                 
261However, it should be recognised that the fact that many diseases are dependent on coinciding abnormalities or 
disturbances in multiple pathways, and therefore non-replicated findings may not at all be a rejection of the first 
finding: the context of other causes may be so different that the association found in the first disappears in the next. 
On the top of that, replication may in fact mean replication of the same confounding or bias. Hence, until a more 
comprehensive knowledge about the multiple pathways is available that lead to the disease, it will be difficult to 
definitely verify or refuse gene-disease associations for the more common complex diseases. These are also the 
problems that make the population sample size requirements so huge and – in spite of the obvious advantages - a bit 
problematic, because there may be many other reasons for moderately strong but very precisely estimated association 
(say odds ratios of 1.2-1.5). 
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more rapidly gain access to the necessary material to work on. Such pooling would be 
especially important for research on “less common but not rare diseases”. For 
example, it would take UK Biobank 29 years to get 2 500 cases of stomach cancer. With 
six UK Biobank equivalents 10 000 cases could be achieved in 20 years. Besides 
enabling earlier analyses, this kind of pooling would facilitate the study of events at 
younger ages and a broad range of environmental exposures”.  
 
Therefore, it would be better to build on and strengthen existing national initiatives. 
Interviews conducted with other biobank experts support the idea of facilitating pooling 
among national biobanks rather than creating a huge single European Biobank. 
However, the creation of a “virtual biobank” is likely more feasible and efficient, 
although the way to achieve this is not entirely clear.  
 
As an expert suggested, the establishment of some kind of international umbrella (or 
network) organization could facilitate in various ways collaboration between different 
biobanks, as several ongoing parallel coordination initiatives, all working on 
harmonization issues already exist. The most important task of this organization would 
be to facilitate the creation of a well-functioning network among independent 
population-based biobanks/studies (Figure 3-3). These should retain the control over 
samples and data. Thus, the merger of samples and data should take place at the level of 
individual studies, which may involve all or a subset of the “partner banks”. If the 
integration of the national resources should go further in the future remains to be seen. 
 
Figure 3-3:  International umbrella organization supporting networking among 
independent population-based biobanks. 
 
 
 
 
The network to be supported by the umbrella organization should probably not be open 
to everyone who wants to join. It should be a dynamic network for selected biobanks 
and the criteria for “membership” would need to be further discussed. But it is assumed 
that candidate biobanks should have a certain target size (e.g., 50 000 or 100 000 
individuals). They must also be willing to share their own resources with others in an 
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open and cooperative atmosphere. How commercial population-based biobanks would 
be involved in such a network would require further investigation.  
 
There are many issues that need to be addressed in order to facilitate large-scale studies 
where samples and data are pooled and used effectively. There is a need to jointly 
investigate how common operating procedures can be established for practices such as 
genotyping and phenotyping, quality assurance, information management. Related legal 
and ethical issues (type of consent, privacy protection, feedback of information to 
donors, etc) must also be considered. In particular, harmonization of data collection and 
management methods is of crucial importance in order to guarantee an even and high 
quality of the data stored in the databases. If the reliability and error frequency of data 
varies too much among participating biobanks, this will have undesirable effects on 
research findings. For example, false associations might be identified due to quality 
differences. Thus, pooling of data can even lead to “dangerous results”, as one 
interviewee put it.  
 
Based on previous collaborative research projects there is already a great deal of 
experience which should be used as an input to this work. For example, the European 
Comission has funded  “Population Biobanks”, which is a Coordination Action under 
FP6 addressing the need for very large sample sizes. The project has been running from 
2006 to 2008 and involved institutions in 13 countries. The Norwegian Institute for 
Public Health is coordinating the project, the aim of which is to help ensure that Europe 
makes the best use of its rich array of population-based biobanks and longitudinal 
cohort studies262. This project was preceded by another initiative called COGENE.  
 
The Cogene project aimed at strengthening the foundation of European biomedical 
science in the post-genome era. The project aims to establish a collaborative research 
network that will identify and explore some of the key issues that will help ensure that 
Europe is able to make best use of its rich array of population-based biobanks and 
longitudinal cohort studies. These include world-leading cohorts that already exist and 
new initiatives that are just beginning. The ultimate long-term aim is to harmonise those 
features that are common to many biobanks and cohort studies and that, when 
implemented in a complementary manner, can act to: (1) promote communication 
between major biobanking initiatives; (2) enhance the effective sharing and synthesis of 
information; and (3) avoid the expensive mistakes and inefficiencies that can arise when 
individual initiatives repeatedly “re-invent the wheel”. 
 
Other examples include GenomEUtwin263, the Danubian Biobank Consortium264 and 
the Cancer Control using Population based Registries and Biobanks (CCPRB)265. This 
is a network of excellence project within FP6, aiming at improved control of cancer by 
facilitating research linking biobanks and cancer registries. One of the goals is to define 
and implement a “European Quality Standard for Biobanking”. The network consists of 
19 partners from 9 European countries. It includes 7 cancer registries, 20 biobank 
projects, and a number of platforms for advanced technological analysis of biosamples. 
Other models for the creation of a European Population Biobank are represented by the 
                                                 
262 http://www.p3gconsortium.org/events/2003Manchester/LifeSciHealth-Population_Biobanks.pdf 
263 www.genomeutwin.org 
264 http://www.danubianbiobank.de/DanubPublic/misc/mscHome.jsp 
265 www.cancerbiobank.org 
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CEPH repository in Paris266 or the TuBaFrost Network267, characterised by the low 
invasiveness on implementation and incentives for the collecting institutes (single 
biobanks keep the collection and the custodianship over their samples). The possibility 
to make a very large scale biobank on the basis of the same principles as the PKU 
biobanks are made in Denmark and Sweden (health service routine drawing of drops of 
blood on filter paper that dry and can be kept in envelops under normal room 
temperature) may also be considered. The efforts in the field of biobanking have been 
continued under the FP 7 program. In addition to the continous funding of research 
projects and networking activities, the European Commission has also agreed to fund 
projects which aim to establish a new infrastructure for the life sciences. BBMRI268 is 
the project which addresses the biobanking domain in Europe. The continuation of the 
enterprise can only be reached if the Member States and affiliated countries make a 
long-term commitment for a strong European hub in the field of biobanking.   
 
However, a key question is whether this type of networking and harmonization should 
take place only at the European level or more globally. Samples and information are 
routinely moved across the globe and research processes are increasingly complex. In 
addition, there are many companies whose activities cross national boundaries, as 
headquarters may be in one country whilst the research is carried out in another. A clear 
message from the experts, participating in the workshops organised in the context of the 
study, was that the biobank network or umbrella organization should be established at 
the global level – not just the European. It was suggested that the EU should be able to 
invest in such an international organization even if it would work with non-European 
biobanks. In this context, it was proposed that the Public Population Project in 
Genomics (P3G) could possibly play the role as umbrella organization for collaboration 
among large population-based biobanks – if it is agreed that such an organization should 
work globally269. However, this is one of several important questions that need to be 
addressed in future studies on European biobank networking. It also needs to be ensured 
through substantial European initiatives that Europe plays a leading role in the 
international biobanking arena.  
 
3.2.1 Networking among “smaller” biobanks 
 
The scenarios presented thus far for networking have largely focused on large-scale 
populations based repositories. However, the value of small or medium-sized disease-
specific biobanks for research should not be disregarded. Experience shows that by 
picking up a small number of informative families in isolate populations one can 
identify loci and subsequently genes in multifactorial disorders. These genes could then 
be searched for in larger cohorts, and also other genes within the pathways could be 
analyzed. Ensuring improved collaboration and networking among such collections is 
therefore just as critical. 
 
                                                 
266 http://www.cephb.fr/ 
267 www.tubafrost.org 
268  www.bbmri.eu  
269 P3G (www.p3gconsortium.org) is an initiative whose mission is to facilitate harmonization between population-
based biobanks and open the way for future international collaboration. Its main objective consists in the creation of 
an open, public and accessible knowledge database. The consortium is international and its members include leading 
public organizations partaking in large-scale genetic epidemiological projects and biobanks. There are several regular 
members from Europe (e.g. UK Biobank, the Estonian Genome Project, LifeGene, KORAGene, The Danubian 
Group, GenomEUtwin). 
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There are already many ongoing collaborative projects involving European scientists 
working with disease-specific biobanks. Some of these projects are small-scale in the 
sense that they involve only few partners. In other cases, projects may bring together ten 
or more different research centres several of which may be contributing biological 
materials collected in their own countries. A typical case is that a number of academic 
groups/centres have a joint research interest related to a particular disease (e.g. 
colorectal cancer, Type 2 diabetes). The efficiency and effectiveness of the research can 
be enhanced by joining forces implying that biobank resources may need to be shared. 
Besides exchanging ideas, knowledge, data and analysis results, samples may 
sometimes (but not always) be transferred from one place to another for the purpose of 
analysis. Sometimes, the researchers come to an agreement that all samples and/or data 
for practical reasons should be stored in one place. Normally, we can assume, this kind 
of “distributed collaboration” is not dependent on large infrastructure investments at the 
European level as the ones discussed above.270  
 
Obviously, all collaboration activities involving biobanks cannot be coordinated 
through one Europe-wide network or one single model. However, in certain research 
areas, for example centred on a specific type of disease, it should be possible to achieve 
substantial benefits by establishing joint network-based infrastructures. Examples of 
such organisation already exist. The EuroBioBank, which is dedicated to research on 
rare diseases, is a case in point. It should be further investigated if this interesting 
organizational concept can be used a model for other research groups around Europe. 
The UK DNA Biobanking Network is another possible model. 
 
The case of EuroBioBank271 
This is a network of biobanks providing human biological material (DNA, tissue, cell) 
for research on rare diseases. The establishment of the network was financed by the EU 
through FP5 from January 2003 to March 2006 (including 3 months extension). The 
consortium presently consists of 15 partners. There are 12 academic and private 
biobanks (Biological Resource Centres, BRCs) which together store a total of 155 000 
documented samples collected in the following eight countries: France, Italy, Spain, 
Belgium, Slovenia, Malta, Germany, and Hungary. At present a total of 65 000 DNA 
samples and 15 000 tissue samples are available from existing collections: 
 
 Cells DNA Tissue 
No of 
collections 
145 546 282 
No of persons 5 038 40 981 8 952 
 
Besides these biobanks, the consortium also includes two information technology 
partners, one academic and one commercial. Both are French. The project is 
coordinated by the European Organization for Rare Diseases (EURORDIS). From the 
                                                 
270 However, each group may, of course, benefit from the availability of a local core facility for biobanking. That is 
why Karolinska Institutet in Stockholm has established KI Biobank, which is hosting collections coming from 
different departments. Such a core facility has advanced equipment for handling of both samples and data. By storing 
samples in the KI Biobank, for example, the researchers who collected the samples gain access not only to state-of-
the-art physical facilities and systems but also specialized biobanking competencies. 
271 This section is mainly based on EuroBioBank’s website (http://morgan.imag.fr:9443/eurobiobank/index.htm) and 
Fabrizia Bigniami’s presentation at the present ESTO project’s kick off meeting in Seville on 20 January 2006. 
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beginning there was also a biotech company involved, but it left the consortium because 
of bankruptcy. 
 
The overall aim of EuroBioBank is to help scientists to gain access to a critical mass of 
collections thereby accelerating research on rare diseases. By creating this project the 
partners are trying to achieve four objectives: 
 
1. Promote the EuroBioBank network in order to improve the links between 
existing biobanks (in the field of rare diseases). 
2. Harmonize and spread quality banking practices with regard to collection, 
preparation, transport, storage, and distribution of samples, adapted to each type 
of material; this is done through a Network Charter and Standard Operating 
Procedures (SOPs) adopted by all partners. 
3. Distribute quality material and associated data through a dynamic updated 
database. 
4. Disseminate knowledge and know-how through a dedicated website and 
specialized training sessions. 
 
An important effect of the network is that it facilitates identification and localisation of 
available samples throughout these countries, thereby optimising the scientific use of 
existing collections. To make this possible the partners have set up a dedicated website 
through which the researchers can access a centralized database. The latter contains 
information on each sample. Appropriate information has been imported from local 
databases using a secured shared data protocol. The website represents the very core of 
the network and also displays other information on the network’s activities. The 
network is open also to external stakeholders through several communication means. To 
further boost the creation of new collections and the exchange of material new partners 
from other European countries are welcome. On EuroBioBank’s website it is explained 
how a researcher at one of the partner institutions can gain access to samples he or she 
would like to use for at certain study:  
 
“When a researcher needs biological material, he only has to access the EuroBioBank 
website and use the search engine to find the samples required. One click on the 
biobank's e-mail address next to the desired sample and a form appears. The researcher 
simply fills the form out and sends it to the biobank to obtain the samples necessary for 
his research project. This way, the biological material is exchanged much more quickly, 
thus speeding up rare disease research.” 
 
So far, thousands of samples have been exchanged in this way between the partners 
(approximately 6 800 in 2004, according to the website). 
 
As to the promotion of quality banking practices, the partners have jointly developed 
harmonized SOPs and a Material Transfer Agreement that comply with the OECD’s 
recommendations for BRCs272. In this context, one expert made the following 
statement: 
 
                                                 
272 OECD Best Practice Guidelines for Biological Resource Centres, 2007, OECD, Paris 
(http://www.oecd.org/dataoecd/7/13/38777417.pdf).  
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"Harmonisation as the key word in EU: Both at the legislative and scientific level, to 
reach high quality standards. Standard definition of «Biological Ressources Centre»: 
OECD recommendations as a starting point. Networking BioBanks to optimise 
resources and boost research more efficiently. A need for structural funds for the 
coordination and networking activities and the recognition of Biobanks public health 
value and as fundamental infrastructures -Reflection on public BioBanks’ long term 
sustainability. Wide and coordinated communication to the general public and all 
interested parties".  
 
The SOPs developed by EuroBioBank, have been published on the website and are now 
available to the scientific community. The network has also worked on ethical and legal 
issues related to these banking practices. For example, the partners have conducted a 
survey which is giving an overview of current legislation in the different member states 
represented at EuroBioBank.273 
 
The EuroBioBank argues that it has been instrumental in increasing research on rare 
diseases. The partners have now worked together for more than three years, and it seems 
that they have succeeded to create a well functioning network where biosamples and 
related data are effectively exchanged. Researchers working on rare diseases in other 
European countries are now invited to become members. Assuming that long-term 
funding can be secured, the EuroBioBank will have a good chance to expand and play 
an even more important role for rare disease research in Europe. 
 
The case of UK DNA Banking Network 
The UK DNA Banking Network (UDBN) is an interesting example of biobanking 
infrastructure274 (see also chapter 2.2.1.7) The UDBN is managing samples and data on 
behalf of thirteen independent research groups (“collectors”) working on different 
diseases. Today, the archive contains samples from 25 000 individuals (the target is 40 
000, but the total capacity of existing facilities is over 100 000 samples). 
 
The experience of using this model for managing samples and data is very positive. The 
UDBN has therefore proposed to scale up the network to the European level. The key 
idea behind this initiative, called European BioBanking Union (UBBU) is to create an 
EU research infrastructure to underpin investigative research in sample-based 
epidemiology. The focus would be solely on logistics and cooperation – not on 
investigation. UBBU would be a nodal network. The nodes could be either national or 
regional. The initial focus would be on linking disease-based collections existing in 
various European countries. By generating hypotheses on gene-environment 
interactions, in a second wave of genome-wide association studies, a case can be made 
for new population-based studies. UBBU cooperation and logistics should thus be 
designed to support future population-based studies. 
 
Other examples of disease specific biobank networks 
NUGENOB (Nutrient-gene interactions in human obesity: implications for dietary 
guidelines) is a randomised study of high vs. low fat content in a hypoenergetic diet for 
weight loss in 771 obese subjects. It was completed FP5 3-year project with 12 partners 
                                                 
273 Martin Uranga, A., Martin-Arribas, M.C., de Donato, J-H, and de la Paz, M.P., “Outstanding legal and ethical 
issues on biobanks: an overview on the regulation of member states of the EuroBioBank project”, EuroBioBank, 
2006 (www.eurobiobank.org). 
274 www.dna-network.ac.uk 
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in 7 European countries, and delivered an analysis of effects on weight loss of a panel of 
SNPs in selected obesity-related candidate genes. 
 
DIOGENES (Diet, obesity and genes) is an ongoing FP6 5-year integrated project with 
29 partners in 14 European countries, which started in January 2005 (coordinator: 
University of Maastricht). Its main objective is to assess if high protein content and low 
glycemic index (post-meal rise in blood glucose) of the diet can prevent weight regain 
in obese after successful weight loss, and weight gain in the general population - and 
thereby prevent obesity and its co-morbidities. 
 
HEPADIP (Hepatic and adipose tissue functions in the metabolic syndrome) is a FP6 5-
year integrated multidisciplinary project with 27 partners in 11 European countries, 
starting November 1, 2005. Its main objective is to investigate the role of – and thereby 
search for possible diagnostic markers and therapeutic or preventive targets in – the 
liver and the adipose tissue in development of central components of the metabolic 
syndrome: the disturbed insulin signaling, glucose homeostasis and lipid metabolism. 
The HEAPDIP planned biobanking activities consist in the exploitation of pre-existing 
biobanks associated with participating centres for genotyping of multiple SNPs in 
selected pertinent candidate genes, the collection of human liver biopsy material for 
genomic and proteomic analysis, storage of residual material and the testing of the 
predictive value of identified novel biomarkers of the hepatic and adipose tissue 
dysfunction related to metabolic syndrome components in associated and external 
biobanks as suitable and available, for example via GenomEUhealth.
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4 CONCLUSIONS 
 
4.1 Biobanking in Europe  
 
Based on the survey conducted, there is an acceleration in biobanking activities in 
recent years in Europe. While a few of the biobanks identified started collection in the 
70's, they have been built up relatively recently (during the 90s) with 37% of the 
surveyed biobanks starting their activity after 2000, obviously reflecting the burst of 
genome-wide association studies and the search for disease susceptibility genes and 
diagnostic biomarkers after the completion of the human genome sequencing project.. 
The majority of the biobanks do not foresee an end to their sampling activities and 
indicate a high potential for growth, showing the dynamic nature of biobanking and an 
increasing role in research.  
 
Significant variability emerged with regards to privacy and data protection requirements 
among biobanks in Europe. Although informed consent for approval of biobank-based 
research is almost ubiquitously required, the actual consent requirements and related 
procedures vary widely among biobanks, depending on the national laws and guidelines 
applied. The present survey demonstrates that the majority of biobanks have at least one 
type of consent form that allows tissue and data sharing. Yet, a significant proportion of 
them utilise more than one type of consent depending on the sample. The use of 
samples defined in the consent form is also highly varied, ranging from research on 
specific diseases to blanket (as practiced for example in the case of the UK biobank). 
Importantly, 13 respondents indicated that they do not apply consent at all. Six of them 
belong to Eastern European Countries with the rest based in Western Europe. 
 
The role of research ethics committees is, in this context, gaining increasing importance, 
as shown by the large majority of the biobanks surveyed which are governed by an 
ethics board.  
 
Although differences amongst practices could hamper collaborative research, our survey 
suggests that this may not yet be the case as more than half of the sampled biobanks had 
been involved in international collaborations and reported no major problems in sample 
sharing. This seems to be in line also with previous findings where "gift and exchange 
relations" were found to be the rule in biobanking interactions [Hirtzlin, 2003 #29]. As a 
consequence of that most of the respondents represented stand-alone (rather than 
networked) collections.  
 
As one measure of the effectiveness of this biobanks in generating knowledge, only 
16% of biobanks have not produced any scientific publication, a positive sign of the 
contribution of biobanks to medical research  
 
4.2 Networking and Harmonisation 
 
Experts widely recognised the need to improve collaboration and networking among the 
numerous existing biobanks, as well as new initiatives in Europe (and world-wide). 
Efficient organisation of these resources through the development, for example, of an 
infrastructure would potentially facilitate financial sustainability and greatly contribute 
to the rapid progress of research and development of better diagnostic and therapeutic 
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approaches. The model most favoured involved the development of a virtual biobank 
that would allow networking of biobanks across different countries and centralisation of 
data rather than samples. However, several organisational challenges (wide variation in 
biospecimen collection, processing, storage techniques, data comparability, definitions) 
may hamper such an effort. The lack of uniform regulatory and ethical requirements 
and/or practices may pose an additional barrier.  
 
 
It should be noted that some of the experts considered the virtual biobank as difficult, 
very resource demanding.  A web-based meta-database on European biobanks (possible 
in collaboration on a world-wide basis with P3G) is seen as a cost-effective bfirst step, 
promoting international collaboration by providing access to biobanks world-wide. The 
European Commission recognised the importance of international biobank projects and 
many of them have been funded and established in the context of the EU Framework 
Programmes (e.g. GenomEUtwin275, EuroBioBank276, NUGENOB277, PHOEBE278 and 
BBMRI279, among others). The European Commission, DG Research in partnership 
with two EU-supported biobanking projects, PHOEBE and BBMRI, has recently 
organised a "Networking Meeting for EU-Funded Biobanking Projects", gathering the 
coordinators or senior investigators of 28 EU-funded projects with a significant 
biobanking component.The meeting identified challenges and critical issues to be 
addressed for the development, success and sustainability of biobanks. Among the 
recommendations formulated, the adoption of measures in favour of harmonisation was 
considered one of the most important [59]. 
 
It has been widely recognised by all stakeholders that in order to accelerate scientific 
discovery it will be critical to improve biobank quality, interoperability and 
sustainability. The report from the aforementioned "Networking Meeting for EU-
Funded Biobanking Projects" [59] , also pinpoints this issue raised by the responsible 
investigators of these projects, and there is a general call for harmonisation of sample 
and data storage practices (standard operating procedures for both) but also clear 
procedures for ethical reviews and clarification of legal international requirements for 
data and sample sharing between different countries. Harmonization was also indicated 
as the critical process to stimulate and accelerate scientific discovery in a recent 
workshop jointly organized by P3G, PHOEBE, and BBMRI and sponsored by the 
European Science Foundation [59]. 
 
Based on the analysis thus far, it is evident that there is a need for creating an umbrella 
organisation which would aim at networking biobanks thus also helping to improve 
their collaboration. Such an organisation should have an international focus and could 
be a web-based (virtual) network with a physical hub. Some models for such 
networking have been discussed earlier. However, several barriers must be overcome to 
ensure the success of such an endeavour.  
 
 
                                                 
275 http://www.genomeutwin.org 
276 European Network of DNA, cells and tissue banks for Rare Diseases (http://www.eurobiobank.org) 
277 Nutrient-Gene Interactions in Human Obesity  (http://www.nugenob.com) 
278 Promoting Harmonisation of Epidemiological Biobanks in Europe (http://www.phoebe-eu.org/) 
279 Biobanking and Biomolecular Resources Research Infrastructure (http://www.bbmri.eu) 
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4.2.1 Regulatory aspects 
 
Bomedical research in Europe still faces substantial problems when it comes to the 
exchange of samples and in particular data. The sample/data dichotomy (are they the 
same or should they be treated as one?) still poses a problem.  While the Data Protection 
Directive serves as a benchmark for the exchange and flow of data, there seems to be no 
competence of the EU to govern the exchange of samples as this part of regulation falls 
under property law in many Member States. Interestingly, the problems in practice are 
rather observed in the field of data protection. To some extend this situation is owed to 
the fact that the field of Public Health is not harmonized in the Data Protection 
Directive.  
 
The current discussion stresses the protection of individuals adequately but it should not 
be neglected that the Directive aims to enable a free flow of information in a common 
European zone. Data protection issues in biobanking need to be seen in the wider 
context of health information, which includes cancer registries, e-health, and 
communicable disease prevention to name just a few. The current Data Protection 
Directive to some extent facilitates a different interpretation, in particular through the 
wording of Art 8 (4). Thus, a interpretation which uses Art 8 (3) would be favorable to 
achieve a better harmonization in Europe. Finally it was stressed that such an open 
research space should not hamper the protection of citizens per se as better barriers and 
the application of new privacy-enhancing technologies can protect the data of citizens. 
A high level of data protection is essential ensure the necessary public trust in Public 
Health institutions an medical research.   
 
Recently, several countries have set up specific regulations for biobanking, biomedical 
research and the use of genome-based information. For the EU Member States these 
new regulations also have to be interpreted and assessed by applying the principles of 
the existing Data Protection Directive. Problems are raised by the differences in 
regulatory frameworks across Member States: 
• Many researchers who share samples and data across jurisdictional boundaries 
may be operating unlawfully because of the differences between the legal 
requirements in  Europe [24].  
• It is difficult to ascertain what the law is in different member states and it is also 
time consuming and expensive for researchers to find out.  
• This is ultimately detrimental to the development of genomic research, which is 
increasingly dependent upon large sample sizes and the networking of 
collections. 
• It is possible that not all participants in research have the same protections 
across the different member states of Europe. 
• It is also possible that research is not equally competitive across all member 
states as different standards apply across Europe. 
 
Other major challenges for setting up an EU-biobank connected globally are hampering 
national regulations and rules that prohibit the transfer / export of DNA samples. Here, 
international agreement should be reached on the transfer of human DNA samples for 
research purposes (UNESCO, WHO, etc) for removing these barriers. The focus should 
be on open global (rather than European) transfer of DNA samples for research.  
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A further barrier to European networking is the differences in data protection measures 
in the Member States (differeces in definitions and in the wording of domestic legal 
documents that implement Directive 95/46/EC.) The reasons for such differences are 
due to: 
 
• The ‘margin of appreciation’ that is given to Member States when implementing 
directives. 
• The lack of a binding legal instrument for biobanks at a European or 
international level, or an international regulatory structure that applies 
specifically to biobanks. In the Explanatory Memorandum to the 
Recommendation of Council of Ministers Recommendation (2006) 4 that was 
passed on the 15th of March 2006, it was stated that:- “There is a need for a 
common international framework, especially in view of increasing border flow 
of biological material of human origin and data and in the light of important 
third party interests (e.g. the pharmaceutical and biotechnology industries).” 
• The fact that the Convention on Human Rights and Biomedicine is voluntary 
and has not been signed by, inter alias, the UK and Germany. 
 
In order to fulfil this legal vacuum specific guidelines have been drafted in member 
states by parliaments and National Ethics Committees. For example, the Nationaler 
Ethikrat and the French Comité Consultatif National d'Ethique have both written 
specific national guidelines for biobanks280. In countries, such as Estonia and Iceland, 
which have undertaken to establish national population biobanks or health-related 
databases, specialist legislation has been drafted to deal with the complexity of the 
issues that surround such activities. In several countries in Northern Europe specialist 
biobank legislation has been developed. However these measures have led to diversity 
rather than uniformity of practice. 
 
The general law of the European Union and the Member States does not apply readily to 
biobanks that are used for genomic research. For example, there can also be different 
requirements that apply for biosamples and information, which can be problematic in 
the case of genomic research where it is difficult to make a clear distinction between the 
samples and the information contained in the sample. In practice, principles of data 
protection are often applied to samples in order to ensure a coherent regulation of the 
field.  
 
A prerequisite to building networks for biobanks across Europe is the better 
understanding of the current legal framework and the nature of the legal obstacles and 
incentives.  
 
Consent issues - Informed consent is a standard ethical requirement in medical 
research, and thus applies also to biobank-based research. In this context, informed 
consent is the process in which a potential sample donor receives the relevant 
information and decides whether or not to authorize storage and various uses of the 
sample, based on that information and his or her own values. Although informed 
consent for approval of biobank-based research is almost ubiquitously required, the 
actual consent requirements and related procedures vary widely among biobanks, 
                                                 
280 Nationaler Ethikrat 2004 ‘Biobanks for Research – Opinion’ and Comité Consultatif National d'Ethique 2003 
Opinion No.77. 
Conclusions 
   147
depending on the national laws and guidelines applied, which may pose difficulties for 
collaborative research. The present survey demonstrates that the majority of biobanks 
have at least one type of consent form that allows tissue (63.5%) and data (69%) 
sharing. Yet, a significant proportion of them utilise more than one type of consent 
depending on the sample. The use of samples defined in the consent form is also highly 
varied, ranging from specific to blanket. Importantly, 13 respondents indicated they 
don’t apply consent at all.  
 
Seeking reconsent from participants, while often viewed as burdensome, is nevertheless 
explicitly required in many cases. In France, for instance, researchers have a legal 
obligation to renew consent before reusing donors’ samples for a new purpose, and an 
effort in Canada to advance population genomics research must renew consent for 
participants every 5 years. 
Generally, public preferences for consent depend on the context, including the country 
or region, the tissue type (e.g., cancer, brain), and the situation (treatment versus death), 
to name only a few. 
 
Two issues of critical concern in biobanking are recontacting study participants with 
research results and getting participants’ reconsent to use their specimens in further 
studies, including for previously unforeseen purposes. Both of these issues highlight the 
importance of balancing the needs of patients with those of scientists. The changing 
landscape with respect to these and other ethical and legal considerations can have long-
term implications for health care and disease. Further, differences between countries in 
handling these issues can pose challenges for international harmonisation. 
 
While some studies recontact participants in cases of abnormal results, most do not 
provide participants with specific information but instead may offer aggregate feedback 
on the progress of the study via Web sites and newsletters. This presents both ethical 
and legal concerns in known cases of serious, treatable conditions and thus has been a 
topic of ongoing discussion. Some contend that recontacting participants with individual 
results would promote public trust while offering meaningful return for individuals’ 
participation. 
 
Further analysis as to whether an open consent is permissible under the existing data 
protection legislation is also required.  Informed consent is a standard ethical 
requirement in medical research, and thus applies also to biobank-based research.  The 
consent requirements and related procedures vary widely among biobanks, depending 
on the national laws and guidelines applied, which may pose difficulties for 
collaborative research. 
 
Purpose - A related observation is that any collection of samples (a biobank for reasons 
other than research) could transform into a biobank for research or, at least could be 
used for biobank research purposes, wholly or partially, permanently or temporarily. 
For example, the blood stored in the Dutch Sanguin transfusion bloodbank has been 
used (with full consent) by researchers to find biomarkers for RA (section 2.2.3.4. 
Biobanks in the Netherlands). A similar phenomenon may occur if cancer registries 
change into biobanks. Does this potential for conversion mean that these potential 
‘incidental convertibles’ should be governed by the proposed harmonisation initiatives 
and be covered by the proposed virtual biobank and umbrella organisation?  In 
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accordance with the Data Protection Directive one might argue that such a change of 
purpose requires certain legal safeguards.  
 
 
4.2.2 Funding sustainability 
 
On EU Commission level a virtual, dynamic international networking platform could 
help consolidate and illustrate the available (European) biobank activities, even though 
networking and capacity building strategies for different biobank clusters require 
different ways of coordination. A distinction has to be made between “networking 
principles” and “capacity building principles”. 
 
There is need for assuring sustainability of biobanks. Most funding resources do not 
accept requests for funding of project for periods exceeding 3 to 5 years. However, 
biobanks by definition are projects that must be run for at least 20 years, or even 
without a preset closing date. For an EU-wide biobank, whether physical (population 
collection) or virtual (a network of biobanks), there must be a funding structure assuring 
sustainability over long (>20 years) periods. 
 
Some experts claims a need for a 'salvation fund' for saving local European collections 
(either private or public) that are about to be lost due to lack of funding. Surely, 
scientific criteria must be applied for eligibility to be saved by such a fund. But the 
necessity is real – it already happened and valuable collections were lost due to lack of 
funding. (An example from Israel was mentioned: is IDgene Pharmaceuticals Ltd., a 
private company which ceased activities in 2004, and the fate of its collection is 
uncertain at the moment281).Whatever model will be realized, e.g. a ”virtual biobank” 
(networking among existing biobanks) or an International Umbrella Organization 
(network of population-based biobanks) on global level, the EC could become active in 
the biobank field through future EU Research activities (FP8 and beyond) for the 
clarification of various open questions, such as: 
 
⇒ Establish biobanking as a new area of research; 
⇒ Develop biobank operation guidelines (data-driven-public comments); 
⇒ Promote professional oversight of biospecimen standards; 
⇒ Develop new technologies for biobank operations; 
⇒ Carry out studies on the whole array of patient derived material ranging from 
tissues to body fluids, blood cell lines xenografts useful for translational cancer 
research; 
⇒ Carry out feasibility study on the development of a European biorepository 
accreditation program 
⇒ Encouraging networking and self-governance 
⇒ Encourage better data-sharing from the private sector – mostly from the 
pharmaceutical industry 
⇒ Support the protection of citizens by EU-wide legislation (or at least regulations) 
prohibiting the use of genomic or proteomic data collected during research for 
employment or insurance reasons (see separate mail with the Israeli Genetic 
Information Law 2000) 
                                                 
281 http://www.biotechcareercenter.com/IDGene.html 
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⇒ Develop EU-wide oversight mechanism to see that benefit sharing from research 
using genomics databases and leading to marketed products (drugs, devices and 
diagnostics) really takes place. This would be essential for building public trust 
in large genetic databases. 
⇒ Develop training activities across and outside the EU Virtual Biobank should 
also represent one major element for development of biobanks and of the 
research with human biological samples.  
 
 
In this context, there is an increasing mobility of samples and data across national 
borders, in particular within Europe. In some cases, such as the European Prospective 
Investigation into Cancer and Nutrition (EPIC)282, samples collected in different 
countries, and associated data about the donors, are stored in a central biobank. But in 
other cases, samples are sent abroad for being analysed at one of the participating 
research centres, which is specializing in carrying out this particular task. It may also be 
that no samples are sent at all. Instead, data and information obtained through the 
research is exchanged among participating centres. Sometimes a “virtual biobank” is 
created where data is kept in a central database, while the collected samples are stored 
locally. TuBaFrost and EuroBoNet are two examples of such partnerships managed by 
the Organization of European Cancer Institutes. Samples are here stored in 9 and 25 
locations respectively. 
 
4.2.3 Appropriate benefit sharing and public engagement in biobanking 
activities 
 
On the question of insurance of appropriate benefit sharing and public engagement in 
biobanking activities, it is clear that research results will be more valid given the 
possibility of making inferences to large populations (European population). There is 
need for the private sector to collaborate with public databases, and the strong need for 
better biomedical data-sharing from pharma companies, which displays a key policy 
issue. Such data would be invaluable in the long term for improving drug safety and 
efficacy.  
 
Clearly, an EU Biobank Networking Structure/Platform must include some mechanism 
for benefit sharing back to the community, for building public trust and reducing public 
fears from large genetic databases. One way could be to include representatives from 
patient groups in a body which oversees sharing of benefits from companies who 
received samples or data from the biobank (medicines / diagnostics at reduced costs to 
communities were the DNA samples were donated).  The same representative 
individuals should also take part in on-going consultation process on biobank policies 
(collection of samples and data; sample distribution and data access; networking on a 
global scale; feedback from researchers; etc.). It needs to be clearly communicated how 
Europe, and in this sense each citizen in Europe, profits from a strong infrastrucuture for 
medical research. Donors may be more likely to see the positive impact of research on 
future generations in disease specific biobanks. Communication tools are needed which 
help citizens to understand the long-term fruits of biobanking and which demonstrate 
that they support the common good by sharing samples and data with researchers.  
 
                                                 
282 http://www.iarc.fr/epic/ 
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4.3 Ways forward 
 
It seems evident and widely recognised the recognition that biobank quality, 
networking, and sustainability are critical to accelerating scientific discovery. Building 
and sustaining biobanking infrastructures and ways to maximise their scientific value 
and international usage have become immediate goals. 
 
To help promote networking of biobanks and thus maximisng the public health benefits 
to be harnessed at least some degree of harmonisation must be achieved.Whether this 
should be achieved solely at level of legal/regulatory requirements and practices and/or 
by technical standardisation requires further investigation. Experts suggested the 
establishment of an international (rathen than just European) umbrella (or network) 
organization, which would establish common operating procedures in e.g. genotyping 
and phenotyping, quality assurance, information management, and common approaches 
to ethical and legal requirments such as consent, data protection and privacy, feedback 
of information to donors, etc. In this context, already existing initiatives with similar 
objectives [examples] should be taken into consideration. On a gobal level p3g and 
ISBER have been working in this domain and in Europe the recently established 
BBMRI has shown great efforts to take Europe to the next level of networking in 
biobanking.  
 
On basis of the knowledge gathered in this report one might conclude the European 
Commission to be the ideal platform for the creation of a European framework for 
biobank networking through a robust, flexible, scalable, and secure bioinformatics 
system that supports the collection, processing, storage, annotation, and distribution of 
biospecimens for research purpose and data using standard operating procedures based 
on best practices, while ensuring that the privacy interests of biospecimen donors are 
preserved. The current development rather envisages having an independent, 
community driven approach. While BBMRI has proven to become a successful 
enterprise for the networking of biobanks in Europe and beyond, a sustainable financing 
and non-discriminatory access to services and tools has to be guaranteed. Apparently a 
long-term commitment from both the Member States and the European Commission 
would be needed to stimulate these activities. Thus, both options require a strategic 
decision on the side of the European Commission.   
 
If a European Biobank Networking Platform were successful in facilitating cooperation 
and creating a European biobanking logistics system,  
 
“then it would, de facto, create or increase the long term security of existing national 
biobanks and biobanking infrastructures (the distinction is between an investigative 
project and a pure logistics operation). Such long term security is essential if the full 
value to molecular epidemiology of population-based and case-based studies is to be 
realised. If the.... concept is developed through cooperation between existing biobanks 
and biobanking infrastructures, then that cooperation will itself help to lay the basis for 
a successful union that also can engage successfully with others in the biomedical 
community and will strengthen (rather than detract from) those existing organisations.” 
(European Biobanking Union: Flyer, MartinYuille, 2006).  
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Today 2010 Tomorrow 2025 
Wide variation in biospecimen 
collection, processing, and storage 
techniques, and difficulty obtaining 
sufficient samples for large-scale 
genomic and proteomic studies 
Single, European/nationally coordinated 
biospecimen collections, employing 
standardized procedures for storage and 
distribution, as well as collection of associated 
clinical data. 
No uniform bioinformatics system 
existing that is capable of remote 
searching and data entry  
European coordinated and centralized 
bioinformatics system for all aspects of 
specimen and data collection and 
dissemination  
Restricted access to researchers 
outside institution at which specimens 
are collected  
Extensive, external specimen-sharing of “EU 
biobank platform” affiliated collection centres  
Consent procedures that are variable 
and may be insufficient for future 
genomics/ proteomics research  
Standardized consent for all specimens 
tailored to genomic and proteomic studies 
while respecting the local and cultural 
differences/values. 
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ANNEX 1: SURVEY QUESTIONNAIRE 
 
1. Name of the biobank:       
2. Contact person:       
3. Contact person Email:       
4. Contact person Phone (include 
prefixes): 
      
5. Does the Biobank consist of a 
partnership of banks? 
 
Yes  No   
6. Does the Biobank consist of several 
geographical locations: 
Yes  No  If Yes how many ………. 
7. Is it “owned” or is there a 
responsible organisation 
Yes  No  
8. Name of “owner”/organisation  
9. Principal reason for the creation of 
the Biobank (Mark all that apply) 
 Public Research  
 Private commercial research 
 Clinical Research diagnostics 
 Others, please specify  
             
10. Participant Selection (Mark all that 
apply) 
 Random, population 
 Disease/condition specific 
 Demographic specific (e.g. isolates) 
 Others, please specify  
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11. Collection of samples done by:  Associated Hospital staff 
 Centres/Staff specifically employed for the Project 
 Primary care workers (including hospital staff) 
 Patient interest groups 
 Others, please specify  
             
12. Current size of the repository  Number of individuals:       
 Number of families:      
13. Targeted size of repository  Number of individuals:      
 Number of families:      
 Open, no target size 
14. Sampling period  Year start of sampling       
Year end of sampling (if applicable)       
15. Type of material in the biobank  DNA 
 Serum  
 Whole Blood 
 Tissues 
 Others, Please specify: 
              
16. Storage of Samples  Samples room temperature 
 4oC refrigerator 
 -20oC freezer 
 -80oC freezer  
 liquid nitrogen 
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17. Type of Data kept  Demographic 
 Ethnicity 
 Medical/Phenotype 
 Environmental/lifestyle 
 Genetic data 
 Others, Please specify: 
              
18. Database connectivity  Stand-alone 
 Networked – intranet 
 Networked – internet – restricted access 
 Networked – internet – open public access 
 Others, Please specify: 
              
19. By whom is the biobank used for 
research? 
 The researchers who collected the samples  
 Other researchers at the same institution  
 Other researchers in the same country 
 Other researchers in other European countries 
 Other researchers from other parts of the world 
20. Access availability:  Payment  
 Free  
 Restricted if yes please specify how: 
             
21. Decision on Access  Curator/Official manager 
 Governing board 
 Others, Please specify:  
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22. Is the Biobank regulated by an 
Research Ethics Board approval 
 Yes  No 
23. Does your current consent form 
/legal framework allow sharing of : 
(i) tissues (ii) data with other 
researchers outside country?   yes 
no 
Tissues:  Yes  No 
Data:  Yes  No 
24. Is it possible for donors to 
withdraw their consent to store 
samples in the biobank? 
 Yes  No 
25. Type of consent (Please mark all 
that are relevant):  
 No explicit consent 
 Consent to a specific study  
 Consent to research in a certain research area  
 Consent to biomedical research  
 Blanket consent  
 Others, Please specify:  
             
26. Is any information arising from 
biobank studies referred back to 
individual (personal results) 
 Yes (if consented to)  Yes (in all cases)   No 
27. How is privacy of the donors 
protected? 
 Anonymization (no code key) 
 Coding (code key) 
 Others, Please specify: 
             
28. Are researchers required to feed 
back results to the biobank? 
 Yes  No 
29. Is publication of research results 
monitored? 
 Yes  No 
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30. How many collaborations have 
been carried out so far utilising the 
Biobank resource? 
 none 
 one 
 2-10 
 more than 10 
31. How many publications are based 
on the biobank? 
 none 
 1- 10 
 11-100 
 more than 100 
32. Has the biobank been used in 
international projects?  
 Yes  No 
If Yes give examples: 
       
      
       
      
Additional Comments: 
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ANNEX 2: EU FUNDED PROJECTS 
 
 
Biobank Contact/Website 
ADDNET harry.holthofer@helsinki.fi 
Autorome hans-juergen.thiesen@med.uni-rostock.de 
Brainnet, Brainnet II http://www.brainnet-europe.org/ 
CCPRB joakim.dillner@mikrobiol.mas.lu.se 
COGENE eero.vuorio@utu.fi 
DIOGENES http://www.diogenes-eu.org/WeightLossStudy/NL/Default.asp 
Early Lung Cancer http://www.euelc.com/partnerships.htm 
ECARUCA http://agserver01.azn.nl:8080/ecaruca/ecaruca.jsp 
ELSAGEN http://www.elsagen.net/ 
EMBIC http://www.embic.org/ 
EMUMITOCOMBAT j.smeitink@cukz.umcn.nl 
EPI-HPV-UV-CA J.N.Bouwes_Bavinck@lumc.nl 
ERICBSB joakim.dillner@mikrobiol.mas.lu.se 
ERSPC http://www.erspc.org/ 
EUGENE2 http://www.eugene2.com/ 
EUGINDAT http://www.ub.es/eugindat/ 
EUHealthGen http://www.wellcome.ac.uk/doc_WTX026759.html 
EURAPS http://www.euraps.org/home.htm 
EuroBioBank www.eurobiobank.org 
EUROCLOT http://www.twin-research.ac.uk/euroclot.html 
EuroGentest  www.eurogentest.org  
EUROSCA www.eurosca.org 
EUROSPAN http://www.chs.med.ed.ac.uk/phs/staffprofile.cfm?profile=hca
mpbel 
EUROWILSON http://www.eurowilson.org/ 
EVGN http://www.evgn.org/ 
EXGENESIS http://gnp8.polestar.demo.eibs.co.uk/projects/exgenesis 
GALEN paul.vancauwenberge@UGent.be 
GEHA http://www.geha.unibo.it/ 
GENADDICT i.kitchen@surrey.ac.uk 
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GENESKIN g.zambruno@idi.it 
GenomEUtwin http://www.genomeutwin.org/ 
Genomos uitterlinden@endov.fgg.eur.nl 
GenOSept http://www.esicm.org/PAGE_genosept 
HUMGERI fesus@indi.biochem.dote.hu (EU-funded, FP6) 
IMPROVE rodolfo.paoletti@unimi.it 
MITOCIRCLE http://mitocircle.unimaas.nl/ 
MOLPAGE http://www.ocdem.com/composite-108.htm 
MOLTOOLS http://www.moltools.org/default.asp 
NUGO http://www.nugo.org/everyone 
OISTER http://www.dkfz.de/oister/OISTERnav.html 
PHGEN www.phgen.eu  
P-MARK http://www.p-mark.org/ 
POLYGENE www.uvs.is; eirikur@uvs.is; oddny@uvs.is; thorunnr@uvs.is 
Population Biobanks camilla.stoltenberg@fhi.no 
PRIVIREAL http://www.privireal.org/ 
PWS http://pwsa.co.uk/main.php?catagory=14&sub_catagory=62 
UBIGENES pnavas@dex.upo.es 
VIRASKIN ola.forslund@mikrobiol.mas.lu.se 
VIRDIAB http://www.uta.fi/laitokset/laaket/VIRDIAB/ 
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ANNEX 3: BIOBANKS IDENTIFIED IN EUROPE 
 
 
Name of Biobank Contact/Website 
Austria 
BioResource-Med http://www.bioresource-med.com/ 
Cells and Tissue Bank Austria http://www.ctba.at/ 
The Austrian Tissue Bank, Österreichische 
Gewebebank GmbH 
http://www.tissuebank.at/ 
Lifecord  www.lifecord.at 
VITA 34 GmbH Österreich www.vita34.at 
Vitacord, Gesellschaft für 
Stammzellenlagerung m.b.H 
www.vitacord.at 
Belgium 
Biobank of the University Hospital of Liege  
DNA Bank of the Renal Unit of the Catholic 
University of Leuven 
 
Tissue Bank of the University Hospital Saint-
Luc 
http://rch.sia.ucl.ac.be:8820/unit_to_printer?un
it=ORTO&newlang=fr 
Belgian Cord Blood Bank  
Cryo-Save www.cryo-save.com 
Bulgaria 
National DNA Bank of the Republic of 
Bulgaria 
http://ivo.medfac.acad.bg/ 
Tissue Bank Pirogov http://www.pirogov.net/ 
Denmark 
The National Danish Birth Cohort http://www.ssi.dk/sw9314.asp 
The National PKU Biobank  
The Diet, Cancer and Health Biobank http://www.cancer.dk/epi/afdelinger/kkh/under
sogelsen/diet,+cancer+and+health.asp 
The Copenhagen City Heart Study http://healthsciences.ku.dk/ 
The Copenhagen General Population Study http://healthsciences.ku.dk/ 
The Copenhagen Ischemic Heart Disease Study http://healthsciences.ku.dk/ 
The Copenhagen Carotid Stenosis Stroke Study http://healthsciences.ku.dk/ 
The Copenhagen Breast Cancer Study http://healthsciences.ku.dk/ 
The Danish Twin Registry http://www.dtr.sdu.dk/?sprog=eng, 
http://www.sdu.dk/health/ 
NUGENOB www.nugenob.com 
ORG/ADIGEN http://www.ipm.hosp.dk/ 
Pelvic Mass hogdall@dadlnet.dk 
Danish HPV Cohort www.cancer.dk 
The Danish Psychiatric Biobank http://www.ribp.dk/page/page.php?page=5&ti
d=7&sid 
Research Centre for Prevention and Health allin01@glostruphosp.dk 
Estonia 
Estonian Biobank http://www.ebc.ee/EBC/ 
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http://www.geenivaramu.ee/ 
Finland 
KTL Biobank http://www.ktl.fi/portal/english/ 
The Finnish Twin Cohort http://www.twinstudy.helsinki.fi/, 
http://www.kttl.helsinki.fi/content_english.asp
?route=4.835.838 
Helsinki Sudden Death Study (Tampere 
University) 
http://www.uta.fi/laitokset/laaket/bio/research/
forensicmedicine.html 
Tampere Coronary Study (TCT) http://www.uta.fi/laitokset/laaket/bio/research/
forensicmedicine.html 
Tampere Acute Coronary Syndrome (TACOS) 
Study 
http://www.uta.fi/laitokset/laaket/bio/research/
forensicmedicine.html 
France 
Généthon DNA and Cell Bank www.genethon.fr 
Biobanque de Picardie www.biobanque-picardie.com 
Germany 
Jose Carreras Cord Blood Bank Düsseldorf http://www.stammzellbank.de/ 
European Searchable Tumour Line Database 
(ESTDAB) 
http://www.medizin.uni-tuebingen.de/estdab/ 
KORA-gen biobank collecting DNA http://www0.gsf.de/kora-gen/index_e.html 
Kryoforschungs- & Demonstrationsbank der 
Fraunhofer Gesellschaft “Eurocroyo SAAR” 
www.ibmt.fraunhofer.de 
Patient DNA collection at Institute of Human 
Genetics Heidelberg 
http://www.klinikum.uni-
heidelberg.de/Humangenetik.5035.0.html 
http://www.klinikum.uni-
heidelberg.de/Mitarbeiter.6978.0.html?&L=0 
Danubian Biobank Consortium http://www.uni-
regensburg.de/Fakultaeten/Medizin/Klinische_
Chemie/englstart.html 
Human Melanoma Biobank http://www.klinikum.uni-
heidelberg.de/index.php?id=6969 
ITI DNA-Bank http://www.iti-ma.blutspende.de/ 
Regiscar www.regiscar.uni-freiburg.de/ 
Tissue Bank, Charité – Universitätsmedizin 
Berlin 
http://www.charite.de/itm/Gewebebank/Geweb
ebank.html 
Greece 
Hellenic Cord Blood Bank cstav@ath.forthnet.gr 
Hungary 
NEPSYBANK www.biobank.hu 
ASTHMA www.biobank.hu 
Uzsoki Teaching Hospital www.biobank.hu 
Preterm infants and full-term neonates www.biobank.hu 
“Prof. Korányi András” Dunántúli 
Transdanubian Génbank 
www.biobank.hu 
ADULT COELIACIA www.biobank.hu 
Biobank of the Cardiovascular Research Group 
of the Hungarian Academy of Sciences-
www.biobank.hu 
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Semmelweis University 
CROHN www.biobank.hu 
FAMILIAR DEAF www.biobank.hu 
HEART ATTACK www.biobank.hu 
HUNTINGTON www.biobank.hu 
METABOLIC SYNDROME www.biobank.hu 
MITOCHONDRIAL DISEASE www.biobank.hu 
ROMA www.biobank.hu 
SHIZOFRENIA www.biobank.hu 
STROKE www.biobank.hu 
KRIO Institut www.krio.hu 
Iceland 
Icelandic Biobank (deCode) www.decode.com 
UVS Biobank (decode) www.decode.com 
The Icelandic Cancer Society Biological 
Specimen Collection 
http://www.krabb.is/?PageID=196 
Reykjavik Heart Study  
Tissue Archives, University Hospital in 
Reykjavik 
http://www4.landspitali.is/lsh_ytri.nsf/htmlpag
es/index.html 
Italy 
Istituto Nazionale Neurologico Carlo Besta http://www.besta-
miopatologia.it/moralab_italiano/morabancada
ti.htm 
Naples Human Mutation Bank of the 
Cardiomyology and Medical Genetics 
(NHGMB) 
http://www.cardiomiologia.it/cardiomiologia/F
ILES/ednabank.html 
Centre of Transfusion Medicine, Cellular 
Therapy and Cryobiology 
http://www.policlinico.mi.it/ 
The Neuromuscular biobank, Department of 
Neurological Science, University of Milano 
 
Bank of DNA cell line and nerve-muscle-
cardiac disease 
http://www.centrodinoferrari.com/sito/servizi/
diagnostica_banca.html 
University of Padova, Department of 
Neurosciences Neuromuscular bank 
www.unipd.it 
CNRB - Centro Nazionale per le Risorse 
Biologiche 
http://www.cnrb.it/ 
European IgA nephropathy Biobank http://www.igan.net/ 
Center of Transfusion Medicine, Cellular 
Therapy and Cryobiology 
http://www.policlinico.mi.it/ 
Latvia 
Latvian Genome Database bmc.biomed.lu.lv/gene, www.lu.lv 
Luxembourg  
Integrated BioBank of Luxembourg  www.ibbl.lu  
Malta 
Biobank Laboratory of Molecular Genetics http://www.biotech.um.edu.mt/ 
The Netherlands 
Erasmus MC Tissue Bank http://www2.eur.nl/fgg/pathol/vtb/index.htm 
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EORTC VTB Biobank http://www.erasmusmc.nl/ 
TuBaFrost http://www.tubafrost.org/ 
BioBank Maastricht http://www.biobank.unimaas.nl/index.html 
LifeLines Biobank www.lifelines.nl 
Netherlands Brain Bank http://www.nih.knaw.nl/ 
EuroBoNeT Biobank http://www.eurobonet.eu/ 
The Chronic Kidney Diseases project m.r.daha@lumc.nl 
Bloodbankof rare bloodgroups of the Council 
of Europe 
www.sanquin.nl 
Cells4Health http://www.cells4health.com/ 
Cryo-Save www.cryo-save.com 
Norway 
JANUS Serumbank (Cancer Registry of 
Norway) 
http://www.kreftregisteret.no/ramme.htm?start.
htm 
HUBRO (Health Study of Oslo) http://www.fhi.no/ 
OPPHED (Health Study of Oppland and 
Hedmark) 
http://www.fhi.no/ 
HUNT Biobank (Health Study of Nord-
Trøndelag) 
www.ntnu.no 
Tromsø Health Survey http://uit.no/samfmed 
HUSK (Health Study of Hordaland) www.helse-bergen.no 
MoBa (The Norwegian Mother and Child 
Cohort Study) 
http://www.fhi.no/ 
Sami Health Survey http://uit.no/samfmed 
Women and Cancer http://uit.no/samfmed 
Poland 
Family Stem Cells Bank ActiVision Life SA  
Department of Transplantology and Central 
Tissue Bank/Research Tissue Bank 
 
Collection of DNA  
Romania 
Skin Bank of the Center of Excellence for 
Scientific and Technological Research 
ENESCUDR@hotmail.com 
Bone bank http://domino.kappa.ro/telemed/ortopedia.nsf/
Home/Page?OpenDocument 
COLENTINA http://www.spitalul-colentina.ro/ 
Heart Valve Bank Timisoar http://www.umft.ro/en/r_index.html 
HUMAN SKIN LIQUID NITROGEN 
STORAGE DEVICE 
ileana.florin@webline.ro 
IVF Center, „Victor Babes” University of 
Medicine and Farmacy, Timisoara 
http://www.umft.ro/en/r_index.html 
Marburg Bone Bank Lobator SD-2 http://www.foisor.ro/index.php?lang=en 
MED NEW LIFE http://www.med-new-life.ro/ 
MEDSANA BUCHAREST MEDICAL 
CENTER 
http://www.medsana.ro/ 
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M.G. – Internatioanal Center RUA gina.munteanu@yahoo.com 
University Hospital “Panait Sarbu” Bucharest  
Assisted Reproduction Departmen, Sperm 
Bank,Embryo Bank 
http://www.psarbu-fiv.ro/ 
Oftalmologie - Spitalul clinic de urgenta militar 
central 
 
Slovak Republic 
Eurocord Slovakia http://www.eurocord.sk/ 
Slovenia 
Neuromuscular Biobank of University of 
Ljubljana, Medical Faculty 
http://www.mf.uni-lj.si/ 
Spain 
National DNA Bank http://www.bancoadn.org/ 
Spanish bank of biological samples from Rare 
Diseases (IIER) 
http://www.isciii.es/htdocs/index.jsp 
Sweden 
Medical Biobank http://www.umu.se/phmed/naringsforskning/fo
rskning/Medical_Biobank/indexB.htm 
Northern Sweden Maternity Cohort  
Malmö Preventive Medicine http://www.med.lu.se/english 
Malmö Diet & Cancer http://www.med.lu.se/english 
Malmö Microbiology Biobank http://www.med.lu.se/english 
Botnia Study http://www.botnia-study.org 
”Biobank SC153” http://www.med.lu.se/english 
Karolinska Instiutet Biobank http://www.meb.ki.se/biobank/about.php 
Swedish Institute for Infectious Disease 
Control Biobank 
http://www.biobanks.se/swedishinstitute.htm 
PKU Biobank  
ULSAM  
ABIS (All babies in Southeast Sweden) http://www.liu.se/hu/ihm/abis/index.htm 
Epidemiology Group, Sahlgrenska University 
Hospital 
http://www.sahlgrenska.se/vgrtemplates/Page_
___27536.aspx 
LifeGene http://lifegene.ki.se/ 
UK 
Generation Scotland: Genetic Health in the 21st 
Century  
www.generationscotland.org 
Generation Scotland: Scottish Family Health 
Study 
www.generationscotland.org 
EPIC Oxford http://www.epic-oxford.org/ 
UK Women’s Heart Study http://www.mhs.manchester.ac.uk/research/fac
ilities_institutes 
Twin Research Unit Laboratory http://www.gstt.nhs.uk/ 
National study of colorectal cancer http://www.icr.ac.uk/ 
International familial CLL consortium http://www.icr.ac.uk/ 
Liverpool Lung Project www.liv.ac.uk 
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EUELC (Early lung cancer) http://www.euelc.com/ 
UK DNA Banking Network http://www.medicine.manchester.ac.uk/cigmr/
Newsarchive/dnabank 
UK Cord Blood Bank Ltd http://www.cordbloodbank.com/ 
Oxagen Ltd http://www.oxagen.co.uk/ 
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ANNEX 4: BIOBANKS IDENTIFIED BEYOND EUROPE 
 
Name of Biobank Contact/Website 
USA 
Penn State Cancer Institute (PSCI) Tissue Bank http://www.hmc.psu.edu/cancer/tissue_bank
/allocation.htm 
TARPS Tissue and Research Pathology 
Services (University of Pittsburgh) 
http://www.upci.upmc.edu/facilities/tarps/se
rv.html 
Pediatric Rheumatology Tissue Repository 
(PRTR) 
http://www.cincinnatichildrens.org/research/
project/rheum-cores/prtp.htm 
Early Detection Research Network Exchange 
(EDRN) -NCI 
http://edrn.nci.nih.gov/ 
Cooperative Family Registry for Breast and 
Colorectal Cancer (NCI) 
 
Tissue Bank Shared Service/Greenbauhm 
Cancer Center/Maryland 
 
Children Oncology Group (NCI funded) http://www.childrensoncologygroup.org/ 
Armed Force Institute of Pathology-National 
Pathology Repository 
 
National Institute of Child Health and 
Development (NICHD), Brain and Tissue Bank 
for Developmental Disorders 
http://medschool.umaryland.edu/BTBank/ 
Kathleen Price Bryan Brain Bank http://adrc.mc.duke.edu/BB.htm 
Stanley Foundation Brain Collection http://www.stanleyresearch.org/programs/br
ain_collection.asp 
Harvard Brain Tissue Resources Center http://www.brainbank.mclean.org/ 
New York Brain Bank http://nybb.hs.columbia.edu/ 
National Parkinson Foundation Brain 
Endowment Bank 
http://www.parkinson.org/NETCOMMUNI
TY/Page.aspx?pid=265&srcid=465 
Human Brain and Spinal Fluid Resource Center http://www.loni.ucla.edu/uclabrainbank/inde
x.html 
McKnight Brain Institute Brain Bank http://www.mbi.ufl.edu/facilities/brainbank/
about.php 
National Alzheimer Coordinating Center http://www.alz.washington.edu/ 
University of California Human Embryonic 
Stem Cell Line 
http://escells.ucsf.edu/main/home.asp 
WiCell Research Institute http://www.wicell.org/ 
Healthy Aging in Neighbourhoods of Diversity 
across the Life Span study 
 
Nun Study http://www.mc.uky.edu/nunnet/ 
Bogalusa Heart Study, (NHLBI) http://www.nhlbi.nih.gov/resources/deca/des
criptions/bhs.htm 
National Health and Nutrition Examination 
Survey (NHANES) (CDC) 
http://www.cdc.gov/nchs/nhanes.htm 
Women’s Interagency HIV Study http://statepiaps.jhsph.edu/wihs/ 
Framingham study (NHLBI) http://www.nhlbi.nih.gov/about/framingham
/ 
Jackson Heart Study (NHLBI) http://www.nhlbi.nih.gov/about/jackson/inde
x.htm 
ARIC study (NHLBI)  
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Physicians’ Health Study, (NIH)  
Nurses’ Health Study (Original cohort) (NIH) http://clinicaltrials.gov/show/NCT00005152 
Nurses' Health Study II (NIH)  
Women's Health Initiative - Observational 
study (NHLBI) 
http://www.nhlbi.nih.gov/whi/ 
Iowa Women's Health Study  
Cancer Prevention Study - 3 (CPS-3) 
(American Cancer Society) 
http://www.cancer.org/docroot/RES/RES_6
_6.asp 
Cancer Prevention Study - II Nutrition Cohort 
(CPS) 
 
Marshfield Clinic Personalized Medicine 
Research 
http://www.marshfieldclinic.org/chg/pages/d
efault.aspx?page=chg_pers_med_res_prj 
Study of Women Across the Nation (SWAN) http://www.edc.gsph.pitt.edu/swan/ 
Cardiovascular Heart Study (CHS) (NHLBI) http://www.nhlbi.nih.gov/resources/deca/des
criptions/chs.htm 
Canada 
Procure Cancer http://www.procure.ca/ 
Cancer Research Network of the FRSQ/ 
Reseau de recherche sur le cancer (FRSQ) 
 
Alberta Research Tumor Bank  http://www.abtumorbank.com/ 
British Columbia Cancer Agency Tumour 
Tissue Repository 
http://www.bccancer.bc.ca/RES/TTR/defaul
t.htm 
Manitoba Breast Tumor Bank http://www.umanitoba.ca/institutes/manitob
a_institute_cell_biology/MBTB/MBTB_Ov
erview.htm 
Ontario Cancer Research Network Ontario Cancer Research Network 
Children's Oncology Group  
Tissue Bank of the Respiratory Health Network 
of the FRSQ 
http://www.frsq.gouv.qc.ca/en/publications/f
rsq_actualites/octobre_2006/banque.shtml 
The Brain Tumour Tissue Bank http://www.braintumour.ca/braintumour.nsf/
eng/BTTB 
Douglas Hospital Brain Bank http://www.douglasrecherche.qc.ca/brain-
banks/general-bank.asp 
LIFEBANC/Arthur and Sonia Labatt BTRC    
Capital Health/Regional Tissue Bank http://www.capitalhealth.ca/NewsAndEvent
s/NewsReleases/2006/CH_Comprehensive_
Tissue_Centre_receives_Medical_Device_L
icence_from_Health_Canada.htm 
Canadian Study on Health and Aging http://www.csha.ca/ 
Genizon BioSciences http://www.genizon.com/ 
Interheart http://www.cihr-irsc.gc.ca/e/26489.html 
Healthy Aging Study http://www.bcgsc.ca/project/healthy-aging-
study/aging_summary 
China 
Kadoorie Study of Chronic Disease in China 
(KSCDC) 
http://www.ctsu.ox.ac.uk/~kadoorie/public/ 
Japan 
Health Science Research Resources 
Bank/Japan Health Science Foundation 
 
Biobank Japan - Riken Institute  
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Japanese collection of research bioresources 
(JCRB Genebank) 
 
Japan National Cancer Center  
Brain Bank Project  
Korea 
MizMedi Women Hospital Research Center  
Biobank for Health Sciences   
Singapore 
National University of Singapore Tissue 
Repository 
http://medicine.nus.edu.sg/tissue/ 
Singapore Consortium of Cohort Studies http://www.a-
star.edu.sg/astar/biomed/action/biomed_strat
egic_initiatives.do#sccs 
ES Cell International Inc. http://www.escellinternational.com/ 
Singapore Tissue Network http://www.stn.org.sg/ 
Taiwan 
Taiwan Biobank  
Other 
Howard's Genomic Research in the African 
Diaspora (GRAD)  
The Western Australian Genome Health 
Project (WAGHP) 
http://www.genepi.org.au/waghp 
Melbourne Collaborative Cohort Study 
(HEALTH 2000) 
http://www.med.monash.edu.au/epidemiolo
gy/cardiores/echidnas.html 
Indian Genome Variation Consortium  
Prospective blood-based study of 200,000 
individuals in Mexico 
 
Genomic variability and haplotype map of the 
Mexican population 
 
National Laboratory for the Genetics of Israeli 
Populations (NLGIP) 
http://www.tau.ac.il/medicine/NLGIP/nlgip.
htm 
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Abstract 
 
Biobanks (i.e. the organised collections consisting of biological samples and associated data, have gained great 
significance for research and personalised medicine) are increasingly recognised as a crucial infrastructure for 
research. However, at the same time the widely varied practices in biobanking regarding for example collection, 
storage and consent procedures may also pose a barrier to cross-border research and collaboration by limiting 
access to samples and data. In this context the limited sharing and linkage of samples is a key barrier for 
research, such as pharmacogenetics. Wide variation is observed in the implementation of relevant existing 
regulation, which may add further burden to harnessing the public health benefit of these collections. It has been 
suggested that there is a strong need for a harmonised approach on biobanking practices and improved 
networking of existing and new collections.  
 
The Report shows information on the extent of biobanking in Europe, collected through a survey of existing 
European biobanks regarding both technical aspects (e.g. storage conditions) and aspects of governance and 
ethics (e.g. sample and data sharing, consent procedures, collaborations etc.). In total, 126 biobanks from 23 
countries in Europe were surveyed.  
 
Significant lack of harmonisation has been found, especially in the legal aspects (e.g. data protection, consent). 
This may be partly attributed to the varied interpretation and implementation of EC directives covering aspects 
of biobanking by national authorities. One of the main complications is that, although the field of data protection 
is harmonised through the EC directive on data protection, the collection, storage, and sharing of samples is 
not. Furthermore, in countries that have introduced special biobanks acts it is not always clear where the 
borderline lies between the scope of these acts and that of the Directive. Indeed, according to the survey, 
biobanks within the same country reported different practices, suggesting that the problems of harmonization 
might be higher than expected and claimed. Not only are there different national laws, but apparently within EU 
member states biobanks do not implement homogenous practices on privacy and data protection issues.  
 
Experts interviews confirmed the need to improve collaboration and networking among the numerous existing 
biobanks. Efficient organisation of these resources through the development, for example, of an infrastructure 
would potentially facilitate financial sustainability and greatly contribute to the rapid progress of research and 
development of better diagnostic and therapeutic approaches. The most favoured model involved the 
development of a virtual biobank that would allow networking of biobanks across different countries and 
centralisation of data rather than samples. However, several organisational challenges (wide variation in 
biospecimen collection, storage techniques, data comparability, etc.) may hamper such an effort.  
 
The European Commission has already recognised the importance of international biobank projects and many 
of them have been funded and established in the context of the EU Framework Programmes. To help promote 
networking of biobanks and thus maximise public health benefits, at least some degree of harmonisation must 
be achieved.  
 
 
 
 
 
 
 
 
    
172 
172
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How to obtain EU publications 
 
Our priced publications are available from EU Bookshop (http://bookshop.europa.eu), where you can place 
an order with the sales agent of your choice. 
 
The Publications Office has a worldwide network of sales agents. You can obtain their contact details by 
sending a fax to (352) 29 29-42758. 
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The mission of the Joint Research Centre is to provide customer-driven scientific 
and technical support for the conception, development, implementation and
monitoring of European Union policies. As a service of the European Commission,
the Joint Research Centre functions as a reference centre of science and technology
for the Union. Close to the policy-making process, it serves the common interest of
the Member States, while being independent of special interests, whether private or
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